Gynaecology — MCQs

Q: A 30-year-old woman presents with amenorrhea, hirsutism, and acne. She has gained 10kg over the past year. Ultrasound shows multiple ovarian cysts. Testosterone and LH are elevated, FSH is normal. What is the most likely diagnosis?

Polycystic ovary syndrome. ***Polycystic ovary syndrome***- Amenorrhea, hirsutism, acne, and weight gain are classic signs of **hyperandrogenism** and **anovulation** characteristic of PCOS.- The presence of **multiple ovarian cysts** on ultrasound combined with **elevated testosterone** and an **elevated LH** with normal FSH strongly points to PCOS. *Congenital adrenal hyperplasia*- Typically involves an enzyme deficiency (e.g., **21-hydroxylase deficiency**) leading to elevated adrenal androgens and often **abnormal cortisol precursors**.- While it can cause virilization, the hormonal profile would differ, usually showing very high **17-hydroxyprogesterone** and not primarily an elevated LH:FSH ratio characteristic of PCOS. *Ovarian tumor*- An **androgen-secreting ovarian tumor** would cause rapid onset and more severe virilization, often with significantly **higher testosterone levels**.- The ultrasound findings of **multiple small cysts** and the specific hormonal imbalance (elevated LH) are more consistent with PCOS than a single tumor. *Cushing's syndrome*- Caused by **excess cortisol**, leading to central obesity, striae, moon facies, and hyperglycemia.- While it can cause weight gain and menstrual irregularity, **hirsutism** and **acne** are less prominent, and the hormonal pattern (e.g., elevated cortisol, suppressed ACTH or pituitary adenoma) is different. *Hypothyroidism*- Symptoms include **fatigue**, **weight gain**, **cold intolerance**, and **bradycardia**, with menstrual irregularities often manifesting as menorrhagia or oligomenorrhea.- It does not cause **hirsutism** or **acne**, and the hormonal profile would show elevated TSH and low free T4, not elevated androgens or LH.

Q: A 41-year-old woman with a 10-month history of heavy menstrual bleeding undergoes hysteroscopy which reveals a 3 cm type 2 submucosal fibroid partially extending into the myometrium (>50% intramural component). She wishes to preserve her fertility. Transvaginal ultrasound confirms no other significant fibroids and normal endometrial cavity. What is the most appropriate initial management?

Abdominal myomectomy. ***Abdominal myomectomy***- A **type 2 submucosal fibroid** with **>50% intramural component** makes hysteroscopic removal technically challenging, increasing the risk of **incomplete resection** or **uterine perforation**.- Given the patient's desire for **fertility preservation**, an open or laparoscopic **abdominal myomectomy** allows for complete removal of the fibroid and meticulous **myometrial reconstruction**, which is crucial for subsequent pregnancies.*Hysteroscopic myomectomy*- This technique is primarily suitable for **type 0 and 1 fibroids**, which are largely or entirely within the uterine cavity.- For a **type 2 fibroid** with a substantial intramural component, hysteroscopic removal is often difficult, risks **uterine injury**, and may require multiple procedures for complete resection.*Trial of levonorgestrel intrauterine system*- The **levonorgestrel intrauterine system (LNG-IUS)** has reduced efficacy and higher rates of **expulsion** in the presence of **submucosal fibroids**.- It does not address the underlying anatomical distortion of the **endometrial cavity** caused by a 3 cm fibroid, which can hinder fertility.*Uterine artery embolisation*- **Uterine artery embolisation (UAE)** is generally not recommended for women who desire **future fertility** due to potential risks to **ovarian reserve** and increased complications like **placental abnormalities** in subsequent pregnancies.- **Myomectomy** remains the preferred surgical option for fertility preservation.*GnRH agonist therapy for 6 months*- **GnRH agonists** are typically used as a short-term **pre-operative adjunct** to reduce fibroid size and improve anemia, making surgery easier, rather than as a definitive treatment.- Fibroids commonly **regrow** after cessation of therapy, and long-term use is limited by side effects such as **bone mineral density loss** and vasomotor symptoms.

Q: A 31-year-old woman presents to the emergency department with left-sided pelvic pain and 7 weeks amenorrhoea. Transvaginal ultrasound demonstrates an empty uterus and a 20 mm left adnexal mass. Initial serum beta-hCG is 1450 IU/L. She is clinically stable. Repeat beta-hCG 48 hours later is 1380 IU/L. What is the most appropriate management?

Expectant management with weekly beta-hCG monitoring. ***Expectant management with weekly beta-hCG monitoring*** - This patient is **clinically stable** with a small **adnexal mass (<35 mm)** and a **declining beta-hCG** (from 1450 to 1380 IU/L), indicating a spontaneously resolving tubal ectopic pregnancy. - **Expectant management** is appropriate when initial beta-hCG levels are low (<2000 IU/L) and declining, requiring weekly monitoring until levels fall below **20 IU/L**. *Intramuscular methotrexate* - **Methotrexate** is a medical management option typically reserved for patients whose beta-hCG levels are **rising or plateauing** rather than declining. - It carries risks of side effects like **hepatotoxicity** and **stomatitis**, which are unnecessary to risk if the ectopic is already resolving on its own. *Diagnostic laparoscopy* - This is an **invasive surgical procedure** indicated for patients who are **hemodynamically unstable**, have severe pain, or have a high risk of rupture. - Given the patient's **clinical stability** and resolving biochemical markers, surgery presents an unnecessary risk of **anesthesia and operative complications**. *Repeat beta-hCG in 48 hours to confirm declining trend* - A 48-hour repeat is used to establish the **initial trend**; once the decline is confirmed (as seen here from 1450 to 1380 IU/L), the protocol shifts to **weekly follow-ups**. - Frequent 48-hour monitoring beyond the initial diagnostic phase is not required for a patient who remains **asymptomatic** and stable. *Arrange MRI pelvis to confirm ectopic location* - **Transvaginal ultrasound (TVUS)** is the gold standard for diagnosing ectopic pregnancy; the presence of an empty uterus and an **adnexal mass** is sufficient for diagnosis. - **MRI** is expensive, time-consuming, and adds no clinical value to the management of a **stable, resolving** ectopic pregnancy.

Q: What is the primary mechanism by which endometrial ablation reduces menstrual bleeding in women with heavy menstrual bleeding?

Destruction of the endometrial basalis layer preventing regeneration. ***Destruction of the endometrial basalis layer preventing regeneration*** - Endometrial ablation targets the **basalis layer**, which is the deep regenerative layer responsible for the monthly growth of the functionalis layer. - By destroying this layer through thermal or other energy sources, the **endometrium cannot regrow**, leading to significant reduction or total cessation of menstrual flow. *Reduction in endometrial blood vessel density through thermal injury* - While **thermal injury** does cauterize local vessels, this is a secondary effect rather than the primary goal of the procedure. - Menstrual reduction is achieved primarily by removing the **source tissue** of bleeding rather than just reducing blood supply. *Decreased prostaglandin production from damaged endometrium* - **Prostaglandins** play a role in dysmenorrhea and heavy bleeding, and their levels may decrease after ablation due to tissue loss. - This decrease is a **consequence** of removing the endometrial tissue, not the fundamental mechanism of action of the procedure. *Hormonal suppression of endometrial proliferation* - Endometrial ablation is a **physical/surgical destruction** of tissue and does not involve the use of exogenous hormones. - Unlike medical therapies like the **Levonorgestrel IUS**, it does not alter the underlying **hypothalamic-pituitary-ovarian axis**. *Formation of intrauterine adhesions reducing cavity volume* - While the procedure can lead to **Asherman-like** scarring and reduced cavity volume, this is an anatomical outcome of the healing process. - The intended mechanism is specifically the **prevention of functional layer regrowth** by targeting the basalis layer during the energy application.

Q: A 29-year-old woman is being monitored for a right tubal ectopic pregnancy with expectant management. Her initial serum beta-hCG was 680 IU/L. She remains clinically stable with minimal pain. Repeat beta-hCG 48 hours later is 890 IU/L. What is the most appropriate next step in management?

Administer intramuscular methotrexate. ***Administer intramuscular methotrexate***- The **rising beta-hCG** (from 680 to 890 IU/L) indicates that **expectant management has failed**, as successful expectant management requires decreasing hCG levels.- **Methotrexate** is the treatment of choice in this stable patient because the hCG is below **1500–3000 IU/L** and there are no clinical signs of tubal rupture.*Continue expectant management with repeat beta-hCG in 48 hours*- This approach is only appropriate if **beta-hCG levels are declining**; a rise indicates the ectopic pregnancy is still actively developing.- Delaying intervention in the presence of rising levels increases the risk of **tubal rupture** and emergency surgery.*Arrange urgent laparoscopy*- Surgical intervention is generally reserved for patients who are **hemodynamically unstable**, have signs of rupture, or have very high beta-hCG levels.- As this patient is **clinically stable** and currently meets criteria for medical management, invasive surgery is not the primary next step.*Repeat transvaginal ultrasound to assess for intrauterine pregnancy*- The diagnosis of **ectopic pregnancy** has already been established; repeating the scan is unnecessary and delays definitive treatment.- Suboptimal hCG rises (less than 35% in 48 hours) are more consistent with an **extrauterine pregnancy** than a viable intrauterine one.*Commence oral misoprostol*- **Misoprostol** is used for the management of miscarriages (intrauterine pregnancies) to induce uterine contractions, but it has no role in treating an **ectopic pregnancy**.- Using misoprostol in this context would be ineffective and dangerous, as it would not resolve the **adnexal mass**.

Q: A 52-year-old woman presents with a 6-month history of irregular vaginal bleeding occurring approximately every 2-3 weeks. She also reports a single episode of postcoital bleeding 2 months ago. She has never had an abnormal cervical smear and her last smear 18 months ago was normal. On speculum examination, the cervix appears healthy with no visible lesions. Bimanual examination reveals a bulky uterus. What is the single most important initial investigation?

Colposcopy. ***Colposcopy*** - **Postcoital bleeding** is a red-flag symptom that mandates urgent exclusion of **cervical malignancy**, even if the cervix appears grossly normal on speculum examination. - While the patient has other symptoms, guidelines (such as **NICE**) prioritize direct visualization of the cervix via **colposcopy** to detect subtle lesions that a recent normal smear might have missed. *Cervical smear* - This patient had a normal smear only **18 months ago**, and a repeat smear is not the diagnostic gold standard for evaluating active symptoms like **postcoital bleeding**. - Screening tests have a known **false-negative rate**; therefore, symptomatic patients require diagnostic visualization rather than repeat screening. *Transvaginal ultrasound* - A TVS is excellent for evaluating the **endometrial thickness** and uterine size (addressing the bulky uterus), but it does not adequately assess the **cervix**. - While it might be performed later to investigate the irregular bleeding, it cannot rule out the primary concern of **cervical cancer**. *Hysteroscopy and endometrial biopsy* - This is the gold standard for investigating **endometrial pathology** in women over 45 with irregular bleeding or suspected hyperplasia. - However, it should follow or be secondary to the exclusion of **cervical pathology** when postcoital bleeding is present. *Pipelle endometrial sampling* - This is an office-based procedure used to sample the **endometrium** to rule out malignancy in the setting of irregular or heavy menstrual bleeding. - It does not address the **postcoital bleeding** component of the history, which specifically points toward the need for **cervical assessment**.

A 35-year-old woman with a 16-month history of heavy menstrual bleeding reports that her periods last 9 days and she passes large clots. She has tried tranexamic acid and mefenamic acid with minimal improvement. She has two children and does not wish for future pregnancy. Examination is normal and transvaginal ultrasound shows a normal uterus (8 cm length) with no fibroids and endometrial thickness of 6 mm on day 5 of cycle. Full blood count shows haemoglobin 101 g/L. She declines hormonal treatment. What is the most appropriate next management option?

A 26-year-old woman presents to the emergency department with sudden onset severe left-sided pelvic pain, nausea, and one episode of syncope 2 hours ago. She has 7 weeks amenorrhoea. On examination, she is alert with heart rate 102 bpm, blood pressure 104/68 mmHg, and temperature 36.8°C. Abdominal examination reveals left iliac fossa tenderness with mild guarding but no rigidity. Transvaginal ultrasound shows an empty uterus, a 35 mm left adnexal mass with a hyperechoic ring, and a small amount of free fluid in the pouch of Douglas. Serum beta-hCG is 5600 IU/L. What is the most appropriate management?

A 41-year-old woman with a 10-month history of heavy menstrual bleeding undergoes hysteroscopy which reveals a 3 cm type 2 submucosal fibroid partially extending into the myometrium (>50% intramural component). She wishes to preserve her fertility. Transvaginal ultrasound confirms no other significant fibroids and normal endometrial cavity. What is the most appropriate initial management?

A 31-year-old woman presents to the emergency department with left-sided pelvic pain and 7 weeks amenorrhoea. Transvaginal ultrasound demonstrates an empty uterus and a 20 mm left adnexal mass. Initial serum beta-hCG is 1450 IU/L. She is clinically stable. Repeat beta-hCG 48 hours later is 1380 IU/L. What is the most appropriate management?

What is the primary mechanism by which endometrial ablation reduces menstrual bleeding in women with heavy menstrual bleeding?

A 29-year-old woman is being monitored for a right tubal ectopic pregnancy with expectant management. Her initial serum beta-hCG was 680 IU/L. She remains clinically stable with minimal pain. Repeat beta-hCG 48 hours later is 890 IU/L. What is the most appropriate next step in management?

A 38-year-old multiparous woman with heavy menstrual bleeding has had a levonorgestrel intrauterine system in situ for 3 years. Initially, her bleeding improved significantly, but over the past 6 months, she has noticed gradually worsening menstrual bleeding returning to pre-treatment levels. She wishes to continue with hormonal management. Pelvic examination is normal. Transvaginal ultrasound shows the IUS in correct position with a normal uterine cavity and no fibroids. What is the most appropriate management?

A 34-year-old woman presents to the emergency department with sudden onset severe right-sided abdominal pain and syncope. She has 6 weeks amenorrhoea. On examination, she is pale with heart rate 118 bpm and blood pressure 88/54 mmHg. Abdominal examination reveals generalised tenderness with guarding. A bedside urine pregnancy test is positive. What is the most appropriate immediate management?

Q10

A 52-year-old woman presents with a 6-month history of irregular vaginal bleeding occurring approximately every 2-3 weeks. She also reports a single episode of postcoital bleeding 2 months ago. She has never had an abnormal cervical smear and her last smear 18 months ago was normal. On speculum examination, the cervix appears healthy with no visible lesions. Bimanual examination reveals a bulky uterus. What is the single most important initial investigation?

Gynaecology UK Medical PG Practice Questions and MCQs

Question 1: A 30-year-old woman presents with amenorrhea, hirsutism, and acne. She has gained 10kg over the past year. Ultrasound shows multiple ovarian cysts. Testosterone and LH are elevated, FSH is normal. What is the most likely diagnosis?

A. Congenital adrenal hyperplasia
B. Polycystic ovary syndrome (Correct Answer)
C. Ovarian tumor
D. Cushing's syndrome
E. Hypothyroidism

Explanation: ***Polycystic ovary syndrome***- Amenorrhea, hirsutism, acne, and weight gain are classic signs of **hyperandrogenism** and **anovulation** characteristic of PCOS.- The presence of **multiple ovarian cysts** on ultrasound combined with **elevated testosterone** and an **elevated LH** with normal FSH strongly points to PCOS. *Congenital adrenal hyperplasia*- Typically involves an enzyme deficiency (e.g., **21-hydroxylase deficiency**) leading to elevated adrenal androgens and often **abnormal cortisol precursors**.- While it can cause virilization, the hormonal profile would differ, usually showing very high **17-hydroxyprogesterone** and not primarily an elevated LH:FSH ratio characteristic of PCOS. *Ovarian tumor*- An **androgen-secreting ovarian tumor** would cause rapid onset and more severe virilization, often with significantly **higher testosterone levels**.- The ultrasound findings of **multiple small cysts** and the specific hormonal imbalance (elevated LH) are more consistent with PCOS than a single tumor. *Cushing's syndrome*- Caused by **excess cortisol**, leading to central obesity, striae, moon facies, and hyperglycemia.- While it can cause weight gain and menstrual irregularity, **hirsutism** and **acne** are less prominent, and the hormonal pattern (e.g., elevated cortisol, suppressed ACTH or pituitary adenoma) is different. *Hypothyroidism*- Symptoms include **fatigue**, **weight gain**, **cold intolerance**, and **bradycardia**, with menstrual irregularities often manifesting as menorrhagia or oligomenorrhea.- It does not cause **hirsutism** or **acne**, and the hormonal profile would show elevated TSH and low free T4, not elevated androgens or LH.

Question 2: A 35-year-old woman with a 16-month history of heavy menstrual bleeding reports that her periods last 9 days and she passes large clots. She has tried tranexamic acid and mefenamic acid with minimal improvement. She has two children and does not wish for future pregnancy. Examination is normal and transvaginal ultrasound shows a normal uterus (8 cm length) with no fibroids and endometrial thickness of 6 mm on day 5 of cycle. Full blood count shows haemoglobin 101 g/L. She declines hormonal treatment. What is the most appropriate next management option?

A. Offer endometrial ablation (Correct Answer)
B. Prescribe oral norethisterone for cycle regulation
C. Arrange hysterectomy
D. Increase dose of tranexamic acid and mefenamic acid
E. Offer trial of levonorgestrel intrauterine system despite preferences

Explanation: ***Offer endometrial ablation*** - **Endometrial ablation** is the appropriate next step for **heavy menstrual bleeding** when medical treatments have failed, a woman has completed her family, and has **declined hormonal therapy**. - This patient meets all criteria: failed medical treatment, completed family, declined hormones, has a **normal uterus** (8 cm length), and her **anemia** (Hb 101 g/L) necessitates effective management. *Prescribe oral norethisterone for cycle regulation* - The patient has explicitly **declined hormonal treatment**, rendering this option unsuitable based on her preferences. - **Oral norethisterone** is a hormonal agent and may not be sufficiently effective for severe **heavy menstrual bleeding** that has not responded to other medical therapies. *Arrange hysterectomy* - While **hysterectomy** offers a definitive cure for heavy menstrual bleeding, it is a **major surgical procedure** and typically considered a last resort after less invasive options. - For a woman with a **structurally normal uterus** and no contraindications, **endometrial ablation** is generally preferred as a less invasive surgical alternative before considering hysterectomy. *Increase dose of tranexamic acid and mefenamic acid* - The patient has already reported **minimal improvement** with these medications, suggesting that simply increasing their dose is unlikely to achieve adequate control of her **heavy menstrual bleeding**. - Her persistent symptoms and **anemia** indicate a need for a more effective intervention beyond dose adjustment of previously ineffective symptomatic treatments. *Offer trial of levonorgestrel intrauterine system despite preferences* - The **levonorgestrel intrauterine system (IUS)** is a **hormonal treatment**, which the patient has specifically **declined**. - Offering a treatment despite a patient's clear refusal disregards **patient autonomy** and established shared decision-making principles.

Question 3: A 26-year-old woman presents to the emergency department with sudden onset severe left-sided pelvic pain, nausea, and one episode of syncope 2 hours ago. She has 7 weeks amenorrhoea. On examination, she is alert with heart rate 102 bpm, blood pressure 104/68 mmHg, and temperature 36.8°C. Abdominal examination reveals left iliac fossa tenderness with mild guarding but no rigidity. Transvaginal ultrasound shows an empty uterus, a 35 mm left adnexal mass with a hyperechoic ring, and a small amount of free fluid in the pouch of Douglas. Serum beta-hCG is 5600 IU/L. What is the most appropriate management?

A. Emergency laparoscopy
B. Intramuscular methotrexate
C. Admit for observation with 4-hourly observations and repeat ultrasound in 24 hours
D. Diagnostic laparoscopy with decision for salpingectomy or salpingotomy at surgery (Correct Answer)
E. Arrange urgent MRI pelvis to better characterise the adnexal mass

Explanation: ***Diagnostic laparoscopy with decision for salpingectomy or salpingotomy at surgery***- The patient's symptoms including **syncope**, severe left-sided pelvic pain, tachycardia (HR 102 bpm), and ultrasound findings of an **empty uterus**, **35 mm adnexal mass**, and **free fluid** in the pouch of Douglas are highly indicative of a ruptured or actively bleeding ectopic pregnancy, requiring immediate surgical intervention.- Surgical management via **laparoscopy** is the most appropriate approach, allowing for direct confirmation of the ectopic, assessment of blood loss, and definitive treatment, either **salpingectomy** for extensive damage or **salpingotomy** for tubal preservation where feasible, considering the high beta-hCG of 5600 IU/L which also contraindicates medical management.*Emergency laparoscopy*- While surgery is urgently indicated,

Question 4: A 41-year-old woman with a 10-month history of heavy menstrual bleeding undergoes hysteroscopy which reveals a 3 cm type 2 submucosal fibroid partially extending into the myometrium (>50% intramural component). She wishes to preserve her fertility. Transvaginal ultrasound confirms no other significant fibroids and normal endometrial cavity. What is the most appropriate initial management?

A. Hysteroscopic myomectomy
B. Trial of levonorgestrel intrauterine system
C. Uterine artery embolisation
D. Abdominal myomectomy (Correct Answer)
E. GnRH agonist therapy for 6 months

Explanation: ***Abdominal myomectomy***- A **type 2 submucosal fibroid** with **>50% intramural component** makes hysteroscopic removal technically challenging, increasing the risk of **incomplete resection** or **uterine perforation**.- Given the patient's desire for **fertility preservation**, an open or laparoscopic **abdominal myomectomy** allows for complete removal of the fibroid and meticulous **myometrial reconstruction**, which is crucial for subsequent pregnancies.*Hysteroscopic myomectomy*- This technique is primarily suitable for **type 0 and 1 fibroids**, which are largely or entirely within the uterine cavity.- For a **type 2 fibroid** with a substantial intramural component, hysteroscopic removal is often difficult, risks **uterine injury**, and may require multiple procedures for complete resection.*Trial of levonorgestrel intrauterine system*- The **levonorgestrel intrauterine system (LNG-IUS)** has reduced efficacy and higher rates of **expulsion** in the presence of **submucosal fibroids**.- It does not address the underlying anatomical distortion of the **endometrial cavity** caused by a 3 cm fibroid, which can hinder fertility.*Uterine artery embolisation*- **Uterine artery embolisation (UAE)** is generally not recommended for women who desire **future fertility** due to potential risks to **ovarian reserve** and increased complications like **placental abnormalities** in subsequent pregnancies.- **Myomectomy** remains the preferred surgical option for fertility preservation.*GnRH agonist therapy for 6 months*- **GnRH agonists** are typically used as a short-term **pre-operative adjunct** to reduce fibroid size and improve anemia, making surgery easier, rather than as a definitive treatment.- Fibroids commonly **regrow** after cessation of therapy, and long-term use is limited by side effects such as **bone mineral density loss** and vasomotor symptoms.

Question 5: A 31-year-old woman presents to the emergency department with left-sided pelvic pain and 7 weeks amenorrhoea. Transvaginal ultrasound demonstrates an empty uterus and a 20 mm left adnexal mass. Initial serum beta-hCG is 1450 IU/L. She is clinically stable. Repeat beta-hCG 48 hours later is 1380 IU/L. What is the most appropriate management?

A. Expectant management with weekly beta-hCG monitoring (Correct Answer)
B. Intramuscular methotrexate
C. Diagnostic laparoscopy
D. Repeat beta-hCG in 48 hours to confirm declining trend
E. Arrange MRI pelvis to confirm ectopic location

Explanation: ***Expectant management with weekly beta-hCG monitoring*** - This patient is **clinically stable** with a small **adnexal mass (<35 mm)** and a **declining beta-hCG** (from 1450 to 1380 IU/L), indicating a spontaneously resolving tubal ectopic pregnancy. - **Expectant management** is appropriate when initial beta-hCG levels are low (<2000 IU/L) and declining, requiring weekly monitoring until levels fall below **20 IU/L**. *Intramuscular methotrexate* - **Methotrexate** is a medical management option typically reserved for patients whose beta-hCG levels are **rising or plateauing** rather than declining. - It carries risks of side effects like **hepatotoxicity** and **stomatitis**, which are unnecessary to risk if the ectopic is already resolving on its own. *Diagnostic laparoscopy* - This is an **invasive surgical procedure** indicated for patients who are **hemodynamically unstable**, have severe pain, or have a high risk of rupture. - Given the patient's **clinical stability** and resolving biochemical markers, surgery presents an unnecessary risk of **anesthesia and operative complications**. *Repeat beta-hCG in 48 hours to confirm declining trend* - A 48-hour repeat is used to establish the **initial trend**; once the decline is confirmed (as seen here from 1450 to 1380 IU/L), the protocol shifts to **weekly follow-ups**. - Frequent 48-hour monitoring beyond the initial diagnostic phase is not required for a patient who remains **asymptomatic** and stable. *Arrange MRI pelvis to confirm ectopic location* - **Transvaginal ultrasound (TVUS)** is the gold standard for diagnosing ectopic pregnancy; the presence of an empty uterus and an **adnexal mass** is sufficient for diagnosis. - **MRI** is expensive, time-consuming, and adds no clinical value to the management of a **stable, resolving** ectopic pregnancy.

Question 6: What is the primary mechanism by which endometrial ablation reduces menstrual bleeding in women with heavy menstrual bleeding?

A. Destruction of the endometrial basalis layer preventing regeneration (Correct Answer)
B. Reduction in endometrial blood vessel density through thermal injury
C. Decreased prostaglandin production from damaged endometrium
D. Hormonal suppression of endometrial proliferation
E. Formation of intrauterine adhesions reducing cavity volume

Explanation: ***Destruction of the endometrial basalis layer preventing regeneration*** - Endometrial ablation targets the **basalis layer**, which is the deep regenerative layer responsible for the monthly growth of the functionalis layer. - By destroying this layer through thermal or other energy sources, the **endometrium cannot regrow**, leading to significant reduction or total cessation of menstrual flow. *Reduction in endometrial blood vessel density through thermal injury* - While **thermal injury** does cauterize local vessels, this is a secondary effect rather than the primary goal of the procedure. - Menstrual reduction is achieved primarily by removing the **source tissue** of bleeding rather than just reducing blood supply. *Decreased prostaglandin production from damaged endometrium* - **Prostaglandins** play a role in dysmenorrhea and heavy bleeding, and their levels may decrease after ablation due to tissue loss. - This decrease is a **consequence** of removing the endometrial tissue, not the fundamental mechanism of action of the procedure. *Hormonal suppression of endometrial proliferation* - Endometrial ablation is a **physical/surgical destruction** of tissue and does not involve the use of exogenous hormones. - Unlike medical therapies like the **Levonorgestrel IUS**, it does not alter the underlying **hypothalamic-pituitary-ovarian axis**. *Formation of intrauterine adhesions reducing cavity volume* - While the procedure can lead to **Asherman-like** scarring and reduced cavity volume, this is an anatomical outcome of the healing process. - The intended mechanism is specifically the **prevention of functional layer regrowth** by targeting the basalis layer during the energy application.

Question 7: A 29-year-old woman is being monitored for a right tubal ectopic pregnancy with expectant management. Her initial serum beta-hCG was 680 IU/L. She remains clinically stable with minimal pain. Repeat beta-hCG 48 hours later is 890 IU/L. What is the most appropriate next step in management?

A. Continue expectant management with repeat beta-hCG in 48 hours
B. Administer intramuscular methotrexate (Correct Answer)
C. Arrange urgent laparoscopy
D. Repeat transvaginal ultrasound to assess for intrauterine pregnancy
E. Commence oral misoprostol

Explanation: ***Administer intramuscular methotrexate***- The **rising beta-hCG** (from 680 to 890 IU/L) indicates that **expectant management has failed**, as successful expectant management requires decreasing hCG levels.- **Methotrexate** is the treatment of choice in this stable patient because the hCG is below **1500–3000 IU/L** and there are no clinical signs of tubal rupture.*Continue expectant management with repeat beta-hCG in 48 hours*- This approach is only appropriate if **beta-hCG levels are declining**; a rise indicates the ectopic pregnancy is still actively developing.- Delaying intervention in the presence of rising levels increases the risk of **tubal rupture** and emergency surgery.*Arrange urgent laparoscopy*- Surgical intervention is generally reserved for patients who are **hemodynamically unstable**, have signs of rupture, or have very high beta-hCG levels.- As this patient is **clinically stable** and currently meets criteria for medical management, invasive surgery is not the primary next step.*Repeat transvaginal ultrasound to assess for intrauterine pregnancy*- The diagnosis of **ectopic pregnancy** has already been established; repeating the scan is unnecessary and delays definitive treatment.- Suboptimal hCG rises (less than 35% in 48 hours) are more consistent with an **extrauterine pregnancy** than a viable intrauterine one.*Commence oral misoprostol*- **Misoprostol** is used for the management of miscarriages (intrauterine pregnancies) to induce uterine contractions, but it has no role in treating an **ectopic pregnancy**.- Using misoprostol in this context would be ineffective and dangerous, as it would not resolve the **adnexal mass**.

Question 8: A 38-year-old multiparous woman with heavy menstrual bleeding has had a levonorgestrel intrauterine system in situ for 3 years. Initially, her bleeding improved significantly, but over the past 6 months, she has noticed gradually worsening menstrual bleeding returning to pre-treatment levels. She wishes to continue with hormonal management. Pelvic examination is normal. Transvaginal ultrasound shows the IUS in correct position with a normal uterine cavity and no fibroids. What is the most appropriate management?

A. Remove and replace the levonorgestrel intrauterine system (Correct Answer)
B. Add tranexamic acid during menstruation
C. Switch to combined oral contraceptive pill
D. Arrange endometrial ablation
E. Continue current IUS for remaining 2 years of licensed duration

Explanation: ***Remove and replace the levonorgestrel intrauterine system***- The **LNG-IUS** efficacy for managing **heavy menstrual bleeding** can decline before its 5-year expiration due to the gradual reduction in daily **progesterone release**.- Since the device is correctly positioned, previously effective, and the patient wishes to continue hormonal management, **early replacement** is the most appropriate step to restore the local hormonal suppressive effect on the **endometrium**.*Add tranexamic acid during menstruation*- While **tranexamic acid** is an effective non-hormonal treatment for heavy menstrual bleeding, it does not address the underlying issue of **waning hormonal levels** from the IUS.- The patient specifically prefers to continue with **hormonal management**, making replacement of the primary hormonal device more suitable than adding a non-hormonal adjunct.*Switch to combined oral contraceptive pill*- The **combined oral contraceptive pill (COCP)** requires daily compliance and has a higher risk of **systemic side-effects** compared to the localized action of the LNG-IUS.- The LNG-IUS is generally considered more effective than the COCP for reducing menstrual blood loss, and the patient had good control with it initially, indicating it's still the preferred hormonal method.*Arrange endometrial ablation*- **Endometrial ablation** is a surgical intervention for heavy menstrual bleeding, typically reserved for women who have completed childbearing and either do not desire or have failed medical/hormonal management.- This patient explicitly requested to continue with **hormonal management**, making a less invasive and reversible option like IUS replacement more appropriate at this stage.*Continue current IUS for remaining 2 years of licensed duration*- Waiting for the full 5-year licensed duration is inappropriate when the **clinical efficacy has clearly diminished** and the patient's symptoms have returned to **pre-treatment levels**.- Prolonging an ineffective treatment can lead to persistent **heavy menstrual bleeding**, potential **iron-deficiency anemia**, and reduced quality of life.

Question 9: A 34-year-old woman presents to the emergency department with sudden onset severe right-sided abdominal pain and syncope. She has 6 weeks amenorrhoea. On examination, she is pale with heart rate 118 bpm and blood pressure 88/54 mmHg. Abdominal examination reveals generalised tenderness with guarding. A bedside urine pregnancy test is positive. What is the most appropriate immediate management?

A. Insert two large-bore intravenous cannulae, cross-match 4 units blood, commence fluid resuscitation, and arrange emergency laparoscopy (Correct Answer)
B. Perform urgent transvaginal ultrasound to confirm diagnosis before proceeding to theatre
C. Administer intramuscular methotrexate and commence fluid resuscitation
D. Request urgent serum beta-hCG and proceed to laparoscopy only if levels are above 1500 IU/L
E. Arrange CT abdomen and pelvis with contrast to localise the ectopic pregnancy

Explanation: ***Insert two large-bore intravenous cannulae, cross-match 4 units blood, commence fluid resuscitation, and arrange emergency laparoscopy*** - The patient presents with classic signs of a **ruptured ectopic pregnancy** and **haemorrhagic shock** (hypotension, tachycardia, and peritonism), requiring immediate **hemostasis** and **volume replacement**. - Priority management involves the **ABCDE approach**, stabilizing the patient with fluids while simultaneously preparing for **emergency surgical intervention** (laparoscopy or laparotomy). *Perform urgent transvaginal ultrasound to confirm diagnosis before proceeding to theatre* - Clinical diagnosis of a ruptured ectopic is evident; delaying definitive surgery for imaging in an **unstable patient** increases the risk of mortality. - **Transvaginal ultrasound** is useful in stable patients (PUL) but should not postpone life-saving surgery when **haemoperitoneum** is clinically suspected. *Administer intramuscular methotrexate and commence fluid resuscitation* - **Methotrexate** is strictly contraindicated in patients who are **haemodynamically unstable** or have evidence of tubal rupture. - Medical management with methotrexate is only suitable for small, unruptured ectopics in stable patients with lower **beta-hCG** levels. *Request urgent serum beta-hCG and proceed to laparoscopy only if levels are above 1500 IU/L* - Routine monitoring of the **discriminatory zone** (1500-2000 IU/L) is irrelevant in the presence of acute **peritonitis** and shock. - Waiting for laboratory results is a dangerous delay; a **positive urine pregnancy test** combined with clinical instability is sufficient to mandate surgery. *Arrange CT abdomen and pelvis with contrast to localise the ectopic pregnancy* - **CT scanning** is not the standard of care for diagnosing ectopic pregnancy and involves unnecessary **radiation** and time delay. - Diagnosis is primarily clinical and sonographic; in emergency settings, surgery serves as both the **definitive diagnosis** and treatment.

Question 10: A 52-year-old woman presents with a 6-month history of irregular vaginal bleeding occurring approximately every 2-3 weeks. She also reports a single episode of postcoital bleeding 2 months ago. She has never had an abnormal cervical smear and her last smear 18 months ago was normal. On speculum examination, the cervix appears healthy with no visible lesions. Bimanual examination reveals a bulky uterus. What is the single most important initial investigation?

A. Cervical smear
B. Transvaginal ultrasound
C. Colposcopy (Correct Answer)
D. Hysteroscopy and endometrial biopsy
E. Pipelle endometrial sampling

Explanation: ***Colposcopy*** - **Postcoital bleeding** is a red-flag symptom that mandates urgent exclusion of **cervical malignancy**, even if the cervix appears grossly normal on speculum examination. - While the patient has other symptoms, guidelines (such as **NICE**) prioritize direct visualization of the cervix via **colposcopy** to detect subtle lesions that a recent normal smear might have missed. *Cervical smear* - This patient had a normal smear only **18 months ago**, and a repeat smear is not the diagnostic gold standard for evaluating active symptoms like **postcoital bleeding**. - Screening tests have a known **false-negative rate**; therefore, symptomatic patients require diagnostic visualization rather than repeat screening. *Transvaginal ultrasound* - A TVS is excellent for evaluating the **endometrial thickness** and uterine size (addressing the bulky uterus), but it does not adequately assess the **cervix**. - While it might be performed later to investigate the irregular bleeding, it cannot rule out the primary concern of **cervical cancer**. *Hysteroscopy and endometrial biopsy* - This is the gold standard for investigating **endometrial pathology** in women over 45 with irregular bleeding or suspected hyperplasia. - However, it should follow or be secondary to the exclusion of **cervical pathology** when postcoital bleeding is present. *Pipelle endometrial sampling* - This is an office-based procedure used to sample the **endometrium** to rule out malignancy in the setting of irregular or heavy menstrual bleeding. - It does not address the **postcoital bleeding** component of the history, which specifically points toward the need for **cervical assessment**.

Question 11: A 27-year-old nulliparous woman undergoes laparoscopy for suspected ectopic pregnancy. She has 7 weeks amenorrhoea with beta-hCG of 4800 IU/L. At surgery, a 4 cm ampullary ectopic pregnancy is identified in the left fallopian tube with no evidence of rupture. The tube is distended but appears viable. The right fallopian tube appears normal. Bilateral ovaries are normal. What is the most appropriate surgical management?

A. Left salpingectomy (Correct Answer)
B. Left salpingotomy
C. Milking the ectopic pregnancy from the fimbrial end
D. Left salpingo-oophorectomy
E. Bilateral salpingectomy

Explanation: ***Left salpingectomy*** - **Salpingectomy** is recommended for larger ectopic pregnancies (such as 4 cm) or when conservative management carries a higher risk of **persistent trophoblastic tissue**, especially with a **healthy contralateral tube**. - This definitive treatment effectively prevents **persistent trophoblastic disease** and recurrence in the affected tube, without significantly compromising future fertility when the other tube is normal. *Left salpingotomy* - This procedure is generally reserved for **smaller ectopic pregnancies** (typically <3.5 cm) or when the contralateral tube is compromised to preserve potential fertility. - It carries a significant risk of **persistent trophoblastic disease** (requiring further intervention) and recurrence in the same tube, which is higher with a 4 cm ectopic. *Milking the ectopic pregnancy from the fimbrial end* - This technique is largely considered outdated due to a very high incidence of **incomplete evacuation** and **persistent trophoblastic disease**. - It also risks causing **tubal trauma** and significant bleeding from the implantation site, making it a less preferred surgical option. *Left salpingo-oophorectomy* - This is an overly invasive procedure as the **ovaries** are described as normal and not involved in the ectopic pregnancy pathology. - Preserving **ovarian function and reserve** is crucial, especially in a young, nulliparous woman, making oophorectomy unwarranted. *Bilateral salpingectomy* - This management is inappropriate because the **right fallopian tube** is healthy and appears normal during laparoscopic inspection. - Performing a bilateral procedure would lead to **permanent infertility**, requiring assisted reproductive technologies for any future conception.

Question 12: A 46-year-old woman attends the gynaecology clinic with a 14-month history of increasingly heavy and irregular menstrual bleeding. Her periods occur every 18-45 days and last 7-10 days. She reports no intermenstrual or postcoital bleeding. Abdominal examination is unremarkable. Transvaginal ultrasound shows a normal-sized uterus with endometrial thickness of 18 mm. Both ovaries appear normal with multiple small follicles. What is the most appropriate next investigation?

A. Hysteroscopy and endometrial biopsy (Correct Answer)
B. Serum follicle-stimulating hormone and luteinising hormone
C. Pelvic MRI scan
D. Repeat ultrasound in early proliferative phase
E. Serum cancer antigen 125

Explanation: ***Hysteroscopy and endometrial biopsy*** - In women over **45 years old** presenting with **abnormal uterine bleeding (AUB)**, particularly with heavy or irregular periods, endometrial sampling is essential to rule out **endometrial hyperplasia** or **malignancy**. - An **endometrial thickness of 18 mm** is significantly increased, necessitating direct visualization via hysteroscopy and tissue biopsy for definitive histological diagnosis. *Serum follicle-stimulating hormone and luteinising hormone* - While **FSH/LH levels** might indicate a **perimenopausal** state, they do not provide information regarding potential structural pathology or malignancy. - Hormonal testing is generally not the primary investigation for AUB in women over 45, where excluding endometrial pathology takes precedence. *Pelvic MRI scan* - **MRI** is not a first-line diagnostic tool for investigating heavy menstrual bleeding and is typically reserved for complex cases or surgical planning for conditions like **adenomyosis** or large fibroids. - Crucially, an MRI cannot provide a **histological diagnosis**, which is the gold standard for evaluating a thickened endometrium. *Repeat ultrasound in early proliferative phase* - Delaying further investigation, particularly in a 46-year-old woman with an **endometrial thickness of 18 mm**, is inappropriate and could delay the diagnosis of a serious condition. - Even if a repeat scan showed a thinner endometrium, it would not negate the need for **histological confirmation** given her symptoms and initial ultrasound findings. *Serum cancer antigen 125* - **CA125** is primarily a tumour marker for **ovarian malignancy** and is not indicated as a first-line investigation for abnormal uterine bleeding when ovaries appear normal on ultrasound. - This test lacks the necessary specificity for **endometrial pathologies** and can be elevated in various benign gynecological and non-gynecological conditions.

Question 13: A 30-year-old woman presents to the emergency department with 5 weeks amenorrhoea, right-sided pelvic pain, and minimal vaginal spotting. She is haemodynamically stable. Transvaginal ultrasound shows an empty uterus with endometrial thickness of 8 mm. A 25 mm adnexal mass with a hyperechoic ring is identified adjacent to the right ovary. There is no free fluid in the pouch of Douglas. Serum beta-hCG is 2200 IU/L. What is the most appropriate initial management?

A. Emergency laparoscopy
B. Repeat beta-hCG in 48 hours
C. Intramuscular methotrexate (Correct Answer)
D. Diagnostic laparoscopy
E. Expectant management with weekly beta-hCG monitoring

Explanation: ***Intramuscular methotrexate***- This patient meets the criteria for medical management of an ectopic pregnancy: she is **haemodynamically stable**, the **serum beta-hCG is 2200 IU/L** (below the typical threshold for surgical intervention), and the **adnexal mass measures 25 mm** (less than 3.5-4 cm).- The absence of **fetal cardiac activity** (implied as not mentioned) and **free fluid** in the pouch of Douglas further supports the use of methotrexate to dissolve the pregnancy.*Emergency laparoscopy*- This intervention is reserved for patients presenting with signs of **haemodynamic instability**, such as shock, or features strongly suggestive of **ectopic rupture** (e.g., severe abdominal pain, significant hemoperitoneum).- The patient is explicitly described as **haemodynamically stable** with only minimal vaginal spotting and no free fluid, thus an emergency procedure is not warranted.*Repeat beta-hCG in 48 hours*- Serial **beta-hCG monitoring** is primarily used in cases of **pregnancy of unknown location (PUL)**, where an intrauterine or extrauterine pregnancy cannot be definitively visualized on ultrasound.- In this patient, a clear **adnexal mass with a hyperechoic ring** (suggestive of an ectopic sac) has been identified adjacent to the right ovary, confirming the diagnosis, making further diagnostic delay unnecessary.*Diagnostic laparoscopy*- While laparoscopy can be diagnostic, in this case, the **transvaginal ultrasound** findings (empty uterus, adnexal mass with hyperechoic ring) combined with the **beta-hCG level** are highly suggestive of an ectopic pregnancy.- Given that medical management is an option, a **less invasive treatment** is preferred over surgical diagnosis when the criteria for methotrexate are met.*Expectant management with weekly beta-hCG monitoring*- **Expectant management** is typically considered for very early ectopic pregnancies with **low and declining serum beta-hCG levels** (usually <1000-1500 IU/L) and no visible ectopic mass, or a very small, asymptomatic one.- A **beta-hCG level of 2200 IU/L** carries a significant risk of progression and potential rupture if left untreated, making active intervention (medical or surgical) necessary.

Question 14: A 43-year-old woman presents with a 5-month history of heavy menstrual bleeding. She reports passing clots larger than a £1 coin and changing pads every 2 hours during the first 3 days of menstruation. Her menstrual cycle is regular at 28 days. She has completed her family and wishes to explore permanent treatment options. Blood tests show haemoglobin 95 g/L, ferritin 8 μg/L. Transvaginal ultrasound reveals a uniformly enlarged uterus measuring 14 cm in length with heterogeneous myometrium and no discrete masses. What is the most appropriate definitive surgical management?

A. Total abdominal hysterectomy (Correct Answer)
B. Uterine artery embolisation
C. Endometrial ablation
D. Myomectomy
E. Hysteroscopic resection of endometrium

Explanation: ***Total abdominal hysterectomy***- The patient's clinical presentation of severe heavy menstrual bleeding and iron deficiency anemia, combined with ultrasound findings of a **uniformly enlarged uterus** and **heterogeneous myometrium** with **no discrete masses**, are highly suggestive of **adenomyosis**.- As the patient has **completed her family** and desires **definitive surgical management** for her severe symptoms, hysterectomy is the **gold standard treatment** and offers a permanent cure. *Uterine artery embolisation*- This is primarily indicated for **uterine fibroids** and, while sometimes used for adenomyosis, it has **lower success rates** and a higher risk of recurrence compared to hysterectomy for this condition.- It is generally considered a **fertility-sparing** or **uterine-sparing** option, which does not align with the patient's request for a permanent, definitive solution after completing her family.*Endometrial ablation*- This procedure aims to destroy the **endometrial lining** and is largely ineffective for **adenomyosis**, as the pathology involves ectopic endometrial tissue deep within the **myometrium**.- A significantly **enlarged uterus** (14 cm) is often a **contraindication** or predictor of high failure rates for endometrial ablation due to the diffuse nature of the disease.*Myomectomy*- Myomectomy is the surgical removal of **uterine fibroids (leiomyomas)**.- The ultrasound explicitly states **"no discrete masses,"** ruling out fibroids as the cause of her symptoms, making myomectomy an inappropriate treatment.*Hysteroscopic resection of endometrium*- Similar to endometrial ablation, this technique focuses on removing the **superficial layers** of the endometrium.- It does not address the underlying **myometrial involvement** characteristic of adenomyosis and is not considered a **definitive permanent treatment** for a significantly enlarged, adenomyotic uterus.

Question 15: A 29-year-old woman undergoes emergency laparoscopy for suspected ruptured ectopic pregnancy. During the procedure, a ruptured left tubal ectopic pregnancy is confirmed with 800 mL of haemoperitoneum. The right fallopian tube appears normal with no evidence of adhesions. The left tube has a 2 cm rupture site with active bleeding. She has had no previous pregnancies and wishes to preserve fertility. What is the single most important factor that should guide the surgical management of the affected tube?

A. The presence of a healthy contralateral fallopian tube (Correct Answer)
B. The size of the rupture site in the affected tube
C. The volume of haemoperitoneum present
D. The patient's desire for future fertility
E. The location of the ectopic pregnancy within the tube

Explanation: ***The presence of a healthy contralateral fallopian tube***- In the management of **ruptured ectopic pregnancy**, **salpingectomy** (removal of the tube) is preferred over **salpingotomy** (incision to remove the pregnancy) if the **contralateral tube** is healthy.- This approach minimizes the risk of **persistent trophoblastic disease** and subsequent **recurrent ectopic pregnancy**, with comparable rates of **future intrauterine pregnancy** for nulliparous patients.*The size of the rupture site in the affected tube*- While the rupture size indicates tubal damage, the primary decision between **salpingectomy** and **salpingotomy** is based on the status of the **contralateral tube**, not solely the rupture's dimensions.- A **ruptured tube** often requires **salpingectomy** regardless of the precise rupture size due to extensive damage and difficulty in achieving hemostasis with tubal preservation.*The volume of haemoperitoneum present*- The **volume of haemoperitoneum** primarily indicates the patient's **hemodynamic stability** and the urgency of intervention, but it does not dictate the choice of tubal management (salpingectomy vs. salpingotomy).- Even with significant **haemoperitoneum**, **laparoscopic salpingectomy** remains the standard for tubal ectopic pregnancy if the patient is stable enough for the procedure.*The patient's desire for future fertility*- While **fertility preservation** is a key consideration, evidence shows that performing a **salpingectomy** on a ruptured tube when a **healthy contralateral tube** is present does not diminish future **fertility outcomes**.- Attempting **salpingotomy** in a ruptured tube, especially when the other tube is healthy, significantly increases the risk of **persistent trophoblastic disease** (15-20%) without improving subsequent pregnancy rates.*The location of the ectopic pregnancy within the tube*- The specific **tubal location** (e.g., ampullary, isthmic) can influence the technical ease of a **salpingotomy**, but it is not the primary factor guiding the choice between **salpingectomy** and **salpingotomy**.- In a **ruptured ectopic pregnancy**, particularly with a healthy contralateral tube, **salpingectomy** is generally recommended irrespective of the exact location within the affected tube.

Question 16: A 25-year-old woman with known polycystic ovary syndrome presents with irregular bleeding over the past 8 months. She has had three periods in this time, each lasting 10-14 days with moderate to heavy flow. Her body mass index is 32 kg/m². She is not currently sexually active and does not wish to conceive. Pelvic examination is normal. What is the most important initial investigation to guide management?

A. Transvaginal ultrasound and endometrial sampling (Correct Answer)
B. Serum follicle-stimulating hormone and luteinizing hormone
C. Serum testosterone and sex hormone-binding globulin
D. Oral glucose tolerance test and fasting lipids
E. Full blood count and ferritin

Explanation: ***Transvaginal ultrasound and endometrial sampling*** - In a patient with **PCOS**, obesity, and **oligomenorrhea** (fewer than 4 periods in 6 months), there is a significant risk of **endometrial hyperplasia** or cancer due to **unopposed estrogen**. - **Endometrial sampling** is the crucial diagnostic step to rule out malignancy and guide management for abnormal uterine bleeding in high-risk patients. *Serum follicle-stimulating hormone and luteinizing hormone* - While the **LH:FSH ratio** is often elevated in PCOS, these levels do not help manage the immediate risk of **endometrial pathology**. - Measurement of these hormones is more useful for diagnosing **menopause** or primary ovarian insufficiency rather than acute bleeding management. *Serum testosterone and sex hormone-binding globulin* - These tests assess **biochemical hyperandrogenism** to confirm a PCOS diagnosis but are not indicated for investigating **prolonged irregular bleeding**. - They provide information on the cause of hirsutism or acne but do not evaluate the status of the **endometrium**. *Oral glucose tolerance test and fasting lipids* - These are important for screening **metabolic syndrome** and diabetes risk in PCOS patients but are not the priority during **acute abnormal bleeding**. - Metabolic screening is part of long-term care and does not address the risk of **endometrial carcinoma**. *Full blood count and ferritin* - These tests assess for **iron deficiency anemia** resulting from heavy flow but do not identify the **underlying cause** of the bleeding. - While supportive, they are secondary to the **histological assessment** required to exclude precancerous changes in the uterus.

Question 17: A 41-year-old woman with heavy menstrual bleeding is found to have a 4 cm submucous fibroid on transvaginal ultrasound. She wishes to retain her uterus and avoid hormonal treatments due to a history of hormone-sensitive breast cancer 3 years ago. Her haemoglobin is 94 g/L. What is the most appropriate management option?

A. Hysteroscopic myomectomy (Correct Answer)
B. Uterine artery embolization
C. Levonorgestrel intrauterine system
D. Abdominal myomectomy
E. Combined oral contraceptive pill

Explanation: ***Hysteroscopic myomectomy***- This is the first-line surgical treatment for **submucous fibroids** (typically up to 4-5 cm) as it is minimally invasive and allows for **uterine preservation**.- It is the most appropriate choice here because it provides a **non-hormonal** definitive treatment for the specific fibroid causing her anemia and heavy bleeding, avoiding risks associated with her **breast cancer history**.*Uterine artery embolization*- While it allows for uterine preservation, it is generally reserved for **multiple intramural fibroids** rather than a single accessible submucous lesion.- There is a small risk of **premature ovarian failure**, and in this case, direct surgical removal of the submucous fibroid is more targeted.*Levonorgestrel intrauterine system*- Although effective for heavy menstrual bleeding, the use of **progestogen-releasing devices** is generally avoided or used with extreme caution in patients with a history of **hormone-sensitive breast cancer**.- It may not be as effective in the presence of a 4 cm **submucous fibroid**, which can distort the uterine cavity and lead to higher **expulsion rates**.*Abdominal myomectomy*- This procedure involves a much higher surgical morbidity, including a larger incision and a longer **recovery time**, compared to the hysteroscopic route.- It is typically reserved for **subserosal or intramural fibroids** that are too large or poorly positioned for hysteroscopic or laparoscopic approaches.*Combined oral contraceptive pill*- This is **absolutely contraindicated** in this patient due to her recent history of **hormone-sensitive breast cancer**, which carries a high risk of recurrence with exogenous estrogen.- Medical management with hormones does not address the **mechanical cause** of bleeding (the fibroid) as effectively as surgical removal in this scenario.

Question 18: A 30-year-old woman presents with 6 weeks amenorrhoea and mild left-sided pelvic discomfort. Her pregnancy test is positive. Transvaginal ultrasound shows an empty uterus with endometrial thickness of 9 mm. No adnexal masses are seen and there is no free fluid. Her serum beta-hCG is 1250 IU/L. She is haemodynamically stable. A repeat beta-hCG 48 hours later is 2780 IU/L. What is the most appropriate management?

A. Arrange repeat transvaginal ultrasound scan in 7-10 days (Correct Answer)
B. Administer intramuscular methotrexate
C. Proceed to diagnostic laparoscopy
D. Arrange suction evacuation of retained products of conception
E. Commence expectant management with weekly beta-hCG monitoring

Explanation: ***Arrange repeat transvaginal ultrasound scan in 7-10 days***- The **beta-hCG rise** from 1250 IU/L to 2780 IU/L over 48 hours represents a 122.4% increase, which is highly suggestive of a **viable intrauterine pregnancy** as it exceeds the minimum expected rise of 63%.- At an initial hCG of 1250 IU/L, an intrauterine gestational sac is often not visible (below the **discriminatory zone** of 1500-2000 IU/L). A repeat scan in **7-10 days** allows the hCG to rise sufficiently for definitive visualization of an intrauterine pregnancy.*Administer intramuscular methotrexate*- **Methotrexate** is indicated for confirmed or highly suspected **stable ectopic pregnancies** without evidence of intrauterine viability.- Administering methotrexate in a case with **appropriately rising hCG** and no clear ectopic signs would be inappropriate, as it could harm a potentially healthy intrauterine pregnancy.*Proceed to diagnostic laparoscopy*- **Diagnostic laparoscopy** is an invasive surgical procedure typically reserved for **haemodynamically unstable** patients or those with strong ultrasound evidence of an ectopic pregnancy requiring immediate intervention.- This patient is **haemodynamically stable**, has no adnexal masses or free fluid on ultrasound, and exhibits an appropriate hCG rise, making an invasive procedure premature.*Arrange suction evacuation of retained products of conception*- **Suction evacuation** is performed for management of **miscarriage** or retained products of conception; it is not indicated for a potentially viable pregnancy.- Given the **normal rise in beta-hCG**, this procedure would result in an iatrogenic **termination** of what is likely a normal developing pregnancy.*Commence expectant management with weekly beta-hCG monitoring*- Expectant management with weekly hCG monitoring is usually reserved for **pregnancies of unknown location (PUL)** where hCG levels are plateauing or declining, suggesting a non-viable or resolving ectopic pregnancy.- In this case, the **hCG is rising appropriately**, warranting efforts to locate and confirm the viability of the pregnancy via ultrasound rather than passive monitoring for a decline.

Question 19: A 35-year-old woman presents with an 18-month history of increasingly heavy menstrual bleeding. She reports using 15 super-absorbent tampons per period and experiences flooding. Her periods last 9 days and occur every 26 days. She has dysmenorrhoea requiring regular analgesia. Examination reveals a mobile tender mass arising from the pelvis. Transvaginal ultrasound shows an enlarged uterus (14 cm) with multiple fibroids, the largest being an 8 cm posterior intramural fibroid. Haemoglobin is 88 g/L. She has completed her family. What is the most appropriate definitive management?

A. Total hysterectomy (Correct Answer)
B. Uterine artery embolization
C. Myomectomy
D. Levonorgestrel intrauterine system insertion
E. Endometrial ablation

Explanation: ***Total hysterectomy***- A **total hysterectomy** offers a **definitive cure** for **heavy menstrual bleeding**, **dysmenorrhoea**, and fibroids, making it the most appropriate choice for a patient who has **completed her family** and seeks permanent relief.- Given the severe **anaemia (Hb 88 g/L)**, large **8 cm intramural fibroid**, and enlarged **14 cm uterus**, hysterectomy provides immediate and complete resolution of symptoms and prevents recurrence. *Uterine artery embolization*- While **uterus-preserving**, **uterine artery embolization** carries a higher **re-intervention rate** and is less definitive, especially with a large uterine and fibroid burden.- It is typically considered when fertility or uterine preservation is desired, which is not the primary goal for this patient seeking definitive management after completing her family. *Myomectomy*- **Myomectomy** is primarily indicated for women who wish to **preserve fertility** or their uterus, which is not a priority for this patient.- There is a significant risk of **fibroid recurrence** and the need for future surgeries, making it less definitive than hysterectomy for this patient's severe symptoms. *Levonorgestrel intrauterine system insertion*- The **LNG-IUS** is often less effective or prone to **expulsion** when the uterine cavity is significantly **distorted by large fibroids**, such as the 8 cm intramural fibroid in this case.- It is unlikely to adequately control the severe **heavy menstrual bleeding**, **anaemia**, and **dysmenorrhoea** associated with such a large fibroid burden and enlarged uterus. *Endometrial ablation*- **Endometrial ablation** is generally **contraindicated** or has very limited success in the presence of large **intramural or submucosal fibroids** that distort the uterine cavity.- Its efficacy is significantly reduced in uteri larger than **10-12 cm**, making it unsuitable for this patient's **14 cm uterus** and unlikely to resolve her severe symptoms.

Question 20: A 33-year-old woman is being monitored following single-dose intramuscular methotrexate (50 mg/m²) for an unruptured tubal ectopic pregnancy. Her pre-treatment beta-hCG was 1850 IU/L. On day 4, her beta-hCG is 1920 IU/L, and on day 7 it is 1440 IU/L. She remains clinically stable with minimal abdominal discomfort. What is the most appropriate next step in management?

A. Administer second dose of methotrexate
B. Proceed to diagnostic laparoscopy
C. Continue weekly beta-hCG monitoring until undetectable (Correct Answer)
D. Arrange urgent transvaginal ultrasound scan
E. Administer multi-dose methotrexate regimen

Explanation: ***Continue weekly beta-hCG monitoring until undetectable***- In the single-dose **methotrexate** protocol for ectopic pregnancy, success is defined by a **fall in beta-hCG of ≥15%** between day 4 and day 7.- This patient showed a **25% decrease** (from 1920 to 1440 IU/L), indicating treatment is effective and requires serial monitoring until the level is below **5 IU/L**.*Administer second dose of methotrexate*- A second dose is only indicated if the **beta-hCG fall is <15%** between day 4 and day 7.- Administering unnecessary methotrexate increases the risk of **side effects** like stomatitis or liver enzyme elevation without clinical benefit here.*Proceed to diagnostic laparoscopy*- Surgical intervention is reserved for patients who are **hemodynamically unstable**, have signs of **tubal rupture**, or fail medical management.- This patient is **clinically stable** and responding well biochemically, making surgery unnecessary and riskier than continued observation.*Arrange urgent transvaginal ultrasound scan*- Routine ultrasound is not required if the patient is stable and beta-hCG levels are **adequately declining** as per protocol.- Ultrasound findings often lag behind biochemical response and may show a persistent or slightly larger mass due to **hematoma**, which does not indicate treatment failure.*Administer multi-dose methotrexate regimen*- The **multi-dose regimen** is a specific primary treatment protocol involving alternating methotrexate and **leucovorin** rescue, not a rescue therapy for successful single-dose treatment.- There is no clinical indication to switch to a more complex and potentially more **toxic regimen** when the single-dose protocol is working.

Question 21: A 52-year-old woman presents with a 7-month history of intermenstrual bleeding occurring irregularly. She has had regular smear tests, the most recent being 18 months ago which was normal. Pelvic examination reveals a normal-sized uterus and no obvious cervical lesion. She is not on any medications. What is the most appropriate initial investigation?

A. Repeat cervical cytology
B. Transvaginal ultrasound scan and endometrial sampling (Correct Answer)
C. Serum follicle-stimulating hormone and luteinizing hormone levels
D. Full blood count and thyroid function tests
E. Diagnostic laparoscopy

Explanation: ***Transvaginal ultrasound scan and endometrial sampling*** - In a 52-year-old woman with **intermenstrual bleeding**, it is essential to exclude **endometrial hyperplasia** or **endometrial cancer** as a primary concern, given her age and symptoms. - **Transvaginal ultrasound** assesses **endometrial thickness**, while **endometrial sampling** (e.g., Pipelle biopsy) provides the necessary **histological diagnosis**. *Repeat cervical cytology* - The patient had a normal **smear test** 18 months ago and no visible **cervical lesions** on examination, making primary cervical pathology less likely as the initial cause. - Cervical cytology is primarily a **screening tool** for cervical cancer and is not the appropriate diagnostic test for investigating abnormal uterine bleeding originating from the uterine cavity. *Serum follicle-stimulating hormone and luteinizing hormone levels* - While these levels can help confirm **perimenopausal** or **menopausal status**, they do not directly explain the cause of abnormal bleeding or rule out potential **malignancy**. - Hormonal assays are secondary to structural and histological investigations when managing **abnormal uterine bleeding** in this age group, where endometrial pathology is a significant concern. *Full blood count and thyroid function tests* - **Thyroid dysfunction** can cause menstrual irregularities, but ruling out serious conditions like **endometrial cancer** is the highest priority in this age group with intermenstrual bleeding. - A **full blood count** may identify **anemia** resulting from the bleeding but will not identify the underlying anatomical or pathological cause. *Diagnostic laparoscopy* - **Laparoscopy** is an invasive surgical procedure primarily indicated for conditions like **pelvic pain**, **endometriosis**, or adnexal masses, not for the initial investigation of **intermenstrual bleeding**. - Intraluminal uterine pathologies, which are the main concern with intermenstrual bleeding, are better visualized and sampled via **hysteroscopy** or assessed with **transvaginal ultrasound** rather than external visualization through laparoscopy.

Question 22: According to the Royal College of Obstetricians and Gynaecologists guidelines, which of the following is an absolute contraindication to medical management of ectopic pregnancy with methotrexate?

A. Serum beta-hCG level of 4500 IU/L
B. Ectopic pregnancy measuring 38 mm on ultrasound scan
C. Presence of fetal heartbeat on ultrasound scan (Correct Answer)
D. Moderate free fluid visible in the pouch of Douglas on ultrasound scan
E. Previous history of one ectopic pregnancy treated surgically

Explanation: ***Presence of fetal heartbeat on ultrasound scan***- According to **RCOG guidelines**, the presence of **visible fetal cardiac activity** is an absolute contraindication for systemic methotrexate as it signifies a high risk of **treatment failure** and tubal rupture.- Medical management is less effective in viable pregnancies with higher metabolic activity, necessitating surgical intervention to ensure patient safety.*Serum beta-hCG level of 4500 IU/L*- While a high **beta-hCG** (typically >3000 IU/L or >5000 IU/L depending on specific protocols) increases the risk of failure, it is generally considered a **relative contraindication** rather than an absolute one.- RCOG suggests that methotrexate is most successful when the initial hCG is below **1500 IU/L**.*Ectopic pregnancy measuring 38 mm on ultrasound scan*- An ectopic mass size greater than **35 mm** is a relative contraindication to medical management.- This criteria is used to select patients likely to respond to a **single-dose regimen**, but a slightly larger mass does not strictly prohibit its use if other factors are favorable.*Moderate free fluid visible in the pouch of Douglas on ultrasound scan*- Significant **intraperitoneal fluid** suggests possible rupture or hemoperitoneum, which usually warrants **laparoscopic surgery**.- However, a small or moderate amount of fluid in a hemodynamically stable patient is not always an absolute contraindication compared to a **fetal heartbeat**.*Previous history of one ectopic pregnancy treated surgically*- A history of prior surgery or ectopic pregnancy does not preclude medical management; in fact, **methotrexate** may be preferred to avoid further **pelvic adhesions**.- The eligibility for medical management focuses on the **current pregnancy characteristics** and patient stability rather than obstetric history.

Question 23: A 28-year-old woman presents to the emergency department with sudden onset severe left-sided abdominal pain and syncope. She has 6 weeks amenorrhoea. On examination, she is pale, heart rate 118 bpm, blood pressure 88/54 mmHg. Abdominal examination reveals generalized tenderness with rebound and guarding. Bedside transvaginal ultrasound shows free fluid in the pelvis and a left adnexal mass. Her haemoglobin is 78 g/L. What is the most appropriate immediate management?

A. Commence rapid intravenous fluid resuscitation, cross-match blood, and arrange emergency laparoscopy (Correct Answer)
B. Administer intramuscular methotrexate after confirming beta-hCG level
C. Arrange urgent MRI pelvis to characterize the adnexal mass
D. Commence intravenous antibiotics for suspected pelvic inflammatory disease
E. Arrange semi-urgent laparoscopy within 24 hours after stabilization

Explanation: ***Commence rapid intravenous fluid resuscitation, cross-match blood, and arrange emergency laparoscopy*** - The patient presents with **hemodynamic instability** (hypotension, tachycardia), **syncope**, **amenorrhoea**, and signs of **hemoperitoneum** (free fluid, generalized tenderness with rebound and guarding, low haemoglobin), strongly indicating a life-threatening **ruptured ectopic pregnancy** and **hemorrhagic shock**.- Immediate management requires rapid **fluid resuscitation** and **blood product preparation** to stabilize the patient while simultaneously preparing for **emergency laparoscopy** to achieve definitive hemostasis and remove the ectopic pregnancy.*Administer intramuscular methotrexate after confirming beta-hCG level* - **Methotrexate** is absolutely contraindicated in patients with **hemodynamic instability**, suspected or confirmed **rupture**, or significant **intra-abdominal bleeding**.- Medical management is reserved only for **hemodynamically stable patients** with small, unruptured ectopic pregnancies and specific **beta-hCG levels** criteria.*Arrange urgent MRI pelvis to characterize the adnexal mass* - Performing an **MRI** would cause a dangerous and unacceptable delay in life-saving surgical intervention for an **unstable patient** in shock.- The diagnosis of a likely ruptured ectopic pregnancy is already clinically evident and supported by **transvaginal ultrasound** findings, making further imaging unnecessary.*Commence intravenous antibiotics for suspected pelvic inflammatory disease* - While **pelvic inflammatory disease (PID)** can cause pelvic pain, it does not typically present with **sudden syncope**, severe **anemia**, **hypovolemic shock**, or free fluid on ultrasound in this acute, life-threatening manner.- The priority in this case is managing **intra-abdominal hemorrhage** and **shock**, not treating a suspected infection.*Arrange semi-urgent laparoscopy within 24 hours after stabilization* - A delay of up to **24 hours** for surgery is inappropriate and potentially fatal for a patient in **hemorrhagic shock** due to ongoing internal bleeding.- **Emergency surgery** must be performed as soon as possible after initial rapid resuscitation to stop the active bleeding and prevent further deterioration.

Question 24: A 46-year-old woman with menorrhagia has been using a levonorgestrel intrauterine system for 8 months. She reports that her bleeding has reduced from very heavy to moderate flow, but she continues to have 7-day periods with flooding on days 2-3. She is anaemic with haemoglobin of 101 g/L. Transvaginal ultrasound shows a bulky uterus (10 cm) with multiple intramural fibroids, the largest measuring 5 cm. The LNG-IUS is correctly positioned. What is the most appropriate next management step?

A. Continue with LNG-IUS for a further 4 months before reassessing (Correct Answer)
B. Remove LNG-IUS and commence oral tranexamic acid and mefenamic acid
C. Refer for uterine artery embolization
D. Commence gonadotrophin-releasing hormone agonist therapy
E. Refer for total hysterectomy

Explanation: ***Continue with LNG-IUS for a further 4 months before reassessing*** - The **Levonorgestrel intrauterine system (LNG-IUS)** can take up to **12 months** to reach its maximum clinical efficacy in reducing menstrual blood flow, especially in the presence of **intramural fibroids**. - Since the patient has already shown a **partial response** (reduction from very heavy to moderate flow) and the device is **correctly positioned**, it is appropriate to allow the full trial period before declaring treatment failure. *Remove LNG-IUS and commence oral tranexamic acid and mefenamic acid* - **Tranexamic acid** and **mefenamic acid** are generally less effective than the **LNG-IUS** for managing heavy menstrual bleeding associated with fibroids. - It would be counterproductive to remove a long-acting treatment that is already providing partial symptom relief for less potent **oral medical therapies**. *Refer for uterine artery embolization* - **Uterine artery embolization (UAE)** is a secondary option for women with fibroids who do not respond to medical management or wish to avoid surgery. - While the fibroids are significant (**5 cm**), more invasive procedures should typically be reserved until **medical management** has been given at least a full 12-month trial. *Commence gonadotrophin-releasing hormone agonist therapy* - **GnRH agonists** are primarily used as **preoperative treatment** to shrink fibroids or as a temporary measure for severe symptoms due to their side effect profile and risk of bone loss. - They are not considered a primary maintenance therapy for **menorrhagia** when a patient is already tolerating and responding to an **LNG-IUS**. *Refer for total hysterectomy* - **Hysterectomy** is the definitive surgical treatment but is generally considered only after **medical treatments** have failed or the patient expresses a specific preference for surgery. - This patient has not yet completed a full trial of the **LNG-IUS**, and her response suggests that continued use along with **iron supplementation** may resolve her symptoms and **anaemia**.

Question 25: A 31-year-old woman undergoes laparoscopy for right-sided pelvic pain and 7 weeks amenorrhoea. A 3.5 cm unruptured ectopic pregnancy is identified in the ampullary region of the right fallopian tube. Her left fallopian tube appears healthy. She is haemodynamically stable. What is the most appropriate surgical management that balances future fertility with treatment efficacy?

A. Right salpingectomy (Correct Answer)
B. Right salpingotomy
C. Right salpingotomy with prophylactic methotrexate
D. Segmental resection of the right fallopian tube
E. Milking the ectopic pregnancy from the fimbrial end

Explanation: ***Right salpingectomy*** - Current **NICE/RCOG guidelines** recommend **salpingectomy** as the first-line surgical management for ectopic pregnancy if the **contralateral tube is healthy**. - Evidence shows that salpingectomy has **no disadvantage regarding future fertility** compared to salpingotomy while avoiding the risk of **persistent trophoblastic tissue**. *Right salpingotomy* - This procedure involves making an incision to remove the pregnancy while preserving the tube but carries a **15-20% risk of persistent trophoblast** requiring further treatment. - It is generally reserved for patients with **contralateral tubal damage** to maximize the chance of future natural conception. *Right salpingotomy with prophylactic methotrexate* - Adding **methotrexate** to salpingotomy does not significantly reduce the risk of persistent trophoblast compared to salpingectomy. - This approach is not recommended as it introduces **medication side effects** and requires rigorous **beta-hCG monitoring**. *Segmental resection of the right fallopian tube* - There is no clinical advantage to **segmental resection** over a total salpingectomy in the context of an ampullary ectopic pregnancy. - This technique is technically more complex and does not improve **future fertility outcomes** for the patient. *Milking the ectopic pregnancy from the fimbrial end* - This technique is associated with a **very high risk of persistent trophoblast** due to incomplete removal of the gestational tissue. - It is not a recommended surgical approach in contemporary gynaecological practice due to high **failure and complication rates**.

Question 26: A 39-year-old nulliparous woman with heavy menstrual bleeding undergoes hysteroscopy and endometrial biopsy. Histology shows endometrial hyperplasia without atypia. She has a body mass index of 36 kg/m² and has polycystic ovary syndrome. She wishes to preserve her fertility. What is the most appropriate management?

A. Levonorgestrel intrauterine system with regular endometrial surveillance (Correct Answer)
B. Total hysterectomy with bilateral salpingo-oophorectomy
C. Endometrial ablation
D. Cyclical oral progestogen therapy with metformin
E. Combined oral contraceptive pill

Explanation: ***Levonorgestrel intrauterine system with regular endometrial surveillance*** - The **LNG-IUS** is the first-line treatment for **endometrial hyperplasia without atypia** because it provides high local progestogen concentrations, leading to a higher **regression rate** compared to oral therapy. - It addresses both the **heavy menstrual bleeding** and the hyperplasia while preserving **fertility**, with repeat biopsy surveillance required every **6 months**. *Total hysterectomy with bilateral salpingo-oophorectomy* - This is an over-treatment for **hyperplasia without atypia** and is generally reserved for cases with **atypia** or failed medical management. - Choosing this option would result in the permanent loss of **fertility**, which contradicts the patient's expressed desire to preserve it. *Endometrial ablation* - This procedure is **contraindicated** in the management of endometrial hyperplasia because it can lead to **intrauterine adhesions** that prevent future endometrial sampling. - Subsequent **endometrial surveillance** becomes impossible, potentially masking the progression of any remaining deeper hyperplastic tissue to **malignancy**. *Cyclical oral progestogen therapy with metformin* - While **oral progestogens** are used to treat hyperplasia, **cyclical** therapy is significantly less effective than **continuous** progestogen or the LNG-IUS in achieving regression. - **Metformin** may help manage her **PCOS** and metabolic profile, but it is not a primary or standalone treatment for histologically confirmed **endometrial hyperplasia**. *Combined oral contraceptive pill* - The **COCP** is less effective than the LNG-IUS for treating established endometrial hyperplasia and carries increased risks due to her **BMI of 36 kg/m²**. - The **estrogen component** of the pill may be undesirable when trying to counteract a state of **unopposed estrogen** causing the hyperplasia.

Question 27: A 27-year-old woman is being monitored for a suspected ectopic pregnancy. Her initial serum beta-hCG level is 980 IU/L. A transvaginal ultrasound scan shows an empty uterus with no adnexal masses visible and no free fluid. She is haemodynamically stable with minimal abdominal discomfort. A repeat beta-hCG level 48 hours later is 1420 IU/L. What is the most appropriate next step in management?

A. Administer intramuscular methotrexate and arrange follow-up
B. Repeat serum beta-hCG in a further 48 hours (Correct Answer)
C. Arrange urgent diagnostic laparoscopy
D. Repeat transvaginal ultrasound scan in 7-14 days
E. Expectant management with weekly beta-hCG monitoring

Explanation: ***Repeat serum beta-hCG in a further 48 hours*** - The patient has a **pregnancy of unknown location (PUL)** with a beta-hCG rise of approximately **45%** over 48 hours, which is suboptimal but inconclusive. - Since the current level (1420 IU/L) is just below the typical **discriminatory zone** (1500–2000 IU/L) for ultrasound visualization, a repeat test is needed to clarify if the pregnancy is **viable**, **ectopic**, or **failing**. *Administer intramuscular methotrexate and arrange follow-up* - **Methotrexate** is contraindicated until a diagnosis of **ectopic pregnancy** is confirmed and a viable intrauterine pregnancy is strictly ruled out. - Intervening at this stage carries the risk of inadvertently terminating a potentially **viable intrauterine pregnancy** that is simply rising slowly. *Arrange urgent diagnostic laparoscopy* - Surgical intervention is not indicated because the patient is **haemodynamically stable** with minimal symptoms and no imaging evidence of an ectopic mass. - **Laparoscopy** is an invasive procedure generally reserved for unstable patients or cases where there is high clinical suspicion with supporting scan findings. *Repeat transvaginal ultrasound scan in 7-14 days* - Waiting up to 14 days is inappropriate for a **suspected ectopic pregnancy** due to the risk of **tubal rupture** as levels continue to rise. - Repeat imaging is typically scheduled once the **beta-hCG** has crossed the discriminatory threshold or if symptoms change, rather than a fixed long-term delay. *Expectant management with weekly beta-hCG monitoring* - **Expectant management** (weekly monitoring) is only appropriate if beta-hCG levels are **low and decreasing** (typically <1000 IU/L and falling). - In this case, the levels are **increasing**, which requires more frequent monitoring (every 48 hours) to ensure patient safety and diagnostic accuracy.

Question 28: A 44-year-old woman presents with heavy menstrual bleeding. She reports flooding and passing large clots. Her periods last 8 days and occur every 28 days. She has completed her family and declines hormonal treatments. Pelvic examination is normal. Transvaginal ultrasound shows a normal anteverted uterus measuring 8 cm with a homogeneous endometrium of 6 mm. Full blood count reveals haemoglobin of 95 g/L. Which of the following is the most appropriate initial pharmacological management?

A. Tranexamic acid 1 g three times daily during menstruation (Correct Answer)
B. Mefenamic acid 500 mg three times daily during menstruation
C. Combined oral contraceptive pill
D. Norethisterone 5 mg three times daily from day 5 to 26 of cycle
E. Gonadotrophin-releasing hormone agonist

Explanation: ***Tranexamic acid 1 g three times daily during menstruation*** - **Tranexamic acid** is the most effective **non-hormonal** treatment for **heavy menstrual bleeding (HMB)**, working by inhibiting **fibrinolysis** to reduce blood loss by 40-50%. - Given the patient's explicit **declination of hormonal treatments** and confirmed anemia (Hb 95 g/L), tranexamic acid is the appropriate first-line pharmacological choice. *Mefenamic acid 500 mg three times daily during menstruation* - This **NSAID** reduces blood loss by inhibiting **prostaglandin synthesis** but is generally less effective than tranexamic acid, offering only a 20-30% reduction. - While it's a non-hormonal option and can be used for HMB, especially if **dysmenorrhea** is present, it is not considered the *most appropriate initial* pharmacological management specifically for heavy flow when tranexamic acid is available. *Combined oral contraceptive pill* - The **combined oral contraceptive pill** is an effective hormonal treatment that helps to regulate the menstrual cycle and significantly reduces menstrual blood loss by thinning the **endometrium**. - However, this option is unsuitable as the patient has explicitly **declined all hormonal treatments** for her heavy menstrual bleeding. *Norethisterone 5 mg three times daily from day 5 to 26 of cycle* - High-dose **progestogens** like norethisterone can reduce heavy menstrual bleeding by stabilizing the **endometrium**. - This treatment is a **hormonal intervention**, making it an inappropriate choice for a patient who has clearly stated her preference to avoid hormonal therapies. *Gonadotrophin-releasing hormone agonist* - **GnRH agonists** induce a temporary hypoestrogenic state, essentially creating a medical menopause, which effectively stops menstruation. - These agents are typically reserved for severe, refractory cases of HMB, often associated with fibroids, or for **preoperative** use, and are not considered initial management for uncomplicated heavy menstrual bleeding due to their significant side effects and hormonal nature.

Question 29: A 49-year-old woman presents with a 13-month history of increasingly heavy and prolonged menstrual bleeding. Over the past 3 months, she has noticed bleeding occurring between periods as well. Examination reveals a slightly bulky uterus. Transvaginal ultrasound shows an endometrial thickness of 18 mm and a normal myometrium. She has a BMI of 33 kg/m², takes metformin for type 2 diabetes, and has a 20 pack-year smoking history. What is the most appropriate next investigation?

A. MRI pelvis to further characterise the endometrium
B. Hysteroscopy and endometrial biopsy (Correct Answer)
C. Repeat transvaginal ultrasound in the early proliferative phase
D. Outpatient endometrial pipelle biopsy
E. Serum CA-125

Explanation: ***Hysteroscopy and endometrial biopsy*** - This patient presents with **abnormal uterine bleeding**, **obesity (BMI 33)**, and **type 2 diabetes**, which are significant risk factors for **endometrial hyperplasia** or **malignancy**. - An **endometrial thickness of 18 mm** is highly abnormal and requires a **hysteroscopy** to allow for direct visualization of focal lesions and targeted histological sampling. *MRI pelvis to further characterise the endometrium* - MRI is generally used for **staging** known endometrial cancer rather than as a primary tool for the initial diagnosis of abnormal bleeding. - It cannot provide a **histological diagnosis**, which is mandatory to rule out cancer in a patient with a thickness of 18 mm. *Repeat transvaginal ultrasound in the early proliferative phase* - Delaying further investigation with a repeat scan is inappropriate when the **endometrium is 18 mm**, especially in a perimenopausal woman with risk factors. - Clinical guidelines mandate **tissue sampling** whenever there is persistent intermenstrual bleeding or a significantly thickened endometrial stripe. *Outpatient endometrial pipelle biopsy* - While pipelle biopsy is a valid tool, its sensitivity is lower for **focal pathology** like polyps, which are likely given the "bulky uterus" and intermenstrual bleeding. - **Hysteroscopy** is the superior investigation in this scenario as it ensures the entire cavity is assessed and biopsy is directed toward the most suspicious areas. *Serum CA-125* - CA-125 is a marker primarily used for **ovarian cancer** screening/monitoring and has no diagnostic role in the initial workup of **abnormal uterine bleeding**. - It lacks the specificity needed for endometrial assessment and cannot substitute for **endometrial sampling**.

Question 30: A 33-year-old woman presents with left iliac fossa pain and 7 weeks amenorrhoea. Her observations are: blood pressure 124/78 mmHg, pulse 76 bpm, temperature 37.1°C. Transvaginal ultrasound shows an empty uterus with a 28 mm left adnexal mass containing a fetal pole with cardiac activity. There is minimal free fluid in the pouch of Douglas. Serum beta-hCG is 5,200 IU/L. She has no previous abdominal surgery and wishes to conceive again in future. What factor most significantly reduces the likelihood of successful medical management with methotrexate?

A. Beta-hCG level of 5,200 IU/L
B. Size of ectopic pregnancy (28 mm)
C. Presence of fetal cardiac activity (Correct Answer)
D. Left-sided location of the ectopic pregnancy
E. Presence of free fluid in pouch of Douglas

Explanation: ***Presence of fetal cardiac activity*** - The presence of **fetal cardiac activity** is a significant negative prognostic factor for **methotrexate** success, as it indicates a more viable and metabolically active trophoblastic tissue. - This factor significantly reduces the likelihood of successful medical management, often leading to **treatment failure** and requiring surgical intervention. *Beta-hCG level of 5,200 IU/L* - While lower **hCG levels** (typically <3,000-5,000 IU/L) are associated with higher methotrexate success rates, a level of 5,200 IU/L is a relative concern but not an absolute contraindication, especially when compared to cardiac activity. - The presence of **cardiac activity** carries a much higher predictive value for methotrexate failure than this specific hCG level alone. *Size of ectopic pregnancy (28 mm)* - Medical management with **methotrexate** is generally considered appropriate for ectopic pregnancies with a maximum diameter of **3.5 cm (35 mm)**. - A 28 mm ectopic mass falls within the acceptable size criteria for medical management, making it a less significant factor for failure. *Left-sided location of the ectopic pregnancy* - The **anatomic location** of the ectopic pregnancy (left versus right) does not influence the efficacy or success rate of **systemic methotrexate** treatment. - This is a descriptive finding and has no bearing on the choice or success of medical management. *Presence of free fluid in pouch of Douglas* - Minimal **free fluid** in the pouch of Douglas is a common finding in ectopic pregnancy and does not necessarily indicate **tubal rupture** or preclude medical management in a stable patient. - Only significant amounts of **free fluid** or signs of **hemodynamic instability** would prompt immediate surgical intervention.

Question 31: A 41-year-old woman with heavy menstrual bleeding has been using a levonorgestrel intrauterine system for 18 months. Her bleeding has improved significantly but she continues to have irregular spotting on 10-15 days per month which she finds bothersome. Pelvic examination confirms the IUS threads are visible and the device is correctly positioned. Transvaginal ultrasound shows the IUS in the correct position within the uterine cavity, a uniform endometrial thickness of 4 mm, and no structural abnormalities. What is the most appropriate management?

A. Removal of the IUS and insertion of a new device
B. Addition of cyclical oral progestogen therapy
C. Reassurance and continuation of current management (Correct Answer)
D. Hysteroscopy to check for endometrial polyps
E. Removal of the IUS and commencement of tranexamic acid

Explanation: ***Reassurance and continuation of current management*** - Irregular **spotting** is a common and expected side effect of the **levonorgestrel intrauterine system (LNG-IUS)**, even after the initial 6-month stabilization period. - Since the device is **correctly positioned**, ultrasound shows a thin **4 mm endometrium**, and heavy bleeding has improved, no further intervention is medically required. *Removal of the IUS and insertion of a new device* - There is no evidence of **device displacement** or failure; therefore, replacing it would not resolve the hormonal side effect of spotting. - This approach unnecessarily exposes the patient to the risks and discomfort of a **re-insertion procedure**. *Addition of cyclical oral progestogen therapy* - Adding **cyclical progestogens** to an LNG-IUS is not a standard evidence-based treatment for spotting and may further destabilize the **endometrium**. - This increases the pill burden and systemic side effects without guaranteeing a reduction in **unscheduled bleeding**. *Hysteroscopy to check for endometrial polyps* - **Transvaginal ultrasound** has already confirmed a uniform **4 mm endometrium** and no structural abnormalities, making polyps highly unlikely. - **Hysteroscopy** is an invasive procedure and is not indicated when non-invasive imaging has already ruled out **intrauterine pathology**. *Removal of the IUS and commencement of tranexamic acid* - **Tranexamic acid** is used only during active heavy bleeding and is ineffective for managing the **intermittent spotting** caused by progestogens. - Removing the IUS would likely cause a return of the patient's **heavy menstrual bleeding**, which was her primary clinical concern.

Question 32: A 26-year-old woman presents to the emergency department with sudden onset severe right-sided abdominal pain and syncope. She has a history of 5 weeks amenorrhoea. On examination, she is pale with blood pressure 88/54 mmHg, pulse 118 bpm, respiratory rate 22/min, and oxygen saturation 97% on air. Her abdomen is distended with generalized tenderness and guarding. A bedside transabdominal ultrasound shows free fluid in the abdomen and pelvis. What is the most appropriate immediate management?

A. Urgent transvaginal ultrasound to confirm ectopic pregnancy location
B. Immediate laparoscopy
C. Serum beta-hCG measurement
D. Intravenous fluid resuscitation and activation of emergency theatre (Correct Answer)
E. CT abdomen and pelvis with intravenous contrast

Explanation: ***Intravenous fluid resuscitation and activation of emergency theatre*** - The patient presents with classic signs of **haemorrhagic shock** (hypotension, tachycardia, pallor, syncope) due to suspected **ruptured ectopic pregnancy**, further supported by free fluid on ultrasound and 5 weeks amenorrhoea. - Immediate priorities are **resuscitation** with intravenous fluids to restore circulating volume and **simultaneous activation of the emergency theatre** for urgent surgical intervention to control the source of bleeding. *Urgent transvaginal ultrasound to confirm ectopic pregnancy location* - In a **haemodynamically unstable** patient with clear signs of internal bleeding, delaying definitive treatment for further diagnostic imaging is **inappropriate** and dangerous. - The clinical presentation and bedside ultrasound findings already provide sufficient evidence for a presumptive diagnosis requiring immediate life-saving intervention. *Immediate laparoscopy* - While surgical intervention is paramount, proceeding directly to laparoscopy without initial **fluid resuscitation** to stabilize the patient risks anaesthetic complications and further deterioration. - In cases of severe **haemorrhagic shock** with massive hemoperitoneum, an **emergency laparotomy** may be a faster and more effective approach than laparoscopy to achieve haemostasis. *Serum beta-hCG measurement* - Although confirming pregnancy is important, the **haemodynamic instability** and signs of rupture mandate immediate action that cannot await lab results. - Clinical findings are sufficient to initiate life-saving management, and waiting for **beta-hCG** would cause a critical delay. *CT abdomen and pelvis with intravenous contrast* - Performing a CT scan on a patient in **shock** is **contraindicated** as it removes them from the resuscitation area and consumes precious time, risking further clinical deterioration. - The combination of **amenorrhoea, severe abdominal pain, syncope, and free fluid on ultrasound** is enough to diagnose a ruptured ectopic pregnancy and proceed to surgery.

Question 33: A 38-year-old woman presents with a 16-month history of heavy menstrual bleeding. She reports flooding and clots, requiring pad changes every 1-2 hours on the heaviest days. Examination reveals a 14-week size uterus which is non-tender. Transvaginal ultrasound demonstrates multiple intramural and subserosal fibroids, the largest measuring 6 cm. Endometrial thickness is 8 mm. Haemoglobin is 97 g/L. She has completed her family. Medical management with tranexamic acid and levonorgestrel IUS has been ineffective. What is the most appropriate next treatment option?

A. Uterine artery embolisation
B. Total abdominal hysterectomy (Correct Answer)
C. GnRH agonist therapy for 6 months
D. Myomectomy
E. Endometrial ablation

Explanation: ***Total abdominal hysterectomy*** - This is the most appropriate **definitive treatment** for a woman who has **completed her family**, failed medical management, and has a significantly enlarged **14-week size uterus** due to fibroids. - It provides a permanent solution to **heavy menstrual bleeding (HMB)**, corrects **anaemia** over time, and eliminates the risk of **fibroid recurrence** or the need for further procedures. *Uterine artery embolisation* - While effective for shrinking fibroids and reducing bleeding, it is typically preferred by women who wish to **preserve their uterus** or **avoid major surgery**, which is not a primary concern for this patient who has completed her family. - It carries a higher risk of **treatment failure** or the need for future re-intervention compared to a hysterectomy, and a 14-week size uterus with a 6 cm fibroid might have a less predictable response. *GnRH agonist therapy for 6 months* - These are primarily used as **pre-operative adjuncts** to temporarily shrink fibroids and correct **anaemia** before surgery, rather than as a long-term definitive treatment. - Symptoms usually recur rapidly once the medication is stopped, and extended use is limited by side effects like **bone mineral density loss** and menopausal symptoms. *Myomectomy* - This surgical option is specifically indicated for women with fibroids who **wish to preserve fertility** or the uterus, which is not a priority for this patient who has completed her family. - It is a more complex surgical procedure with potential for **significant blood loss** and does not prevent the growth of new fibroids, meaning recurrence of symptoms is possible. *Endometrial ablation* - This procedure is generally **contraindicated** in this patient because her uterus is larger than **10-12 weeks size** and contains fibroids greater than **3 cm**, especially intramural or subserosal ones. - Ablation is significantly less effective when the **uterine cavity is distorted** by large fibroids, and for subserosal fibroids, it would not address the issue.

Question 34: A 32-year-old woman with 6 weeks amenorrhoea presents with minimal vaginal spotting. Transvaginal ultrasound shows an empty uterus with 8 mm endometrial thickness and a 22 mm right adnexal mass containing a yolk sac but no fetal pole. There is no free fluid. Serum beta-hCG is 1,850 IU/L. She is clinically stable and wishes to avoid surgery if possible. What is the most appropriate management approach?

A. Immediate laparoscopic salpingectomy
B. Single-dose intramuscular methotrexate 50 mg/m² with day 4 and 7 beta-hCG monitoring (Correct Answer)
C. Expectant management with serial beta-hCG and ultrasound
D. Two-dose methotrexate regimen with days 0, 4, and 7 beta-hCG monitoring
E. Uterine curettage to exclude intrauterine pregnancy

Explanation: ***Single-dose intramuscular methotrexate 50 mg/m² with day 4 and 7 beta-hCG monitoring***- The patient is a suitable candidate for **medical management** as she is **haemodynamically stable**, has an adnexal mass **<3.5 cm** (22 mm), **no fetal heartbeat**, and a **beta-hCG <5,000 IU/L** (1,850 IU/L).- The **single-dose protocol** is the first-line medical intervention for eligible patients, requiring monitoring on days 4 and 7 to ensure a **≥15% decline** in beta-hCG levels from day 0 to day 4, or day 4 to day 7.*Immediate laparoscopic salpingectomy*- Surgical intervention is typically reserved for patients who are **clinically unstable**, have signs of **tubal rupture**, or have **beta-hCG levels >5,000 IU/L** with fetal cardiac activity.- Since the patient is **clinically stable** and meets all criteria for medical management, along with expressing a wish to **avoid surgery**, immediate laparoscopy is not indicated.*Expectant management with serial beta-hCG and ultrasound*- Expectant management is generally considered only when **beta-hCG levels are low** (typically <1,000-1,500 IU/L) and are already spontaneously declining.- The presence of a **yolk sac** and beta-hCG of **1,850 IU/L** indicates active trophoblastic tissue, making spontaneous resolution less likely and carrying a significant risk of rupture without intervention.*Two-dose methotrexate regimen with days 0, 4, and 7 beta-hCG monitoring*- A **two-dose methotrexate regimen** is usually reserved for cases where the initial **beta-hCG is higher** (e.g., 3,000-5,000 IU/L) or if the single-dose protocol fails to achieve the required decline.- Given the beta-hCG of **1,850 IU/L**, the **single-dose protocol** is the standard and preferred approach to minimize drug toxicity and side effects.*Uterine curettage to exclude intrauterine pregnancy*- **Uterine curettage** is unnecessary here because the **transvaginal ultrasound** has already definitively identified an **adnexal mass with a yolk sac**, confirming an ectopic pregnancy.- This procedure is primarily used in cases of **pregnancy of unknown location (PUL)** with rising hCG where an intrauterine pregnancy cannot be excluded, not when an ectopic pregnancy is clearly visualized.

Question 35: According to the Royal College of Obstetricians and Gynaecologists guidance, what is the definition of heavy menstrual bleeding that should prompt investigation and treatment?

A. Menstrual blood loss exceeding 80 mL per cycle
B. Menstrual blood loss that interferes with the woman's physical, emotional, social and material quality of life (Correct Answer)
C. Menstrual periods lasting longer than 7 days
D. Requiring the use of more than 16 pads or tampons per menstrual cycle
E. Haemoglobin level less than 120 g/L in association with menstrual bleeding

Explanation: ***Menstrual blood loss that interferes with the woman's physical, emotional, social and material quality of life*** - The **Royal College of Obstetricians and Gynaecologists (RCOG)**, in line with **NICE guidelines**, defines heavy menstrual bleeding based on its subjective impact on a woman's **quality of life**. - This definition recognizes that the patient's perception of her bleeding and its disruption to her daily activities is the primary indicator for investigation and treatment. *Menstrual blood loss exceeding 80 mL per cycle* - While 80 mL was historically used as an **objective measure** in research, it is **impractical** to accurately quantify blood loss in routine clinical practice. - This definition does not fully encompass the individual variation in how women experience and are affected by their menstrual flow. *Menstrual periods lasting longer than 7 days* - This describes **prolonged menstrual bleeding**, which can coexist with heavy bleeding but is not the sole defining characteristic of heavy menstrual bleeding that warrants investigation. - A woman can experience significant heavy bleeding in a shorter duration that still severely impacts her **quality of life**, necessitating intervention. *Requiring the use of more than 16 pads or tampons per menstrual cycle* - The number of **sanitary products** used can be a useful clinical indicator for assessing menstrual volume, but it is not a standardized or definitive criterion for diagnosis. - This method is highly variable, depending on product absorbency, individual habits, and does not directly capture the **personal impact** of the bleeding. *Haemoglobin level less than 120 g/L in association with menstrual bleeding* - A low **haemoglobin level**, indicating **anaemia**, is a common *consequence* of heavy menstrual bleeding and a reason for intervention, but it is not the definition of the condition itself. - Many women experience significant disruption to their lives due to heavy bleeding long before their **haemoglobin levels** drop to an anaemic range.

Question 36: A 29-year-old woman undergoes laparoscopy for suspected ectopic pregnancy. Intraoperatively, a 25 mm unruptured right ampullary ectopic pregnancy is identified. Both fallopian tubes appear normal with no evidence of hydrosalpinx or adhesions. The patient has no history of subfertility and has one previous uncomplicated vaginal delivery. She wishes to have more children. What is the most appropriate surgical management?

A. Right salpingectomy
B. Right salpingotomy with tubal lavage
C. Right salpingotomy without tubal lavage (Correct Answer)
D. Bilateral salpingectomy
E. Right cornual resection

Explanation: ***Right salpingotomy without tubal lavage*** - **Salpingotomy** is the preferred surgical approach for an **unruptured ectopic pregnancy** in patients who desire **future fertility** and have healthy contralateral tubes. It allows for the removal of the ectopic while preserving the integrity of the fallopian tube. - Current evidence and guidelines, such as those from the RCOG, do not recommend **tubal lavage** after salpingotomy, as it has not been shown to improve subsequent fertility outcomes and may increase the risk of **tubal damage** or prolong operative time unnecessarily. *Right salpingectomy* - This procedure involves the **complete removal** of the fallopian tube. While it is a definitive treatment for ectopic pregnancy, it reduces the patient's future fertility potential, which goes against her expressed wish for **more children**. - **Salpingectomy** is typically indicated for ruptured ectopic pregnancies, recurrent ectopics in the same tube, severely damaged tubes, or in patients who do not desire future fertility. *Right salpingotomy with tubal lavage* - While **salpingotomy** aims to preserve fertility by saving the tube, the addition of **tubal lavage** (flushing the tube) is not supported by current clinical guidelines. - Studies have shown that lavage does not improve the chances of a successful **intrauterine pregnancy** or reduce the risk of future **ectopic pregnancy**, making it an unnecessary step. *Bilateral salpingectomy* - This surgical option would result in **permanent sterilization**, as both fallopian tubes would be removed. This directly contradicts the patient's clear desire to have **more children**. - **Bilateral salpingectomy** is reserved for specific indications, such as bilateral tubal disease, or as a method of permanent contraception. *Right cornual resection* - **Cornual resection** is a highly specific procedure indicated for **interstitial** or **cornual pregnancies**, which implant within the muscular wall of the uterus at the utero-tubal junction. - The patient in this scenario has an **ampullary ectopic pregnancy**, which is located in the widest part of the fallopian tube, making cornual resection anatomically inappropriate and unnecessarily invasive for this type of ectopic.

Question 37: A 47-year-old woman presents to her GP with a 14-month history of menstrual periods occurring every 18-35 days with variable flow. Some cycles are heavy lasting 8 days, others are light lasting 3 days. Pelvic examination reveals a normal-sized, mobile uterus. She has no intermenstrual or postcoital bleeding. What is the most appropriate initial investigation?

A. Full blood count and serum ferritin
B. Transvaginal ultrasound scan (Correct Answer)
C. Hysteroscopy and endometrial biopsy
D. Serum FSH, LH and oestradiol
E. Thyroid function tests

Explanation: ***Transvaginal ultrasound scan*** - This is the first-line imaging modality to identify structural abnormalities like **endometrial polyps**, **submucosal fibroids**, or thickened endometrium in perimenopausal women with irregular bleeding. - In women over 45 with changed menstrual patterns, excluding **structural pathology** or malignancy is a priority, even if the physical examination is unremarkable. *Full blood count and serum ferritin* - These tests are used to evaluate **iron-deficiency anaemia** resulting from heavy menstrual bleeding but do not diagnose the underlying cause of irregularity. - While important for supportive care, they are secondary to investigations aimed at identifying **structural or neoplastic causes**. *Hysteroscopy and endometrial biopsy* - **Hysteroscopy** is generally reserved as a second-line investigation or when a **transvaginal ultrasound** suggests intracavitary pathology or an abnormal endometrial thickness. - Endometrial biopsy is specifically indicated for **postmenopausal bleeding** or persistent **intermenstrual bleeding**, which this patient does not currently exhibit. *Serum FSH, LH and oestradiol* - These hormones are often used to confirm **perimenopause** or **menopause**, but they are not recommended for routine use in women over 45 to guide management of abnormal bleeding. - Confirming a hormonal status does not negate the need to rule out **endometrial hyperplasia** or structural lesions in the setting of irregular bleeding. *Thyroid function tests* - **Hypothyroidism** or hyperthyroidism can cause menstrual irregularities, but they are rarely the primary cause in a 47-year-old without other systemic symptoms. - Clinical guidelines prioritize the exclusion of **uterine pathology** over endocrine screening in the perimenopausal age group presenting with variable flow.

Question 38: A 35-year-old nulliparous woman presents with 7 weeks amenorrhoea and left-sided pelvic pain. Transvaginal ultrasound demonstrates a 35 mm left tubal ectopic pregnancy with fetal cardiac activity visible. Serum beta-hCG is 8,500 IU/L. There is a small amount of free fluid in the pouch of Douglas. She is haemodynamically stable with blood pressure 118/76 mmHg and pulse 78 bpm. She strongly desires future fertility. What is the most appropriate definitive management?

A. Expectant management with serial beta-hCG monitoring
B. Single-dose intramuscular methotrexate 50 mg/m²
C. Two-dose intramuscular methotrexate regimen
D. Laparoscopic salpingotomy
E. Laparoscopic salpingectomy (Correct Answer)

Explanation: ***Laparoscopic salpingectomy***- Surgical management is mandated due to the presence of **fetal cardiac activity**, a **mass size of 35 mm**, and a high **beta-hCG of 8,500 IU/L**, all of which contraindicate medical or expectant management.- **Salpingectomy** is the definitive treatment, reducing the risk of **persistent trophoblastic tissue** and recurrent ectopic pregnancy in the affected tube, and is generally preferred for high-risk features even in women desiring future fertility if the contralateral tube is healthy.*Expectant management with serial beta-hCG monitoring*- This approach is suitable only for **clinically stable** patients with small, non-growing ectopic pregnancies, no fetal cardiac activity, and **decreasing beta-hCG levels** (typically <1,000-1,500 IU/L).- The patient's **fetal cardiac activity**, large mass size, and high beta-hCG level indicate a high risk of rupture, making expectant management unsafe.*Single-dose intramuscular methotrexate 50 mg/m²*- Medical management with methotrexate is contraindicated when **fetal cardiac activity** is detected, and its efficacy significantly decreases with **beta-hCG levels >5,000 IU/L**.- The ectopic mass size of 35 mm is also at the upper limit for methotrexate treatment, increasing the risk of failure and subsequent rupture.*Two-dose intramuscular methotrexate regimen*- Although potentially more effective than single-dose for higher beta-hCG, the presence of **fetal cardiac activity** remains a strong contraindication for any methotrexate regimen.- This regimen still carries a significant risk of treatment failure and **tubal rupture** in cases with visible cardiac activity and larger ectopic masses.*Laparoscopic salpingotomy*- While preserving the tube, **salpingotomy** carries a higher risk of **persistent trophoblastic tissue** requiring further intervention, especially with a large mass (35 mm) and **fetal cardiac activity**.- Given the high-risk features, **salpingectomy** offers a more definitive resolution and reduces the risk of complications, making it the safer choice even with the desire for fertility.

Question 39: A 42-year-old woman with heavy menstrual bleeding undergoes endometrial biopsy which shows complex endometrial hyperplasia without atypia. Her BMI is 36 kg/m² and she has type 2 diabetes mellitus. She wishes to preserve her fertility as she is planning conception with her new partner. What is the most appropriate management?

A. Levonorgestrel intrauterine system and endometrial surveillance at 6 months
B. Cyclical oral progestogen therapy for 6 months then repeat biopsy
C. Total hysterectomy with bilateral salpingo-oophorectomy
D. High-dose continuous oral progestogen therapy with repeat biopsy at 3-6 months (Correct Answer)
E. Endometrial ablation followed by assisted conception

Explanation: ***High-dose continuous oral progestogen therapy with repeat biopsy at 3-6 months*** - In a woman with **complex endometrial hyperplasia without atypia** who wishes to **preserve fertility**, high-dose **continuous oral progestogens** are the treatment of choice to induce regression. - **Repeat endometrial biopsy at 3-6 months** is crucial to confirm regression and ensure no progression to atypical hyperplasia or carcinoma before attempting conception. *Levonorgestrel intrauterine system and endometrial surveillance at 6 months* - While the **LNG-IUS** is an effective treatment for endometrial hyperplasia, the patient's desire for **immediate conception** makes an indwelling device less suitable. - For active management aiming for rapid regression and subsequent conception, a 3-6 month surveillance interval with oral therapy is often preferred over the 6-month interval mentioned. *Cyclical oral progestogen therapy for 6 months then repeat biopsy* - **Cyclical progestogens** are significantly less effective than **continuous progestogen therapy** for inducing regression of complex endometrial hyperplasia. - The patient's risk factors of **obesity (BMI 36)** and **type 2 diabetes** contribute to unopposed estrogen, requiring continuous progestogen exposure for effective management. *Total hysterectomy with bilateral salpingo-oophorectomy* - **Hysterectomy** is a definitive treatment for endometrial hyperplasia but is contraindicated here as the patient specifically **wishes to preserve her fertility**. - This surgery is typically reserved for cases with atypia, malignancy, or when fertility preservation is not desired. *Endometrial ablation followed by assisted conception* - **Endometrial ablation** destroys the uterine lining, making **future pregnancy impossible** or extremely high-risk due to inadequate endometrial support and potential complications. - Ablation also prevents effective **endometrial surveillance** with biopsies, which is essential to monitor for persistence or progression of hyperplasia.

Question 40: A 30-year-old woman is found to have a right cornual ectopic pregnancy measuring 18 mm with a serum beta-hCG of 2,400 IU/L. She is haemodynamically stable with mild right lower quadrant pain. There is no haemoperitoneum on ultrasound. She has had two previous lower segment caesarean sections. What is the most appropriate initial management for this patient?

A. Expectant management with serial beta-hCG monitoring
B. Single-dose intramuscular methotrexate 50 mg/m²
C. Laparoscopic cornual resection (Correct Answer)
D. Laparotomy and cornual resection with hysterectomy
E. Ultrasound-guided potassium chloride injection into the gestational sac

Explanation: ***Laparoscopic cornual resection*** - **Cornual (interstitial) pregnancies** are high-risk due to their location within the **myometrium**, near major **uterine blood vessels**, posing a significant risk of rupture and severe hemorrhage. - Given the patient's stability, **laparoscopic cornual resection** is the preferred definitive surgical management to remove the ectopic tissue and prevent catastrophic rupture, especially since medical management often has lower success rates for cornual pregnancies.*Expectant management with serial beta-hCG monitoring* - This approach is unsuitable for cornual pregnancies due to their inherent **high risk of rupture** and potentially life-threatening hemorrhage, even if the patient is currently stable. - Expectant management is typically reserved for **low-risk, resolving tubal ectopics** with very low and declining beta-hCG levels.*Single-dose intramuscular methotrexate 50 mg/m²* - **Methotrexate** has a significantly **lower success rate** for cornual pregnancies compared to tubal ectopics because of the thick surrounding **myometrium** and rich vascularity, which limits drug penetration. - There is a persistent risk of **delayed rupture** with methotrexate, making surgical intervention a safer and more definitive option for cornual pregnancies.*Laparotomy and cornual resection with hysterectomy* - **Laparotomy** (open surgery) is usually reserved for **hemodynamically unstable** patients or cases of ruptured ectopic pregnancy with significant hemorrhage. This patient is currently stable, making laparoscopy more appropriate. - **Hysterectomy** is an extreme measure not indicated as initial management for a stable cornual ectopic; it's reserved for situations of **uncontrollable bleeding** or extensive uterine damage.*Ultrasound-guided potassium chloride injection into the gestational sac* - This local injection method is typically used for specific types of ectopic pregnancies, such as **cervical** or certain **abdominal pregnancies**, or in cases where systemic medical or surgical options are contraindicated. - For **cornual pregnancies**, **surgical resection** (laparoscopic) is generally considered the gold standard due to its higher success rates and ability to definitively remove the tissue and manage potential vascular complications.

Question 41: A 44-year-old woman presents with heavy menstrual bleeding lasting 8 days each cycle for the past 10 months. She has no intermenstrual or postcoital bleeding. Pelvic examination is normal and transvaginal ultrasound shows a uniformly enlarged uterus measuring 11 cm with heterogeneous myometrium and no focal lesions. Endometrial thickness is 9 mm in the secretory phase. Full blood count shows haemoglobin of 102 g/L. She has completed her family and desires definitive treatment. What is the most appropriate next step in management?

A. Hysteroscopy and endometrial biopsy
B. Levonorgestrel intrauterine system insertion (Correct Answer)
C. MRI pelvis to characterise myometrial pathology
D. Referral for endometrial ablation
E. Referral for hysterectomy

Explanation: ***Levonorgestrel intrauterine system insertion*** - The clinical presentation of **heavy menstrual bleeding** along with a **uniformly enlarged uterus** and **heterogeneous myometrium** on ultrasound strongly suggests **adenomyosis**. - The **Levonorgestrel Intrauterine System (LNG-IUS)** is the recommended **first-line medical treatment** for heavy menstrual bleeding, including cases of adenomyosis, as it significantly reduces menstrual blood loss. *Hysteroscopy and endometrial biopsy* - **Endometrial sampling** is typically indicated for women **over 45 years** with heavy menstrual bleeding or those with **risk factors for malignancy**, such as intermenstrual bleeding or thickened endometrium. - This patient is **44 years old** with no intermenstrual bleeding and a normal endometrial thickness (9 mm in secretory phase), making endometrial pathology less likely to be the primary cause. *MRI pelvis to characterise myometrial pathology* - While **MRI** is the **gold standard** for diagnosing adenomyosis, the ultrasound findings are already highly suggestive, and the initial management with LNG-IUS remains the same. - MRI is usually reserved for cases where the diagnosis is uncertain, or for **surgical planning** if medical management fails and more invasive treatment is being considered. *Referral for endometrial ablation* - **Endometrial ablation** is often less effective in patients with **adenomyosis** because the ectopic endometrial tissue is located deep within the myometrium. - It is also generally less successful or contraindicated in uteri larger than 10-12 cm, and medical management should be exhausted first. *Referral for hysterectomy* - Although the patient has completed her family and desires definitive treatment, current guidelines recommend attempting **medical management** first, such as the LNG-IUS. - **Hysterectomy** is a major surgical intervention and is typically reserved for cases where medical treatments have failed, are contraindicated, or are declined by the patient after thorough discussion of alternatives.

Question 42: A 27-year-old woman presents to the emergency department with 6 weeks amenorrhoea and mild cramping lower abdominal pain. Transvaginal ultrasound shows an empty uterus with endometrial thickness of 12 mm and no adnexal masses. Serum beta-hCG is 950 IU/L. A repeat beta-hCG test 48 hours later shows a level of 1,280 IU/L. She is haemodynamically stable with mild tenderness in the right iliac fossa. What is the most appropriate classification of this clinical scenario?

A. Intrauterine pregnancy too early to visualise
B. Pregnancy of unknown location with suboptimal rise in beta-hCG (Correct Answer)
C. Ectopic pregnancy requiring immediate surgical intervention
D. Complete miscarriage with residual beta-hCG
E. Heterotopic pregnancy

Explanation: ***Pregnancy of unknown location with suboptimal rise in beta-hCG*** - A **Pregnancy of Unknown Location (PUL)** is defined when serum beta-hCG is positive but there is no evidence of an intrauterine or extrauterine pregnancy on **transvaginal ultrasound**. - A rise of only 34.7% (from 950 to 1,280 IU/L) over 48 hours is considered a **suboptimal rise**, as a viable intrauterine pregnancy typically shows an increase of at least **53-66%**. *Intrauterine pregnancy too early to visualise* - While a pregnancy may be too small to see below the **discriminatory zone** (usually 1,500 –2,000 IU/L), the slow rate of rise makes a viable **intrauterine pregnancy (IUP)** less likely. - Most viable IUPs would demonstrate a much more robust doubling or significant percentage increase in **beta-hCG** levels over 48 hours. *Ectopic pregnancy requiring immediate surgical intervention* - Surgical intervention is indicated for patients who are **haemodynamically unstable**, have signs of **peritonitis**, or have a large adnexal mass on scan. - This patient is **stable** with a low beta-hCG and no adnexal mass, meaning expectant or medical management is often prioritized over **immediate surgery**. *Complete miscarriage with residual beta-hCG* - In a **complete miscarriage**, beta-hCG levels are expected to **resolve or decline** significantly (usually by >50%) rather than increase. - The rising hCG trend in this case contradicts the diagnosis of a completed passing of products of conception. *Heterotopic pregnancy* - This refers to the rare simultaneous occurrence of an **intrauterine** and **extrauterine** pregnancy, often associated with **assisted reproductive technology (ART)**. - There is no ultrasound evidence of an **intrauterine sac** or an extrauterine mass to support this complex diagnosis in this patient.

Question 43: A 40-year-old woman with von Willebrand disease type 1 presents with heavy menstrual bleeding that significantly impacts her quality of life. She reports flooding, passing large clots, and requiring time off work. Previous treatments with tranexamic acid and mefenamic acid provided insufficient improvement. She does not wish to have more children. Pelvic examination and ultrasound are normal. What is the most appropriate next management step?

A. Total hysterectomy
B. Levonorgestrel intrauterine system insertion (Correct Answer)
C. Combined oral contraceptive pill
D. Desmopressin (DDAVP) during menstruation
E. Endometrial ablation

Explanation: ***Levonorgestrel intrauterine system insertion*** - The **LNG-IUS** is highly effective for heavy menstrual bleeding in patients with **von Willebrand disease**, reducing blood loss by up to 97% through local **endometrial suppression**. - It is particularly suitable for this patient as she has **normal pelvic anatomy**, does not wish to have more children, and has failed initial medical management with tranexamic and mefenamic acid. *Total hysterectomy* - This is a **definitive surgical treatment** but carries significant risks of **perioperative hemorrhage** in patients with baseline bleeding disorders, especially with vWD. - It should only be considered after less invasive treatments have failed and requires meticulous coordination with a **hematologist** due to the underlying bleeding disorder. *Combined oral contraceptive pill* - While the **COCP** can increase factor VIII and vWF levels and reduce bleeding, it typically provides less **menstrual suppression** than the LNG-IUS for severe menorrhagia in vWD. - It carries systemic risks such as **venous thromboembolism**, making local hormonal delivery often preferable if the patient is suitable for an IUD. *Desmopressin (DDAVP) during menstruation* - **DDAVP** works by releasing **vWF and Factor VIII** from endothelial stores, which is helpful in **Type 1 vWD**, but is often insufficient as a monotherapy for severe menorrhagia. - Frequent use during menstruation can lead to **tachyphylaxis** and risks like **hyponatremia** due to its antidiuretic effect, limiting its long-term efficacy. *Endometrial ablation* - This procedure has a higher **failure rate** in women with systemic bleeding disorders like vWD compared to those with local pathology. - It carries a risk of **uncontrolled intraoperative bleeding** and may lead to hematometra or difficult-to-monitor bleeding in the future due to the underlying coagulopathy.

Question 44: A 36-year-old woman with a history of pelvic inflammatory disease presents with 6 weeks amenorrhoea and minimal brown vaginal discharge. She has mild left iliac fossa discomfort but is haemodynamically stable. Transvaginal ultrasound shows an empty uterus and a 28 mm left adnexal mass with a hyperechoic ring. Free fluid is visible in the pouch of Douglas. Serum beta-hCG is 2200 IU/L. She has normal renal and liver function and agrees to medical management. What additional investigation should be performed before administering methotrexate?

A. Serum progesterone level
B. Full blood count including white cell differential (Correct Answer)
C. Pelvic MRI scan
D. Diagnostic laparoscopy to confirm diagnosis
E. Repeat beta-hCG in 48 hours to confirm trend

Explanation: ***Full blood count including white cell differential*** - **Methotrexate** is a **folate antagonist** and **cytotoxic agent** known to cause **bone marrow suppression**, which can lead to **leukopenia**, **neutropenia**, and **thrombocytopenia**. A baseline **Full Blood Count (FBC)** is essential to assess the patient's haematological status before starting treatment. - Ensuring a normal **white cell differential** and **platelet count** is crucial to establish a baseline, identify any pre-existing haematological issues, and mitigate the risk of severe adverse effects or contraindications to **medical management**. *Serum progesterone level* - **Serum progesterone levels** are sometimes used to help differentiate between viable and non-viable pregnancies or **pregnancies of unknown location (PUL)**, but they do not guide the immediate decision for **methotrexate** administration in a diagnosed ectopic pregnancy. - Given the strong evidence for **ectopic pregnancy** from the clinical picture, **beta-hCG level**, and **transvaginal ultrasound** (empty uterus, adnexal mass, free fluid), this test provides no additional utility for initiating treatment. *Pelvic MRI scan* - **Transvaginal ultrasound (TVUS)** is the **gold standard** for diagnosing and localizing **ectopic pregnancies**, and in this case, it has already provided sufficient diagnostic information with the identification of an **adnexal mass** and free fluid. - A **pelvic MRI** scan is not a routine investigation for **ectopic pregnancy** and would unnecessarily delay the initiation of **medical management** without adding crucial information for treatment decisions. *Diagnostic laparoscopy to confirm diagnosis* - **Diagnostic laparoscopy** is an invasive surgical procedure with associated risks and is typically reserved for cases of **haemodynamic instability**, suspected rupture, or when the diagnosis remains uncertain despite non-invasive investigations. - The patient is **haemodynamically stable** and meets the criteria for **medical management** of an **ectopic pregnancy**, making an invasive procedure like laparoscopy unnecessary at this stage. *Repeat beta-hCG in 48 hours to confirm trend* - While **serial beta-hCG measurements** are vital for monitoring **pregnancies of unknown location (PUL)** or assessing the effectiveness of **methotrexate treatment** post-administration, they are not a prerequisite for initiating treatment once an **ectopic pregnancy** is clearly diagnosed and medical management is indicated. - Delaying **methotrexate** for 48 hours to confirm an hCG trend, especially with a confirmed **adnexal mass** on ultrasound, could potentially increase the risk of **tubal rupture** in a patient eligible for immediate treatment.

Question 45: According to NICE guidelines, which of the following beta-hCG thresholds is used as the discriminatory level above which an intrauterine gestational sac should be visible on transvaginal ultrasound in a viable intrauterine pregnancy?

A. 1000 IU/L
B. 1500 IU/L (Correct Answer)
C. 2000 IU/L
D. 2500 IU/L
E. 3000 IU/L

Explanation: ***1500 IU/L***- In accordance with **NICE guidelines**, this is the standard **discriminatory level** where a gestational sac must be visible via **transvaginal ultrasound (TVUS)**.- A beta-hCG above this threshold without a visible intrauterine sac significantly increases the clinical suspicion for an **ectopic pregnancy** or **pregnancy of unknown location (PUL)**.*1000 IU/L*- While some historical protocols used this lower threshold, it has a lower **sensitivity** for identifying viable intrauterine pregnancies compared to current UK standards.- Relying on this value may lead to premature diagnostic interventions when a **viable intrauterine pregnancy** is simply too early to be seen.*2000 IU/L*- Although some international bodies like the **ACOG** suggest a higher threshold to avoid misdiagnosing a viable pregnancy, it is not the standard level specified by **NICE**.- Using this threshold in the UK context might delay the diagnosis and management of a potential **ectopic pregnancy**.*2500 IU/L*- This level is well above the **discriminatory zone**; by this stage, a **yolk sac** or even a **fetal pole** is typically expected to be visible.- It is not used as the primary guideline threshold for distinguishing between early viable and non-viable/ectopic pregnancies.*3000 IU/L*- A beta-hCG of this magnitude without a visible sac almost definitively indicates an **abnormal pregnancy** (failed or ectopic).- Like the 2500 IU/L value, it is too high to serve as the baseline **discriminatory level** used for early triage and decision-making.

Question 46: A 48-year-old perimenopausal woman presents with a 13-month history of increasingly irregular and heavy menstrual bleeding. She experiences flooding with clots and cycles varying between 18-45 days. Pelvic examination is normal. Transvaginal ultrasound shows endometrial thickness of 14 mm and normal ovaries. What is the most important next investigation?

A. Serum FSH and LH levels
B. Endometrial sampling (Correct Answer)
C. MRI pelvis
D. Hysteroscopy and dilation and curettage
E. Coagulation screen

Explanation: ***Endometrial sampling*** - In women over **45 years** with irregular, heavy menstrual bleeding or an **endometrial thickness >10-12 mm**, tissue diagnosis is mandatory to rule out **endometrial hyperplasia or malignancy**. - This patient is at high risk due to her **perimenopausal status** and potential for **unopposed estrogen** exposure during anovulatory cycles. *Serum FSH and LH levels* - While these levels can confirm the **perimenopausal transition**, they provide no information regarding the structural or pathological cause of the bleeding. - Hormonal testing does not replace the need for tissue diagnosis to exclude **uterine cancer**. *MRI pelvis* - **Transvaginal ultrasound** has already provided sufficient imaging by identifying a thickened endometrium; MRI is not a first-line investigation for **abnormal uterine bleeding**. - MRI is generally reserved for staging known malignancies or characterizing complex **myomas/adenomyosis**, not for initial endometrial assessment. *Hysteroscopy and dilation and curettage* - While this can provide a diagnosis, **outpatient endometrial sampling** (e.g., Pipelle) is the preferred, less invasive initial step before considering surgical intervention. - **Hysteroscopy** is typically indicated if outpatient sampling is unsuccessful, providing inadequate samples, or if structural lesions like **polyps** are suspected. *Coagulation screen* - This is primarily indicated in younger women with heavy bleeding since menarche or those with a clinical history suggestive of **bleeding disorders**. - Age-related pathology like **endometrial hyperplasia** is a much more critical and likely diagnosis to exclude in a 48-year-old before investigating systemic coagulation.

Question 47: A 26-year-old woman is being followed up after receiving intramuscular methotrexate for an unruptured tubal ectopic pregnancy. Her initial beta-hCG was 2400 IU/L. On day 4 post-treatment, beta-hCG is 2600 IU/L, and on day 7 it is 1900 IU/L. She remains clinically stable with minimal abdominal discomfort. What is the most appropriate management?

A. Continue expectant management with weekly beta-hCG monitoring (Correct Answer)
B. Administer second dose of methotrexate
C. Arrange urgent laparoscopy
D. Commence oral misoprostol
E. Arrange outpatient hysteroscopy

Explanation: ***Continue expectant management with weekly beta-hCG monitoring***- In the single-dose **methotrexate protocol**, a successful response is defined as a fall in **beta-hCG levels of ≥15%** between Day 4 and Day 7 post-administration.- This patient had a **27% reduction** (from 2600 to 1900 IU/L), and since she is **clinically stable**, the correct management is to monitor hCG weekly until it reaches a non-pregnant level (<15 IU/L).*Administer second dose of methotrexate*- A **second dose** is indicated only if the beta-hCG levels fall by **less than 15%** between Day 4 and Day 7.- Administering an unnecessary dose increases the risk of **methotrexate side effects**, such as stomatitis, liver enzyme elevation, and bone marrow suppression.*Arrange urgent laparoscopy*- **Surgical intervention** (salpingectomy or salpingotomy) is reserved for patients who are **hemodynamically unstable**, have signs of **tubal rupture**, or fail medical management.- This patient is **clinically stable** with minimal discomfort and has a biochemical response to medical treatment, making surgery unnecessary.*Commence oral misoprostol*- **Misoprostol** is a prostaglandin analogue used for the medical management of **miscarriage** or termination of intrauterine pregnancies, not ectopic pregnancies.- It acts by causing **cervical ripening and uterine contractions**, which would not address a pregnancy located in the **fallopian tube**.*Arrange outpatient hysteroscopy*- **Hysteroscopy** involves endoscopic visualization of the **uterine cavity** and is not used in the diagnosis or management of an **extrapelvic (ectopic) pregnancy**.- This procedure has no role in assessing the resolution of a **tubal ectopic pregnancy** and could potentially cause uterine trauma in a patient recently treated with methotrexate.

Question 48: A 43-year-old woman with heavy menstrual bleeding undergoes hysteroscopy which reveals a normal uterine cavity with no polyps or fibroids. Endometrial biopsy shows proliferative endometrium with no atypia. She has regular cycles every 28 days. Full blood count shows haemoglobin 102 g/L. She does not wish to use hormonal treatments. What is the most appropriate pharmacological management?

A. Tranexamic acid during menstruation only (Correct Answer)
B. Continuous combined hormone replacement therapy
C. Cyclical oral progestogens days 5-26 of cycle
D. Danazol
E. GnRH analogues

Explanation: ***Tranexamic acid during menstruation only***- **Tranexamic acid** is the first-line **non-hormonal** treatment for heavy menstrual bleeding, effectively reducing blood loss by 40-50% through its **antifibrinolytic** action.- It is ideal for this patient because it is only taken during the duration of menses and respects her preference to avoid **hormonal treatments**.*Continuous combined hormone replacement therapy*- This therapy is primarily indicated for **menopausal symptom relief** and is not appropriate for a 43-year-old with regular ovulatory cycles.- It contains hormones, which specifically contradicts the patient's expressed preference for **non-hormonal** management.*Cyclical oral progestogens days 5-26 of cycle*- This regimen is a **hormonal treatment** typically used for **anovulatory** heavy menstrual bleeding, whereas this patient has regular cycles and a proliferative endometrium suggesting normal ovulation.- The patient explicitly stated she does not wish to use **hormonal treatments**, making this an inappropriate choice.*Danazol*- **Danazol** is an androgenic steroid that is rarely used as first-line therapy due to significant side effects like **weight gain**, acne, and hirsutism.- It is a **hormonal** intervention, which falls outside the patient's request for non-hormonal options.*GnRH analogues*- These medications induce a state of **medical menopause** and are generally reserved as a short-term pre-operative measure for fibroids.- They carry a high risk of **bone mineral density loss** and vasomotor symptoms, and they represent a form of intensive **hormonal** manipulation.

Question 49: A 31-year-old woman with confirmed right tubal ectopic pregnancy measuring 32 mm with no fetal heartbeat is being considered for medical management. Serum beta-hCG is 2800 IU/L. She is haemodynamically stable with minimal pain. She has normal renal and liver function. Which additional factor would be an absolute contraindication to methotrexate treatment?

A. Body mass index of 32 kg/m²
B. Previous caesarean section
C. Breastfeeding her 14-month-old child (Correct Answer)
D. Taking folic acid supplementation
E. Mild asthma controlled with salbutamol inhaler

Explanation: ***Breastfeeding her 14-month-old child*** - **Methotrexate** is an absolute contraindication in breastfeeding women as it is excreted into **breast milk** and can cause serious adverse effects, including **bone marrow suppression** and gastrointestinal toxicity in the infant. - The patient meets criteria for medical management based on **ectopic size (<35 mm)**, **beta-hCG (<3000 IU/L)**, and haemodynamic stability, but must stop breastfeeding if choosing this route. *Body mass index of 32 kg/m²* - A high **Body Mass Index (BMI)** is not a contraindication to methotrexate; however, dosing is typically calculated based on **Body Surface Area (BSA)** to ensure efficacy. - While obesity can theoretically impact drug distribution, it does not preclude the use of medical management in a stable patient. *Previous caesarean section* - A history of **caesarean section** is not a contraindication for methotrexate and does not interfere with the mechanism of **folate antagonism**. - It is only clinically relevant for locating the pregnancy, such as excluding a **caesarean scar ectopic**, but does not change the suitability for medical therapy if guidelines are met. *Taking folic acid supplementation* - **Folic acid** is a relative concern because it acts as an **antagonist** to methotrexate, potentially reducing the drug's effectiveness in resolving the ectopic pregnancy. - However, this is not an absolute contraindication; patients are simply instructed to **discontinue supplements** and avoid folate-rich foods during treatment. *Mild asthma controlled with salbutamol inhaler* - **Mild asthma** is not a contraindication for methotrexate therapy; concerns are usually reserved for patients with severe **pulmonary fibrosis** or active lung disease. - Absolute contraindications typically include established **immunodeficiency**, significant **renal/hepatic impairment**, or active **peptic ulcer disease**.

Question 50: What is the primary reason that women with previous ectopic pregnancy are at increased risk of recurrent ectopic pregnancy?

A. Hormonal imbalance affecting tubal motility
B. Underlying tubal pathology affecting ciliary function and transport (Correct Answer)
C. Increased circulating beta-hCG affecting implantation
D. Uterine factors preventing normal intrauterine implantation
E. Immunological factors causing rejection of intrauterine pregnancy

Explanation: ***Underlying tubal pathology affecting ciliary function and transport***- A previous ectopic pregnancy often indicates **damage to the fallopian tubes**, typically from conditions like **pelvic inflammatory disease (PID)**, endometriosis, or previous tubal surgery.- This damage impairs the **ciliary function** and **muscular contractions** of the tube, hindering the normal transport of the fertilized ovum to the uterus. *Hormonal imbalance affecting tubal motility*- While hormones like **progesterone** can influence tubal smooth muscle activity, they are not the primary cause of the structural damage leading to recurrent ectopic pregnancy.- The main issue is a **structural defect** or functional impairment of the tube, not transient hormonal fluctuations affecting motility.*Increased circulating beta-hCG affecting implantation*- **Beta-hCG** is a hormone produced by the placenta after implantation and indicates pregnancy, it does not determine the **site of implantation**.- High levels of hCG are a consequence of a developing pregnancy, whether intrauterine or ectopic, not a cause of its mislocation.*Uterine factors preventing normal intrauterine implantation*- Uterine issues such as **fibroids** or **polyps** are more likely to cause infertility or recurrent miscarriage by affecting the uterine cavity.- These factors do not primarily explain why an embryo would specifically implant in the **fallopian tube** rather than the uterus.*Immunological factors causing rejection of intrauterine pregnancy*- **Immunological factors** are more commonly associated with recurrent **miscarriage** due to the body's rejection of an otherwise normal intrauterine pregnancy.- They do not account for the embryo's initial implantation in an **extrauterine location**, which is fundamentally a problem of ovum transport.

Question 51: A 38-year-old woman with heavy menstrual bleeding has been using a levonorgestrel intrauterine system for 8 months. She initially experienced reduced bleeding for the first 4 months, but for the past 3 months has noticed increasing menstrual blood loss returning to previous heavy levels. Pelvic examination reveals a mobile uterus with no palpable masses. What is the most appropriate next investigation?

A. Hysteroscopy
B. Transvaginal ultrasound to check LNG-IUS position (Correct Answer)
C. Serum progesterone level
D. Endometrial biopsy
E. Full blood count and ferritin

Explanation: ***Transvaginal ultrasound to check LNG-IUS position*** - When a **levonorgestrel intrauterine system (LNG-IUS)** initially reduces bleeding but then fails, the primary concern is a **change in its position**, such as partial expulsion or malposition, reducing its local effect. - A **transvaginal ultrasound** is the most appropriate first-line investigation to quickly and non-invasively confirm the **fundal placement** of the IUS and rule out other uterine pathologies like **polyps** or **fibroids**. *Hysteroscopy* - **Hysteroscopy** is an invasive procedure that is usually reserved for cases where **ultrasound findings are inconclusive**, or when there is a need for direct visualization, removal of a displaced device, or biopsy of a suspected lesion. - It is not the initial investigation of choice when a less invasive method like **ultrasound** can provide crucial diagnostic information first. *Serum progesterone level* - A **serum progesterone level** is primarily used to assess **ovulation** or luteal phase function and has no relevance in diagnosing the cause of a failing **LNG-IUS**. - The therapeutic effect of the LNG-IUS is mainly local on the **endometrium**, making systemic hormone levels unhelpful in this context. *Endometrial biopsy* - While an **endometrial biopsy** is crucial for investigating abnormal uterine bleeding in certain situations, especially to exclude **endometrial hyperplasia** or **carcinoma**, it is not the first step when device malfunction is suspected. - This invasive procedure should be considered if the **LNG-IUS position is confirmed correct** and heavy bleeding persists, or if other risk factors warrant it. *Full blood count and ferritin* - **Full blood count (FBC)** and **ferritin** are important tests to assess the **secondary effects of heavy menstrual bleeding**, such as **iron-deficiency anemia**. - However, these tests do not help in diagnosing the **underlying cause** of the LNG-IUS failure or the return of heavy bleeding, making them less immediate than checking device integrity.

Question 52: A 29-year-old woman presents to the emergency department with sudden onset severe right iliac fossa pain and shoulder tip pain. She has 6 weeks amenorrhoea. On examination, she is pale, tachycardic at 115 bpm, and blood pressure is 95/60 mmHg. There is generalised abdominal tenderness with guarding and rebound. Urine pregnancy test is positive. What is the most appropriate immediate management?

A. Arrange urgent transvaginal ultrasound scan
B. Commence intravenous fluid resuscitation and arrange emergency laparoscopy (Correct Answer)
C. Obtain serum beta-hCG level before further management
D. Administer intramuscular methotrexate
E. Perform culdocentesis to confirm haemoperitoneum

Explanation: ***Commence intravenous fluid resuscitation and arrange emergency laparoscopy*** - The patient's presentation with **sudden onset severe abdominal pain**, **shoulder tip pain**, signs of **shock** (tachycardia, hypotension, pallor), and **peritoneal irritation** (guarding, rebound) in a pregnant woman strongly indicates a **ruptured ectopic pregnancy**. - Immediate management involves **resuscitation with intravenous fluids** to stabilize her haemodynamics and **emergency laparoscopy** to control the bleeding and remove the ectopic gestation, which is a life-saving procedure. *Arrange urgent transvaginal ultrasound scan* - While a **transvaginal ultrasound** is the gold standard for diagnosing ectopic pregnancy, it is not the immediate priority for a **haemodynamically unstable patient** suspected of having a ruptured ectopic. - Delaying definitive surgical intervention for an ultrasound would further compromise the patient's condition and increase the risk of **maternal morbidity and mortality**. *Obtain serum beta-hCG level before further management* - Measuring **serum beta-hCG levels** is crucial in managing stable ectopic pregnancies, but in this emergency scenario, the **positive urine pregnancy test** combined with severe clinical signs of rupture is sufficient for immediate surgical intervention. - Waiting for **quantitative hCG results** would cause an unacceptable delay in a rapidly deteriorating patient. *Administer intramuscular methotrexate* - **Methotrexate** is a medical management option for **small, unruptured ectopic pregnancies** in **haemodynamically stable patients** with specific hCG levels and no evidence of haemoperitoneum. - It is **absolutely contraindicated** in this patient due to her **haemodynamic instability**, signs of rupture, and the need for immediate surgical intervention. *Perform culdocentesis to confirm haemoperitoneum* - **Culdocentesis** is an **invasive and largely outdated procedure** used to detect free fluid in the pouch of Douglas. - It has been replaced by more modern and less invasive diagnostic tools and would **delay crucial surgical management** in this critically ill patient.

Question 53: A 45-year-old woman presents with a 9-month history of heavy menstrual bleeding. She has tried tranexamic acid and mefenamic acid with minimal improvement. She has completed her family. Pelvic examination reveals a 12-week sized, irregular, non-tender uterus. Pelvic ultrasound shows multiple intramural and subserosal fibroids, the largest measuring 7 cm. Her haemoglobin is 88 g/L. She wishes to avoid major surgery if possible. What is the most appropriate next management option?

A. Levonorgestrel intrauterine system insertion
B. Uterine artery embolisation (Correct Answer)
C. Total abdominal hysterectomy
D. Oral norethisterone
E. GnRH agonist therapy

Explanation: ***Uterine artery embolisation*** - This is the most appropriate choice for a patient with **large symptomatic fibroids** (7 cm) and **menorrhagia** who explicitly wishes to **avoid major surgery**. - It is highly effective for reducing bleeding and shrinking fibroids in a **12-week sized uterus**, providing a minimally invasive alternative to hysterectomy. *Levonorgestrel intrauterine system insertion* - The presence of a **7 cm fibroid** and a **12-week sized irregular uterus** suggests significant cavity distortion, which increases the risk of **expulsion** and reduces efficacy. - It is generally not the first-line choice when fibroids are large enough to significantly alter the **uterine anatomy**. *Total abdominal hysterectomy* - While this provides a definitive cure for fibroids and anemia, the patient specifically requested to **avoid major surgery**. - Hysterectomy carries a longer **recovery time** and higher surgical risk compared to interventional radiological procedures like UAE. *Oral norethisterone* - This is a hormonal treatment that is generally **less effective** for managing heavy bleeding caused by large structural lesions like **intramural fibroids**. - It does not address the **bulk symptoms** or provide a long-term solution for a patient who has already failed first-line medical therapies. *GnRH agonist therapy* - These are typically used as **short-term** measures (3-6 months) to shrink fibroids **pre-operatively** or to bridge to menopause. - They are not suitable as a standalone long-term management option due to significant **side effects** like bone mineral density loss and menopausal symptoms.

Question 54: A 27-year-old nulliparous woman undergoes laparoscopy for suspected ectopic pregnancy. At surgery, a 3.5 cm unruptured left ampullary ectopic pregnancy is identified. The left fallopian tube appears healthy apart from the ectopic gestation. The right tube appears normal. She wishes to preserve her fertility. What is the most appropriate surgical management?

A. Left salpingectomy (Correct Answer)
B. Left salpingotomy
C. Bilateral salpingectomy
D. Left salpingectomy with right prophylactic salpingectomy
E. Milking the ectopic pregnancy from the fimbrial end

Explanation: ***Left salpingectomy***- Current **NICE/RCOG guidelines** recommend **salpingectomy** as the first-line surgical treatment for women with a healthy contralateral tube, even when desiring future fertility.- It offers a lower risk of **persistent trophoblastic disease** (requiring methotrexate) and avoids the significantly increased risk of a **repeat ectopic pregnancy** in the same tube associated with salpingotomy.*Left salpingotomy*- This procedure involves making an incision to remove the pregnancy while leaving the tube; however, it is generally reserved for patients with only **one functioning fallopian tube** or significant contralateral tubal disease.- It carries a **20% risk** of **persistent trophoblast** and does not significantly improve long-term **intrauterine pregnancy rates** compared to salpingectomy when the other tube is healthy.*Bilateral salpingectomy*- There is no clinical indication to remove the **normal-appearing right tube**, which is essential for future natural conception in this young woman.- This procedure would render the patient **permanently sterile**, necessitating **In Vitro Fertilization (IVF)** for any future pregnancy.*Left salpingectomy with right prophylactic salpingectomy*- Removing a healthy fallopian tube is medically unjustifiable and contradicts the patient's goal of **preserving fertility**.- **Prophylactic salpingectomy** is only considered in specific contexts like reducing ovarian cancer risk in high-risk patients during unrelated pelvic surgeries, which does not apply here.*Milking the ectopic pregnancy from the fimbrial end*- This technique is associated with a high rate of **retained products of conception** and subsequent pelvic hemorrhage or persistent hCG elevation.- It is discouraged due to a higher likelihood of **tubal damage** and failure compared to established surgical excision methods.

Question 55: A 42-year-old multiparous woman presents with a 14-month history of heavy menstrual bleeding. She reports flooding and clots, requiring double protection. Examination is unremarkable with a normal-sized uterus. Full blood count shows haemoglobin 95 g/L. She has completed her family and requests definitive treatment. Pelvic ultrasound shows a uniformly enlarged uterus measuring 11 cm in length with heterogeneous myometrium and no focal lesions. What is the most likely diagnosis?

A. Endometrial hyperplasia
B. Adenomyosis (Correct Answer)
C. Multiple small intramural fibroids
D. Endometrial polyp
E. Dysfunctional uterine bleeding

Explanation: ***Adenomyosis***- The presence of **heavy menstrual bleeding** in a multiparous woman with a **uniformly enlarged uterus** and **heterogeneous myometrium** on ultrasound, without focal lesions, is highly characteristic of **adenomyosis**.- This condition involves the invasion of endometrial tissue into the myometrium, leading to diffuse thickening of the uterine wall and often causes **dysmenorrhea** and **menorrhagia**.*Endometrial hyperplasia*- This condition is characterized by an **abnormal proliferation of the endometrial glands**, typically resulting in a **thickened endometrial stripe** on ultrasound.- It does not explain the **uniformly enlarged uterus** or the **heterogeneous myometrium** described, as it primarily affects the lining, not the muscle.*Multiple small intramural fibroids*- Fibroids are **well-defined, focal masses** within the myometrium, which would be visible as distinct lesions on ultrasound.- The report explicitly states **"no focal lesions"**, making this diagnosis unlikely despite potentially causing heavy menstrual bleeding and uterine enlargement.*Endometrial polyp*- An endometrial polyp is a **focal growth arising from the endometrium** and protruding into the uterine cavity, visible as an intracavitary mass on ultrasound.- It does not cause the diffuse **heterogeneous myometrium** or the overall **uniformly enlarged uterus** observed in this case.*Dysfunctional uterine bleeding*- This is a diagnosis of **exclusion**, implying no identifiable structural or histological abnormality to account for the bleeding.- The ultrasound findings of a **uniformly enlarged uterus** and **heterogeneous myometrium** clearly indicate a structural abnormality (adenomyosis), thereby ruling out dysfunctional uterine bleeding.

Question 56: A 34-year-old woman presents to the emergency department with 7 weeks amenorrhoea, mild left iliac fossa pain, and minimal vaginal spotting. She is haemodynamically stable. Transvaginal ultrasound shows an empty uterus with no adnexal mass visible. Serum beta-hCG is 1200 IU/L. A repeat beta-hCG 48 hours later is 1350 IU/L. What is the most appropriate next step in management?

A. Arrange repeat beta-hCG in 48 hours (Correct Answer)
B. Administer intramuscular methotrexate
C. Perform diagnostic laparoscopy
D. Arrange expectant management with weekly beta-hCG
E. Perform endometrial curettage

Explanation: ***Arrange repeat beta-hCG in 48 hours*** - This patient has a **Pregnancy of Unknown Location (PUL)** with a suboptimal rise in **beta-hCG** (12.5% in 48 hours), which is less than the expected **53% minimum rise** for a viable intrauterine pregnancy. - As the patient is **haemodynamically stable** and the initial hCG is below the **discriminatory zone** (1500–2000 IU/L), repeating the test in 48 hours is the safest next step to determine if the pregnancy is failing or ectopic. *Administer intramuscular methotrexate* - **Methotrexate** is a medical management for a confirmed **ectopic pregnancy**; it is premature to administer it without a definitive diagnosis or a visualized adnexal mass. - Clinical guidelines require multiple hCG readings or ultrasound evidence to ensure an **intrauterine pregnancy** isn't inadvertently terminated. *Perform diagnostic laparoscopy* - **Laparoscopy** is an invasive surgical procedure reserved for patients who are **haemodynamically unstable**, have severe pain, or have ultrasound evidence of an **ectopic pregnancy**. - In a stable patient with low hCG levels and no visible mass, the risk of surgery outweighs the benefit when monitoring is an option. *Arrange expectant management with weekly beta-hCG* - **Weekly monitoring** is inappropriate at this stage because the suboptimal rise (12.5%) carries a high risk of an **ectopic pregnancy** that needs closer surveillance. - **48-hour intervals** are necessary until the hCG trend or a diagnosis is clearly established to prevent potential rupture. *Perform endometrial curettage* - **Endometrial curettage** is used to differentiate between a non-viable intrauterine pregnancy and an ectopic pregnancy by looking for **chorionic villi**. - This is generally not the first-line step in a stable patient with hCG below the **discriminatory zone**, as it does not rule out an ectopic pregnancy definitively.

Question 57: A 50-year-old woman presents to her GP with a 7-month history of irregular heavy vaginal bleeding. Her periods were previously regular 28-day cycles but are now unpredictable, occurring every 18-45 days with variable flow. Her last menstrual period was 3 weeks ago. She is a non-smoker with BMI 26 kg/m². On examination, her abdomen is soft and non-tender. Speculum examination shows a healthy-appearing cervix with no active bleeding. Her cervical screening is up to date with normal results. What is the most appropriate initial investigation?

A. Transvaginal ultrasound scan (Correct Answer)
B. Serum follicle-stimulating hormone and luteinising hormone levels
C. Outpatient hysteroscopy with endometrial biopsy
D. Full blood count and thyroid function tests
E. Pelvic MRI scan

Explanation: ***Transvaginal ultrasound scan*** - In a 50-year-old woman with **irregular heavy vaginal bleeding**, a **transvaginal ultrasound scan** is the most appropriate initial investigation to assess for **endometrial pathology** like hyperplasia or malignancy. - It can effectively measure **endometrial thickness** and identify structural abnormalities such as **fibroids** or **polyps** which could be contributing to the bleeding. *Serum follicle-stimulating hormone and luteinising hormone levels* - While the patient's age and symptoms suggest **perimenopause**, hormone levels are not the primary investigation to rule out significant **endometrial pathology**. - Clinical diagnosis of perimenopause often suffices, and these tests do not identify the structural causes of heavy bleeding. *Outpatient hysteroscopy with endometrial biopsy* - **Hysteroscopy with biopsy** is a more invasive procedure and is typically performed *after* a transvaginal ultrasound has identified suspicious findings like **endometrial thickening**. - It is not the initial investigation but rather a follow-up if ultrasound results are concerning or inconclusive, allowing for direct visualization and tissue sampling. *Full blood count and thyroid function tests* - A **full blood count** is important to check for **anaemia** due to heavy bleeding but does not determine the underlying cause of the bleeding itself. - **Thyroid function tests** are not routinely indicated as a first-line investigation for irregular bleeding unless other clinical symptoms suggest thyroid dysfunction. *Pelvic MRI scan* - A **pelvic MRI scan** is a more advanced and expensive imaging modality not used as a first-line investigation for abnormal uterine bleeding. - It is usually reserved for complex cases, further characterization of findings from ultrasound, or for **surgical planning** in conditions like extensive fibroids or adenomyosis.

Question 58: A 32-year-old woman is admitted with suspected ectopic pregnancy. She has 8 weeks amenorrhoea and right-sided pelvic pain. Initial serum beta-hCG is 3200 IU/L. Transvaginal ultrasound shows an empty uterus and a 32mm right adnexal mass with no fetal heartbeat. There is minimal free fluid in the pelvis. She is haemodynamically stable. Following counselling, she opts for expectant management. Under which circumstance during expectant management should medical or surgical intervention be initiated?

A. Beta-hCG level plateaus for 7 days without rising or falling
B. Patient develops mild increase in abdominal pain but remains stable
C. Beta-hCG rises by 15% over 48-hour period (Correct Answer)
D. Repeat ultrasound shows increase in adnexal mass size to 38mm
E. Beta-hCG level remains above 1000 IU/L after 2 weeks

Explanation: ***Beta-hCG rises by 15% over 48-hour period*** - Intervention is required if **beta-hCG levels rise** or plateau, as this indicates the **ectopic pregnancy** is viable or not resolving spontaneously. - A **15% increase** in initial monitoring periods suggests active trophoblastic growth, necessitating a shift to **medical management** (methotrexate) or surgery. *Beta-hCG level plateaus for 7 days without rising or falling* - A **plateauing beta-hCG** is considered a failure of expectant management because it signifies persistent **trophoblastic activity**. - Decisions for intervention are typically made within shorter windows (48-72 hours) rather than waiting for **7 days** to verify a plateau. *Patient develops mild increase in abdominal pain but remains stable* - Mild increases in pain can occur during the **spontaneous resolution** of an ectopic pregnancy and do not always mandate immediate surgery if the patient is **hemodynamically stable**. - Only significant clinical deterioration, signs of **hemoperitoneum**, or hemodynamic instability are absolute indications for abandoning expectant management. *Repeat ultrasound shows increase in adnexal mass size to 38mm* - Changes in **adnexal mass size** on ultrasound are less reliable indicators of failure than **biochemical trends** and clinical status. - An increase in size may be due to **hematoma formation** rather than continued trophoblastic growth and is not an absolute indication for intervention on its own. *Beta-hCG level remains above 1000 IU/L after 2 weeks* - The **absolute value** of beta-hCG after two weeks is less important than the **downward trend** of the hormone levels. - Expectant management is considered successful as long as the **beta-hCG levels continue to fall** appropriately, regardless of the baseline value.

Question 59: A 36-year-old woman with heavy menstrual bleeding has been using a levonorgestrel intrauterine system for 18 months with good initial symptom control. She now presents with recurrence of heavy bleeding over the past 3 months. Examination shows the IUS threads are visible at the cervical os and the uterus is normal size. Pelvic ultrasound confirms the IUS is correctly positioned in the uterine cavity and shows a 4cm subserosal fibroid on the posterior uterine wall that was not present on her pre-insertion scan. What is the most likely explanation for her recurrent heavy bleeding?

A. The levonorgestrel intrauterine system has lost its efficacy over time
B. The subserosal fibroid is causing increased menstrual blood loss
C. The intrauterine system has become partially expelled
D. Endometrial polyps have developed despite the intrauterine system
E. Adenomyosis has developed and is not controlled by the intrauterine system (Correct Answer)

Explanation: ***Adenomyosis has developed and is not controlled by the intrauterine system*** - **Adenomyosis** involves endometrial tissue within the **myometrium**, which can progress over time and lead to recurrent **heavy menstrual bleeding (HMB)** even when an IUS is in place. - While the LNG-IUS provides local suppression of the **endometrium**, its hormonal effect may be insufficient to control symptoms if the adenomyosis is deep or extensive within the muscle wall. *The levonorgestrel intrauterine system has lost its efficacy over time* - The **LNG-IUS (Mirena)** is licensed for 5 years and maintains a therapeutic **hormone release rate** well beyond the 18-month mark mentioned. - A sudden recurrence of bleeding after 18 months of good control is more suggestive of **new pathology** than drug exhaustion. *The subserosal fibroid is causing increased menstrual blood loss* - **Subserosal fibroids** grow on the outer surface of the uterus and do not distort the **endometrial cavity**, meaning they typically do not cause HMB. - Only **submucosal** or large **intramural fibroids** significantly increase the surface area of the uterine lining or interfere with contractility to cause heavy bleeding. *The intrauterine system has become partially expelled* - Ultrasound confirmation shows the device is **correctly positioned** in the uterine cavity, and the **threads** are visible at the os. - Clinical and radiological evidence directly contradicts **expulsion** as the cause of the recurrent bleeding. *Endometrial polyps have developed despite the intrauterine system* - Although polyps can cause irregular bleeding, the **pelvic ultrasound** would likely have identified them as discrete lesions within the cavity. - The scenario points toward a more likely progressive myometrial condition like **adenomyosis**, especially given the development of other uterine growth (the fibroid).

Question 60: A 29-year-old woman presents to the emergency department with sudden onset severe right-sided abdominal pain and shoulder tip pain. She has 7 weeks amenorrhoea. On examination, she is pale, with blood pressure 88/55 mmHg and heart rate 122 beats per minute. She has generalised abdominal tenderness with guarding and rebound tenderness. Her cervical os is closed with minimal old blood in the vagina. A bedside urine pregnancy test is positive. What physiological mechanism is responsible for the shoulder tip pain in this patient?

A. Direct compression of the brachial plexus by haemoperitoneum
B. Stretching of the round ligament causing referred pain
C. Inflammation of the parietal peritoneum adjacent to the fallopian tube
D. Irritation of the diaphragm by intraperitoneal blood (Correct Answer)
E. Ischaemia of the shoulder muscles due to hypovolaemic shock

Explanation: ***Irritation of the diaphragm by intraperitoneal blood*** - This patient presents with a **ruptured ectopic pregnancy** and **haemoperitoneum**, where blood irritates the **phrenic nerve** (C3-C5) under the diaphragm. - Pain is referred to the **C3-C5 dermatomes**, which correspond to the **shoulder tip**, a classic sign of significant internal bleeding known as **Kehr's sign**. *Direct compression of the brachial plexus by haemoperitoneum* - The **brachial plexus** is located in the neck and axilla, which are anatomically isolated from the **peritoneal cavity**. - Blood in the abdomen cannot exert the physical pressure required to compress these nerves directly. *Stretching of the round ligament causing referred pain* - **Round ligament pain** typically manifests as sharp, pulling sensations in the **lower quadrants** or inguinal area during pregnancy. - It does not cause **shoulder tip pain** or the sudden hemodynamic collapse seen in this patient. *Inflammation of the parietal peritoneum adjacent to the fallopian tube* - Irritation of the **parietal peritoneum** near the tube causes localized **rebound tenderness** and guarding in the lower abdomen. - Somatic nerves in the lower abdomen do not share pathways that would result in **referred pain** to the shoulder. *Ischaemia of the shoulder muscles due to hypovolaemic shock* - While **hypovolaemic shock** causes systemic hypoperfusion, it leads to general symptoms like **tachycardia** and **pallor**, not focal muscle ischaemia. - Musculoskeletal ischaemia does not present as localized **shoulder tip pain** following a sudden abdominal event.

Question 61: A 48-year-old woman presents with heavy menstrual bleeding for 11 months. Examination reveals a 12-week sized irregular uterus. Ultrasound confirms multiple intramural fibroids, the largest measuring 6cm. She has tried the levonorgestrel intrauterine system but it was expelled after 2 months. She has completed her family. Her haemoglobin is 92 g/L. She wishes to avoid major surgery if possible. What is the most appropriate next management option?

A. Uterine artery embolisation (Correct Answer)
B. Total abdominal hysterectomy
C. Repeated attempt at levonorgestrel intrauterine system insertion
D. Tranexamic acid and ferrous sulphate supplementation
E. Myomectomy via laparotomy

Explanation: ***Uterine artery embolisation***- **Uterine artery embolisation (UAE)** is a minimally invasive radiological procedure that induces **fibroid ischaemia** and shrinkage, making it ideal for patients wishing to avoid **major surgery**.- It is highly effective for women with **symptomatic fibroids** who have completed their family and where the **LNG-IUS** has already failed or been expelled.*Total abdominal hysterectomy*- While **hysterectomy** is a definitive treatment for heavy menstrual bleeding and fibroids, it is classified as **major surgery** with a long recovery period.- This option is unsuitable here because the patient specifically expressed a desire to **avoid major surgery** if possible.*Repeated attempt at levonorgestrel intrauterine system insertion*- The **LNG-IUS** was already expelled, likely due to the **distorted uterine cavity** and large **intramural fibroids**.- A repeated attempt has a high **risk of failure** and is unlikely to provide a long-term solution for symptomatic 6cm fibroids.*Tranexamic acid and ferrous sulphate supplementation*- These address the symptoms of **anaemia** and acute bleeding but do not treat the underlying **fibroid pathology** causing the 12-week sized uterus.- **Medical management** alone is typically insufficient for significant fibroid-related heavy menstrual bleeding and does not meet the patient's need for definitive management of the mass.*Myomectomy via laparotomy*- **Myomectomy** is considered a major surgical procedure involving significant blood loss risks and a long **post-operative recovery**.- This approach is generally reserved for women who wish to **preserve fertility**, whereas this patient has completed her family and wants to avoid surgery.

Question 62: A 34-year-old woman presents to the emergency department with 6 weeks amenorrhoea, minimal vaginal spotting, and mild left-sided pelvic discomfort. Her serum beta-hCG is 800 IU/L. Transvaginal ultrasound shows an empty uterus with no adnexal masses visualised and no free fluid. She is haemodynamically stable. A repeat beta-hCG 48 hours later is 920 IU/L. What is the most likely diagnosis?

A. Molar pregnancy
B. Ectopic pregnancy (Correct Answer)
C. Heterotopic pregnancy
D. Viable intrauterine pregnancy
E. Complete miscarriage

Explanation: ***Ectopic pregnancy***- A **suboptimal rise in beta-hCG** (15% in 48 hours, significantly less than the expected 53-66%) combined with an **empty uterus** on transvaginal ultrasound is highly indicative of an ectopic pregnancy.- The clinical symptoms of **amenorrhoea**, **vaginal spotting**, and **unilateral pelvic discomfort** further support this diagnosis, even without a visible adnexal mass. *Molar pregnancy*- This condition is characterized by **abnormally high beta-hCG levels** (often >100,000 IU/L) and a distinctive **"snowstorm" or vesicular appearance** of the placenta on ultrasound.- The patient's relatively low beta-hCG and empty uterus on ultrasound do not align with the typical presentation of a **hydatidiform mole**. *Heterotopic pregnancy*- A heterotopic pregnancy involves the **coexistence of both an intrauterine and an extrauterine pregnancy**.- The ultrasound report explicitly states an **empty uterus**, ruling out the presence of an intrauterine gestation, which is a prerequisite for this rare diagnosis. *Viable intrauterine pregnancy*- For a viable intrauterine pregnancy, **beta-hCG levels** are expected to increase by at least **53-66% over 48 hours**; the 15% rise seen here is significantly suboptimal.- An **empty uterus** on transvaginal ultrasound with a beta-hCG level of 800 IU/L (which is near or within the discriminatory zone for some institutions) strongly suggests an abnormal pregnancy. *Complete miscarriage*- A **complete miscarriage** is typically associated with **rapidly declining beta-hCG levels** as the pregnancy tissue has been expelled.- While the uterus is empty, the patient's **rising beta-hCG trend** (800 to 920 IU/L) indicates ongoing, albeit non-viable, trophoblastic activity, contradicting a complete miscarriage.

Question 63: What is the primary mechanism by which non-steroidal anti-inflammatory drugs such as mefenamic acid reduce menstrual blood loss in women with heavy menstrual bleeding?

A. Inhibition of prostaglandin synthesis in the endometrium (Correct Answer)
B. Promotion of endometrial fibrinolysis inhibition
C. Direct vasoconstriction of spiral arterioles
D. Enhancement of platelet aggregation and clot formation
E. Suppression of the hypothalamic-pituitary-ovarian axis

Explanation: ***Inhibition of prostaglandin synthesis in the endometrium*** - NSAIDs like **mefenamic acid** inhibit the **cyclooxygenase (COX)** enzymes, which leads to a significant decrease in endometrial **prostaglandin E2 and F2-alpha** levels. - By reducing these prostaglandins, which are potent vasodilators, NSAIDs decrease uterine blood flow and promote **hemostasis**, thereby reducing menstrual blood loss. *Promotion of endometrial fibrinolysis inhibition* - This is the primary mechanism of **tranexamic acid**, an antifibrinolytic agent that prevents the breakdown of existing blood clots. - Unlike NSAIDs, it specifically blocks **plasminogen activation** and does not primarily target prostaglandin synthesis. *Direct vasoconstriction of spiral arterioles* - While reduced prostaglandin levels indirectly contribute to a more favorable environment for **vasoconstriction**, NSAIDs do not act as direct vasoconstrictors on the spiral arterioles. - Their effect is primarily biochemical (COX inhibition) rather than a direct pharmacological stimulation of **vascular smooth muscle** receptors. *Enhancement of platelet aggregation and clot formation* - Most NSAIDs, including mefenamic acid, have a reversible **inhibitory effect on platelet aggregation** by blocking thromboxane A2 synthesis. - The reduction in blood loss occurs despite this mild anti-platelet effect, because the decrease in **endometrial vasodilation** is the more dominant mechanism. *Suppression of the hypothalamic-pituitary-ovarian axis* - This mechanism is characteristic of **hormonal therapies**, such as combined oral contraceptives or GnRH agonists, which regulate the menstrual cycle and ovulation. - NSAIDs treat menstrual bleeding locally and symptomatically, having no direct effect on **ovulation** or systemic hormone levels.

Question 64: A 26-year-old woman undergoes laparoscopy for suspected ectopic pregnancy. At surgery, a 3.5cm unruptured left ampullary ectopic pregnancy is identified. The left fallopian tube appears otherwise healthy. The right tube appears normal. The patient is nulliparous and wishes to preserve fertility. She is haemodynamically stable. What is the most appropriate surgical management?

A. Left salpingectomy
B. Left salpingotomy with follow-up beta-hCG monitoring (Correct Answer)
C. Left salpingectomy and right salpingoscopy
D. Bilateral salpingectomy
E. Left salpingotomy without follow-up

Explanation: ***Left salpingotomy with follow-up beta-hCG monitoring***- In a **nulliparous**, haemodynamically stable patient with an **unruptured** ectopic pregnancy and a healthy appearing tube, **salpingotomy** is the preferred approach to **preserve fertility**.- Since there is a 5-20% risk of **persistent trophoblast** tissue remainining in the tube, mandatory **serial beta-hCG monitoring** is required until levels are undetectable.*Left salpingectomy*- This involves the **complete removal** of the fallopian tube, which is typically indicated if the tube is **ruptured**, severely damaged, or if there is uncontrolled bleeding.- While it reduces the risk of persistent trophoblast, it is less desirable in a nulliparous patient strictly wishing to **maximize future fertility** when the tube is otherwise healthy.*Left salpingectomy and right salpingoscopy*- **Salpingoscopy** of the contralateral tube is not routinely indicated or necessary when the right tube appears **grossly normal** during laparoscopy.- Performing a **salpingectomy** in this clinical scenario contradicts the patient's primary goal of **preserving the affected tube** for future conception.*Bilateral salpingectomy*- This procedure would result in **permanent tubal infertility**, requiring IVF for any future pregnancies, which is inappropriate for a patient wishing to preserve fertility.- There is no clinical indication to remove the **normal-appearing right tube** in this patient.*Left salpingotomy without follow-up*- Performing a salpingotomy without **post-operative monitoring** is medically unsafe due to the risk of **re-growth of trophoblastic tissue**.- Failure to monitor **beta-hCG levels** could lead to a delayed tubal rupture from persistent ectopic tissue even after the initial surgery.

Question 65: A 44-year-old woman with a BMI of 29 kg/m² presents with a 10-month history of heavy menstrual bleeding. She has tried tranexamic acid with limited improvement. She does not wish to have more children. Examination reveals a mobile anteverted uterus of normal size. Ultrasound shows endometrial thickness of 14mm on day 20 of a 30-day cycle, with normal myometrium and ovaries. Endometrial biopsy shows benign proliferative endometrium with no atypia. Thyroid function and coagulation screen are normal. What underlying diagnosis should be considered?

A. Von Willebrand disease
B. Subclinical hypothyroidism
C. Endometrial hyperplasia without atypia
D. Anovulatory cycles with unopposed oestrogen (Correct Answer)
E. Occult endometrial malignancy

Explanation: ***Anovulatory cycles with unopposed oestrogen*** - The **endometrial biopsy** showing **benign proliferative endometrium** on day 20, when a **secretory phase** is expected, strongly indicates **anovulation**. - In **anovulatory cycles**, progesterone is not produced, leading to continuous **unopposed oestrogen stimulation** of the endometrium, causing it to thicken excessively and shed irregularly, resulting in **heavy menstrual bleeding**. *Von Willebrand disease* - The patient's **coagulation screen** is explicitly stated as **normal**, which makes **Von Willebrand disease** highly unlikely. - Inherited bleeding disorders typically present with **heavy menstrual bleeding** since **menarche** rather than an onset in the mid-40s. *Subclinical hypothyroidism* - The clinical vignette notes that the **thyroid function** tests are **normal**, explicitly ruling out thyroid-related menstrual dysfunction. - Hypothyroidism usually presents with other systemic symptoms like **weight gain**, **lethargy**, or **cold intolerance**, which are not described. *Endometrial hyperplasia without atypia* - The **endometrial biopsy** specifically showed **benign proliferative endometrium**, which is a physiological state, not a hyperplastic one. - While a thickness of 14mm is high, the histological evaluation is the **gold standard** and it ruled out **hyperplasia**. *Occult endometrial malignancy* - The biopsy results specifically confirmed there was **no atypia** or **malignancy**, making this diagnosis highly improbable. - Additionally, the uterus was described as **normal size** and mobile, which is less suggestive of advanced malignant processes.

Question 66: A 31-year-old woman with a confirmed right tubal ectopic pregnancy measuring 28mm with no fetal heartbeat is being considered for medical management. Her serum beta-hCG is 2800 IU/L. She is haemodynamically stable and asymptomatic apart from minimal lower abdominal discomfort. She has normal renal and liver function tests. Which finding would be an absolute contraindication to treatment with intramuscular methotrexate?

A. Patient unwilling to attend for weekly follow-up
B. History of previous ectopic pregnancy
C. Serum beta-hCG level above 1500 IU/L
D. Ectopic mass measuring 28mm in diameter
E. Presence of fetal cardiac activity on ultrasound (Correct Answer)

Explanation: ***Presence of fetal cardiac activity on ultrasound*** - The presence of **fetal cardiac activity** indicates a more advanced and viable ectopic pregnancy, which results in a significantly **higher risk of treatment failure** with methotrexate. - It is considered an **absolute contraindication** to medical management, necessitating surgical intervention due to the low success rates (often <10%) and risk of rupture. *Patient unwilling to attend for weekly follow-up* - While **inability to comply** with follow-up is a contraindication as it prevents safety monitoring of hCG levels and vital signs, being "unwilling" is a patient choice issue rather than a direct medical finding. - It's a logistical contraindication that prevents safe management, not an **absolute medical contraindication** based on the clinical characteristics of the ectopic pregnancy itself. *History of previous ectopic pregnancy* - A history of a previous **ectopic pregnancy** is a risk factor for recurrence but is not a contraindication to using **methotrexate** for the current pregnancy if other criteria for medical management are met. - Management is determined by the characteristics of the **current pregnancy** and the patient's clinical stability, not solely by past history. *Serum beta-hCG level above 1500 IU/L* - This is often a **relative contraindication** or a factor predicting lower success, but many protocols allow methotrexate for hCG levels up to **3000-5000 IU/L**, and even higher in some cases. - In this scenario, 2800 IU/L is within an acceptable range for a single-dose **methotrexate** treatment protocol, provided other criteria (like absence of fetal cardiac activity) are met. *Ectopic mass measuring 28mm in diameter* - An ectopic mass size of **28mm** is typically below the common threshold of **35mm or 40mm** used to exclude candidates for medical management with methotrexate. - Larger masses increase the risk of **tubal rupture** and treatment failure, but 28mm is generally considered acceptable for systemic methotrexate therapy.

Question 67: A 39-year-old nulliparous woman presents with heavy menstrual bleeding for 14 months that has not responded to tranexamic acid or mefenamic acid. She reports using 15-20 pads per cycle and her haemoglobin is 105 g/L. She wishes to preserve her fertility. Pelvic examination is normal. Transvaginal ultrasound shows a normal-sized uterus with endometrial thickness of 6mm on day 8 of her cycle and both ovaries appear normal. Hysteroscopy shows a normal uterine cavity with no polyps or fibroids. What is the most appropriate next management step?

A. Levonorgestrel intrauterine system insertion
B. Cyclical oral progestogens for 21 days per cycle
C. Endometrial ablation
D. Referral for myomectomy
E. Combined oral contraceptive pill (Correct Answer)

Explanation: ***Combined oral contraceptive pill*** - For a nulliparous woman with **heavy menstrual bleeding (HMB)**, no identifiable structural pathology after extensive investigation, and failure of non-hormonal treatments, the **Combined Oral Contraceptive Pill (COCP)** is an effective hormonal treatment. - It significantly reduces menstrual blood loss, regulates the menstrual cycle, and allows for **rapid return to fertility** upon cessation, aligning with her desire to preserve fertility. *Levonorgestrel intrauterine system insertion* - While the **Levonorgestrel intrauterine system (LNG-IUS)** is highly effective for HMB and often considered first-line hormonal treatment, the patient's explicit desire to **preserve fertility** might mean she prefers a method with a quicker or more immediate return to conception plans compared to a long-acting device. - However, it is an excellent option for HMB and does preserve fertility, but COCP is also a very appropriate medical alternative in this scenario. *Cyclical oral progestogens for 21 days per cycle* - High-dose cyclical oral progestogens are generally **less effective** at reducing menstrual blood loss compared to the LNG-IUS or COCP for unexplained HMB. - They are often reserved for women with **contraindications to estrogen** or when other more effective hormonal options are not suitable. *Endometrial ablation* - **Endometrial ablation** is a procedure that destroys the uterine lining and is **contraindicated** in women who wish to **preserve fertility** as it can lead to severe pregnancy complications and typically results in infertility. - It is considered a definitive surgical treatment for HMB when medical management fails and the woman has completed her family. *Referral for myomectomy* - This option is **inappropriate** because the patient's **transvaginal ultrasound** and **hysteroscopy** were normal, explicitly stating no polyps or fibroids were found. - **Myomectomy** is a surgical procedure specifically indicated for the removal of **uterine fibroids** causing HMB, which are absent in this case.

Question 68: A 27-year-old woman presents to the emergency department with sudden onset severe right lower abdominal pain that started 3 hours ago. She has 5 weeks amenorrhoea and uses the combined oral contraceptive pill inconsistently. On examination, she is in severe distress with tenderness and guarding in the right iliac fossa. Her blood pressure is 95/60 mmHg, heart rate 115 beats per minute, and she appears pale. Urine pregnancy test is positive. What is the most appropriate immediate management?

A. Diagnostic laparoscopy under general anaesthesia
B. Arrange urgent transvaginal ultrasound scan
C. Immediate resuscitation and emergency laparotomy (Correct Answer)
D. Administer intramuscular methotrexate 50 mg/m²
E. Serum beta-hCG measurement and repeat in 48 hours

Explanation: ***Immediate resuscitation and emergency laparotomy*** - The patient's presentation with **sudden severe abdominal pain**, **amenorrhoea**, a **positive pregnancy test**, and signs of **hypovolaemic shock** (hypotension, tachycardia, pallor) strongly indicates a **ruptured ectopic pregnancy**. - **Immediate resuscitation** to stabilize vital signs and **emergency laparotomy** are critical to achieve rapid **haemostasis** and manage life-threatening intra-abdominal haemorrhage. *Diagnostic laparoscopy under general anaesthesia* - While laparoscopy is preferred for *stable* ectopic pregnancies, it is generally **contraindicated** in haemodynamically unstable patients due to the need for pneumoperitoneum and potential delays. - **Laparotomy** offers faster access and better control for managing massive bleeding in patients presenting with **shock**. *Arrange urgent transvaginal ultrasound scan* - Delaying definitive surgical intervention to perform imaging in a patient with suspected **ruptured ectopic pregnancy** and **shock** is inappropriate and potentially fatal. - The clinical picture dictates the need for immediate **resuscitation and surgery**, as imaging will not change the immediate management of an unstable patient. *Administer intramuscular methotrexate 50 mg/m²* - **Methotrexate** is a medical treatment option reserved for *haemodynamically stable* patients with *unruptured*, small ectopic pregnancies, or specific criteria for expectant management. - It is **contraindicated** in cases of suspected or confirmed ectopic rupture and haemodynamic instability, as it does not address active bleeding. *Serum beta-hCG measurement and repeat in 48 hours* - Serial **beta-hCG monitoring** is used to manage **pregnancies of unknown location (PUL)** or to confirm the resolution of an ectopic pregnancy in *stable* patients. - Waiting 48 hours for repeat testing in a patient with active bleeding and **shock** is inappropriate and would lead to significant morbidity and mortality.

Question 69: A 42-year-old woman presents to her general practitioner with heavy menstrual bleeding for 9 months. She reports flooding through super-absorbent pads every 2 hours on the heaviest days and passing large clots. Her periods last 8-9 days and occur regularly every 28 days. She has completed her family and is considering treatment options. Physical examination reveals a bulky, smooth uterus consistent with 14-week gestational size. Her haemoglobin is 98 g/L. Transvaginal ultrasound shows a uniformly enlarged uterus with heterogeneous myometrium and no focal lesions. What is the most appropriate definitive management option?

A. Total abdominal hysterectomy (Correct Answer)
B. Endometrial ablation
C. Levonorgestrel intrauterine system insertion
D. Tranexamic acid 1g three times daily during menstruation
E. Gonadotropin-releasing hormone analogue therapy

Explanation: ***Total abdominal hysterectomy*** - A **definitive management** for **adenomyosis** in a patient who has **completed her family**, providing a permanent cure for heavy menstrual bleeding and pain. - The uterus size (14-week gestation) and **heterogeneous myometrium** are classic features of adenomyosis where surgical removal is superior to medical management. *Endometrial ablation* - This procedure is generally **contraindicated** in a uterus larger than **10-12 weeks' size** due to technical difficulty and high failure rates. - It often fails to treat **adenomyosis** effectively as the pathology is located deep within the **myometrium**, beyond the reach of ablation. *Levonorgestrel intrauterine system insertion* - Although often first-line for heavy menstrual bleeding, its efficacy is significantly reduced in a **bulky uterus (14-week size)** due to a higher risk of **expulsion**. - It is a medical management option rather than a **definitive** surgical solution for a patient seeking a permanent fix. *Tranexamic acid 1g three times daily during menstruation* - This is a **non-hormonal** symptomatic treatment that reduces blood loss but does not address the underlying **adenomyosis** pathology. - It is unsuitable as **definitive management**, especially in a patient already suffering from **iron deficiency anaemia** (Hb 98 g/L). *Gonadotropin-releasing hormone analogue therapy* - These agents provide only a **temporary reduction** in uterine size and bleeding by inducing a hypoestrogenic state. - They are primarily used as **pre-operative** adjuncts rather than definitive long-term treatments due to side effects like **bone mineral density loss**.

Question 70: A 35-year-old woman presents to the emergency department with 6 weeks amenorrhoea, right iliac fossa pain, and light vaginal bleeding. Her serum beta-hCG is 1200 IU/L. Transvaginal ultrasound shows an empty uterus with no adnexal masses visible. Free fluid is seen in the pouch of Douglas. She is haemodynamically stable with blood pressure 125/78 mmHg and heart rate 82 beats per minute. A repeat beta-hCG 48 hours later is 1450 IU/L. What is the most appropriate next step in management?

A. Diagnostic laparoscopy (Correct Answer)
B. Repeat ultrasound scan in 1 week
C. Administer intramuscular methotrexate
D. Emergency laparotomy
E. Continue expectant management with weekly beta-hCG monitoring

Explanation: ***Diagnostic laparoscopy*** - The combination of **amenorrhoea**, **abdominal pain**, **vaginal bleeding**, a **suboptimal beta-hCG rise** (from 1200 to 1450 IU/L over 48h), and **free fluid in the pouch of Douglas** strongly suggests a **leaking or ruptured ectopic pregnancy**. - Given the **haemodynamic stability** and these concerning findings, **diagnostic laparoscopy** is the most appropriate next step to confirm the diagnosis and provide definitive surgical treatment. *Repeat ultrasound scan in 1 week* - Delaying investigation for a week is unsafe due to the risk of **tubal rupture**, especially with **free fluid** in the pouch of Douglas. - An **intrauterine pregnancy** should be detectable via transvaginal ultrasound at beta-hCG levels of 1500-2000 IU/L; an empty uterus at 1200 IU/L with rising hCG and free fluid warrants immediate action, not observation. *Administer intramuscular methotrexate* - **Methotrexate** is a medical management option for **unruptured ectopic pregnancies** in stable patients without signs of bleeding. - The presence of **free fluid in the pouch of Douglas** indicates potential intra-abdominal bleeding, which is a contraindication for methotrexate and necessitates surgical intervention. *Emergency laparotomy* - **Emergency laparotomy** is typically reserved for patients who are **haemodynamically unstable** or have evidence of massive **haemoperitoneum**. - As the patient is **haemodynamically stable**, **laparoscopy** is the less invasive and preferred surgical approach for diagnosis and treatment of a suspected ectopic pregnancy. *Continue expectant management with weekly beta-hCG monitoring* - **Expectant management** is suitable only for asymptomatic patients with **declining beta-hCG** levels and no evidence of rupture or intrauterine pregnancy. - This patient has persistent symptoms (**right iliac fossa pain**) and a **rising beta-hCG** (even if suboptimal), making expectant management inappropriate and risky.

Question 71: A 28-year-old woman is being monitored following intramuscular methotrexate for a 2.8 cm unruptured tubal ectopic pregnancy. Her beta-hCG levels are: Day 0: 3200 IU/L, Day 4: 3400 IU/L, Day 7: 2500 IU/L. She remains clinically well with minimal abdominal discomfort. What is the most appropriate management at this stage?

A. Single repeat dose of methotrexate as the day 4-7 fall is less than 15% (Correct Answer)
B. Continue monitoring with beta-hCG on day 14 as treatment is progressing satisfactorily
C. Arrange urgent laparoscopy for surgical management due to treatment failure
D. Administer second dose of methotrexate immediately due to initial rise in beta-hCG
E. Perform transvaginal ultrasound to assess for tubal rupture

Explanation: ***Continue monitoring with beta-hCG on day 14 as treatment is progressing satisfactorily***- The **success** of single-dose **methotrexate** for ectopic pregnancy is defined by a **≥15% decline in beta-hCG** levels between Day 4 and Day 7.- Here, the **beta-hCG** fell from **3400 IU/L** (Day 4) to **2500 IU/L** (Day 7), representing a **26.47% decrease**, indicating a satisfactory response and requiring continued weekly monitoring.*Single repeat dose of methotrexate as the day 4-7 fall is less than 15%*- The calculation shows a **26.47% fall** in **beta-hCG** between Day 4 and Day 7, which is **greater than the 15% threshold**, thus making the premise of this option incorrect.- A **repeat dose of methotrexate** would only be considered if the Day 4-7 decline was **less than 15%** or if **hCG levels plateaued or rose** during subsequent monitoring.*Arrange urgent laparoscopy for surgical management due to treatment failure*- Urgent **surgical management** is indicated for **hemodynamic instability**, suspected **tubal rupture**, or clear **medical treatment failure** (e.g., persistent rise in hCG after multiple doses).- This patient is **clinically well** with **minimal abdominal discomfort** and a satisfactory **hCG decline**, indicating successful medical management, not failure.*Administer second dose of methotrexate immediately due to initial rise in beta-hCG*- An **initial rise** in **beta-hCG** between Day 0 and Day 4 after methotrexate administration is a **common and expected finding** as trophoblastic tissue may continue to produce hCG briefly.- Management decisions are primarily based on the **Day 4 to Day 7 hCG trend**, which in this case shows a significant fall, not on the initial rise.*Perform transvaginal ultrasound to assess for tubal rupture*- Given the patient's **clinical stability**, lack of significant symptoms (minimal discomfort is common), and a positive **beta-hCG decline**, routine ultrasound for **tubal rupture** is not warranted.- Ultrasound would be indicated if there were new or worsening symptoms suggesting rupture, such as **severe abdominal pain**, **hemodynamic instability**, or a **rising beta-hCG** after treatment.

Question 72: A 51-year-old woman presents with a 6-month history of irregular heavy bleeding. Her last menstrual period was 3 months ago. She reports occasional hot flushes. BMI is 27 kg/m². Pelvic examination is normal. Transvaginal ultrasound shows endometrial thickness of 6 mm with no focal abnormalities. FSH is 38 IU/L. What is the most appropriate management regarding endometrial assessment?

A. Endometrial biopsy is essential due to her age and prolonged bleeding
B. No endometrial sampling required; proceed with treatment for heavy menstrual bleeding (Correct Answer)
C. Perform endometrial biopsy only if bleeding persists after 3 months of treatment
D. Hysteroscopy with directed biopsy is mandatory in this age group
E. Repeat ultrasound in 3 months to monitor endometrial thickness

Explanation: ***No endometrial sampling required; proceed with treatment for heavy menstrual bleeding*** - In a **perimenopausal** woman with vasomotor symptoms and elevated **FSH (38 IU/L)**, irregular bleeding is typically due to **anovulation** rather than malignancy. - An **endometrial thickness (ET)** of 6 mm is considered benign in perimenopausal women (threshold for concern is typically **>10-12 mm**), making invasive sampling unnecessary. *Endometrial biopsy is essential due to her age and prolonged bleeding* - While age **>45 years** is a risk factor, the **reassuring ultrasound findings** (thin, regular endometrium) and clinical context of perimenopause allow for initial observation. - Selective sampling is preferred over routine biopsy when the **ET is <10 mm** and there are no focal abnormalities or high-risk factors like **morbid obesity**. *Perform endometrial biopsy only if bleeding persists after 3 months of treatment* - This approach is partially correct in terms of **safety-netting**, but the immediate need is to treat the **heavy menstrual bleeding (HMB)** first. - Biopsy is indicated if there is a **failure of medical management** or if the bleeding pattern becomes significantly more suspicious later on. *Hysteroscopy with directed biopsy is mandatory in this age group* - **Hysteroscopy** is the gold standard for diagnosing **focal pathology** (like polyps or fibroids), which was specifically ruled out by the normal ultrasound. - It is not mandatory as a first-line step for a patient with a **normal pelvic exam** and a thin endometrial stripe. *Repeat ultrasound in 3 months to monitor endometrial thickness* - Repeating the scan is unnecessary because the **perimenopausal status** naturally causes thickness fluctuations; a single reassuring scan is sufficient to start treatment. - Monitoring does not address the patient's primary complaint of **heavy bleeding**, which requires active management with options like **LNG-IUS** or tranexamic acid.

Question 73: A 24-year-old woman presents to the emergency department with 5 weeks amenorrhoea and light vaginal bleeding. She reports mild lower abdominal discomfort. Observations: BP 125/78 mmHg, pulse 76 bpm, temperature 36.8°C. Abdominal examination reveals mild suprapubic tenderness with no guarding. Transvaginal ultrasound shows an empty uterus with 11 mm endometrium and a 2 cm right adnexal mass with a hyperechoic ring. No free fluid is visible. Serum beta-hCG is 1650 IU/L. What is the most appropriate initial management?

A. Expectant management with repeat beta-hCG in 48 hours (Correct Answer)
B. Arrange same-day methotrexate administration
C. Emergency laparoscopy for suspected ectopic pregnancy
D. Repeat ultrasound in one week when beta-hCG will be above discriminatory zone
E. Diagnostic uterine curettage to exclude intrauterine pregnancy

Explanation: ***Expectant management with repeat beta-hCG in 48 hours*** - The patient is **hemodynamically stable** and presents with a **Pregnancy of Unknown Location (PUL)**, as the ultrasound findings are suggestive but not definitively diagnostic of an ectopic pregnancy at this beta-hCG level. - A **repeat beta-hCG in 48 hours** is essential to monitor the trend, which helps differentiate between a viable intrauterine pregnancy, a miscarriage, or an ectopic pregnancy based on its rise, fall, or plateau. *Arrange same-day methotrexate administration* - **Methotrexate** is indicated for stable patients with a **confirmed ectopic pregnancy** without a fetal heartbeat and beta-hCG below certain thresholds (e.g., <5000 IU/L), which is not the case here. - Administering methotrexate now would be premature and could **terminate a potentially viable intrauterine pregnancy** if the current ultrasound findings are simply due to very early gestation. *Emergency laparoscopy for suspected ectopic pregnancy* - **Emergency laparoscopy** is reserved for patients who are **hemodynamically unstable**, show signs of **tubal rupture**, or have significant **free fluid** on ultrasound. - This patient is stable with mild symptoms and no free fluid, making an invasive surgical procedure an inappropriate initial management step. *Repeat ultrasound in one week when beta-hCG will be above discriminatory zone* - Waiting an entire week for a repeat ultrasound is **unsafe** and carries a significant risk of **tubal rupture** if the pregnancy is indeed ectopic. - Her current beta-hCG of 1650 IU/L is already around the **discriminatory zone** (1500-2000 IU/L), where an intrauterine pregnancy should ideally be visible; thus, closer monitoring (48 hours) is warranted. *Diagnostic uterine curettage to exclude intrauterine pregnancy* - **Diagnostic uterine curettage** is an **invasive procedure** used to identify chorionic villi, but it is not a first-line diagnostic tool for a stable patient with a **PUL**. - This procedure carries the risk of **terminating a potentially viable intrauterine pregnancy** if the gestation is simply too early to be detected by ultrasound.

Question 74: A 40-year-old woman with heavy menstrual bleeding is found to have a 6 cm posterior wall intramural fibroid on ultrasound. She wishes to preserve her fertility as she is planning pregnancy in the next year. Her haemoglobin is 95 g/L. She has no other significant medical history. After counselling about risks and benefits, what is the most appropriate management to address both her fertility wishes and current symptoms?

A. Insert levonorgestrel intrauterine system to control bleeding and preserve uterus
B. Perform myomectomy after 3 months of GnRH analogue therapy (Correct Answer)
C. Arrange uterine artery embolisation to shrink fibroid
D. Commence tranexamic acid and iron therapy, then reassess after pregnancy
E. Proceed with immediate myomectomy without pretreatment

Explanation: ***Perform myomectomy after 3 months of GnRH analogue therapy*** - **Myomectomy** is the gold standard surgical treatment for symptomatic intramural fibroids in women who wish to **preserve fertility** and achieve pregnancy. - Pretreatment with **GnRH analogues** for 3 months reduces **fibroid volume** and vascularity while allowing for the correction of **anaemia (Hb 95 g/L)** before surgery. *Insert levonorgestrel intrauterine system to control bleeding and preserve uterus* - While effective for **heavy menstrual bleeding**, the **LNG-IUS** acts as a contraceptive and must be removed to allow for the patient's planned pregnancy next year. - A **6 cm fibroid** may distort the uterine cavity, increasing the risk of device **expulsion** or failed symptom control. *Arrange uterine artery embolisation to shrink fibroid* - **Uterine artery embolisation (UAE)** is generally avoided in women actively seeking pregnancy due to potential risks to **ovarian reserve** and placental blood flow. - It is associated with higher rates of **pregnancy complications** compared to surgical myomectomy. *Commence tranexamic acid and iron therapy, then reassess after pregnancy* - **Tranexamic acid** manages symptoms only and does not address the physical presence of a **6 cm fibroid**, which may hinder conception or increase miscarriage risk. - Delaying definitive treatment is inappropriate as the fibroid's size and location are likely contributing significantly to both her **anaemia** and fertility concerns. *Proceed with immediate myomectomy without pretreatment* - Operating immediately on a large fibroid with significant **anaemia (Hb 95 g/L)** increases the risk of requiring an intraoperative **blood transfusion**. - Lack of pretreatment makes the surgery technically more difficult due to higher **vascularity** and larger fibroid dimensions compared to a pre-shrunk fibroid.

Question 75: A 33-year-old woman presents with sudden onset severe right-sided pelvic pain, shoulder tip pain, and one episode of syncope. She has 6 weeks amenorrhoea. On examination, she is pale with blood pressure 95/60 mmHg, pulse 115 bpm, and has rebound tenderness in the right iliac fossa. Urine pregnancy test is positive. What is the most appropriate immediate management?

A. Arrange urgent transvaginal ultrasound to confirm diagnosis before any intervention
B. Obtain intravenous access, commence fluid resuscitation, and arrange emergency laparoscopy (Correct Answer)
C. Administer intramuscular methotrexate as she is still conscious and responding
D. Take blood for full blood count and group and save, then transfer for ultrasound
E. Request urgent serum beta-hCG level to guide management decision

Explanation: ***Obtain intravenous access, commence fluid resuscitation, and arrange emergency laparoscopy*** - The patient's presentation with sudden severe pelvic pain, shoulder tip pain, syncope, and **haemodynamic instability** (hypotension, tachycardia) in a pregnant woman strongly indicates a **ruptured ectopic pregnancy** with internal bleeding. - Immediate management involves **aggressive fluid resuscitation** to stabilize the patient and **emergency laparoscopy** for definitive diagnosis and control of haemorrhage, as delay can be fatal. *Arrange urgent transvaginal ultrasound to confirm diagnosis before any intervention* - While ultrasound is crucial for diagnosing ectopic pregnancy, in a **haemodynamically unstable** patient with signs of rupture, it should not delay life-saving surgical intervention. - The clinical picture of **shock** and **peritoneal signs** takes precedence over imaging in this emergent scenario. *Administer intramuscular methotrexate as she is still conscious and responding* - **Methotrexate** is a medical management option for **stable ectopic pregnancies** without rupture or significant bleeding. - It is absolutely contraindicated in cases with **haemodynamic instability**, suspected rupture, or significant pain, as it would delay definitive surgical treatment and worsen outcomes. *Take blood for full blood count and group and save, then transfer for ultrasound* - Taking blood for **full blood count** and **group and save** is essential for surgical preparation, but transferring an unstable patient for ultrasound will dangerously delay definitive treatment. - **Resuscitation** and preparation for surgery should be initiated simultaneously, with the patient heading directly to the operating theatre once stabilized for surgery. *Request urgent serum beta-hCG level to guide management decision* - A **positive urine pregnancy test** is sufficient to confirm pregnancy in this acute setting; quantitative serum **beta-hCG levels** are primarily used for managing stable, non-ruptured ectopics or pregnancies of unknown location. - Waiting for laboratory results in a patient presenting with **syncope** and signs of **intra-abdominal haemorrhage** would lead to a critical delay in emergency surgical management.

Question 76: What is the primary mechanism by which ectopic pregnancy most commonly occurs in the fallopian tube?

A. Impaired tubal motility preventing embryo transport to the uterus (Correct Answer)
B. Premature activation of trophoblast adhesion molecules
C. Reduced progesterone receptor expression in tubal epithelium
D. Abnormal embryonic development causing delayed implantation
E. Increased tubal blood flow promoting ectopic implantation

Explanation: ***Impaired tubal motility preventing embryo transport to the uterus*** - The primary mechanism of **tubal ectopic pregnancy** is the delay or arrest of the fertilized egg's transport to the uterus, often due to **impaired tubal motility** or **ciliary dysfunction**. - Factors like **pelvic inflammatory disease** (PID) causing **scarring** or congenital tubal abnormalities can disrupt the coordinated movements necessary for embryo transit. *Premature activation of trophoblast adhesion molecules* - While **trophoblast adhesion** is essential for implantation, its premature activation is typically a *consequence* of the embryo being retained in the tube, rather than the primary cause of its initial entrapment. - The fundamental issue leading to ectopic implantation is the embryo's inability to reach the **endometrium**, which is usually due to tubal transport problems. *Reduced progesterone receptor expression in tubal epithelium* - Progesterone is crucial for maintaining pregnancy and influencing tubal physiology, but a primary reduction in **progesterone receptor expression** in the tubal epithelium is not an established main cause of ectopic pregnancy. - Hormonal imbalances might play a role in tubal function, but **mechanical obstruction** or **motility defects** are more central to ectopic implantation. *Abnormal embryonic development causing delayed implantation* - Most embryos in ectopic pregnancies are **genetically normal**; hence, abnormal embryonic development is generally not the primary cause of the ectopic location. - If an embryo's development is significantly abnormal, it is more likely to result in **non-implantation** or early **pregnancy loss**, rather than successful implantation in an ectopic site. *Increased tubal blood flow promoting ectopic implantation* - **Increased tubal blood flow** is a physiological response to implantation (angiogenesis) to support the developing embryo, not the initial factor that causes the embryo to implant in the tube. - The ectopic location is determined by factors that prevent the embryo from reaching the uterus, such as **tubal damage** or **dysfunction**, before vascular changes occur.

Question 77: A 37-year-old woman with adenomyosis presents with heavy menstrual bleeding that has failed to respond adequately to tranexamic acid and mefenamic acid. She has had a levonorgestrel intrauterine system in situ for 18 months but continues to experience heavy bleeding and dysmenorrhoea affecting her work. She has two children and her family is complete. Examination reveals a tender, bulky uterus. What is the most appropriate next management step?

A. Trial of GnRH analogue for 6 months to assess response
B. Remove LNG-IUS and commence combined hormonal contraceptive
C. Refer for endometrial ablation procedure
D. Discuss hysterectomy as definitive treatment option (Correct Answer)
E. Increase dose by inserting second levonorgestrel intrauterine system

Explanation: ***Discuss hysterectomy as definitive treatment option***- The patient has **completed her family** and has **failed multiple medical therapies** including NSAIDs, tranexamic acid, and 18 months of **LNG-IUS**, for her adenomyosis-related heavy bleeding and dysmenorrhea.- **Hysterectomy** is the **definitive cure** for adenomyosis, as it removes the entire uterus which contains the ectopic endometrial tissue within the myometrium.*Trial of GnRH analogue for 6 months to assess response*- **GnRH analogues** induce a **temporary menopause**, which can alleviate symptoms, but are typically used for **short-term management** due to side effects like **bone mineral density loss**.- Symptoms almost always **recur upon cessation** of GnRH analogues, making it an unsuitable long-term solution for a patient seeking definitive management.*Remove LNG-IUS and commence combined hormonal contraceptive*- The **LNG-IUS** delivers **progesterone directly to the uterus** and is generally more effective for managing adenomyosis-related bleeding and pain than systemic combined hormonal contraceptives.- Given the failure of the **LNG-IUS** after an adequate trial, it is unlikely that a less potent systemic **combined hormonal contraceptive** would provide better symptom control.*Refer for endometrial ablation procedure*- **Endometrial ablation** targets the superficial endometrium and is generally **ineffective for adenomyosis** because the disease involves endometrial glands deep within the **myometrium**.- Ablation in adenomyosis can potentially lead to **trapped blood** within the myometrium, worsening pain and dysmenorrhea.*Increase dose by inserting second levonorgestrel intrauterine system*- Inserting **two LNG-IUS devices** is **not a standard or evidence-based practice** for increasing hormonal dosage or efficacy in managing adenomyosis.- If a single **LNG-IUS** has failed after a sufficient trial (18 months), the appropriate next step is to consider **alternative treatment modalities**, not simply to double the existing one.

Question 78: A 26-year-old woman with confirmed left tubal ectopic pregnancy receives intramuscular methotrexate. Her initial beta-hCG is 2400 IU/L. On day 4 post-injection, she reports increased left-sided abdominal pain but remains haemodynamically stable. Repeat beta-hCG is 2800 IU/L. What is the most likely explanation for these findings?

A. Treatment failure requiring immediate surgical intervention
B. Separation pain from tubal abortion, which is expected with methotrexate (Correct Answer)
C. Ruptured ectopic pregnancy requiring emergency laparoscopy
D. Inadequate methotrexate dose requiring second injection
E. Persistent ectopic pregnancy requiring repeat methotrexate on day 7

Explanation: ***Separation pain from tubal abortion, which is expected with methotrexate*** - **Separation pain** occurs in up to 80% of patients 3–7 days after **methotrexate** administration as the pregnancy detaches from the tubal wall. - An initial rise in **beta-hCG** between Day 1 and Day 4 is a normal physiological response and does not indicate **treatment failure** provided the patient is **haemodynamically stable**. *Treatment failure requiring immediate surgical intervention* - **Treatment failure** is not determined on Day 4; it is defined by a <15% fall in **hCG levels** between Day 4 and Day 7. - **Surgical intervention** is reserved for patients who are clinically deteriorating or show definitive signs of **tubal rupture**. *Ruptured ectopic pregnancy requiring emergency laparoscopy* - While pain is a symptom, **haemodynamic stability** (normal BP and heart rate) makes **acute rupture** less likely than expected separation pain. - Rupture typically presents with **peritoneal signs**, shoulder tip pain, or clinical evidence of **intra-abdominal hemorrhage**. *Inadequate methotrexate dose requiring second injection* - The decision to administer a **second dose** can only be made after comparing Day 4 and Day 7 **hCG levels**. - A single dose of **methotrexate** is often sufficient if the levels drop by 15% later in the first week. *Persistent ectopic pregnancy requiring repeat methotrexate on day 7* - Persistence is assessed on Day 7; if the **hCG decline** is less than 15% from the Day 4 value, a repeat dose is then considered. - Assessing persistence on Day 4 is premature because the **hCG** frequently plateaus or rises initially following the injection.

Question 79: A 48-year-old woman presents with a 10-month history of increasingly heavy and unpredictable menstrual bleeding. Her periods occur every 21-35 days and last 7-10 days. Pelvic examination is unremarkable. Transvaginal ultrasound shows a normal-sized uterus with 9 mm endometrium and normal ovaries. FSH level is 42 IU/L. Endometrial biopsy shows proliferative endometrium with no atypia. What is the most appropriate initial management?

A. Levonorgestrel intrauterine system insertion (Correct Answer)
B. Tranexamic acid for symptomatic relief
C. Cyclical progestogen therapy days 15-26 of cycle
D. Combined hormonal contraceptive pill
E. Total hysterectomy with bilateral salpingo-oophorectomy

Explanation: ***Levonorgestrel intrauterine system insertion*** - The **LNG-IUS** is the first-line treatment for **heavy menstrual bleeding (HMB)** as it provides both symptom control and **endometrial protection** by thinning the uterine lining. - For this patient in the **perimenopause** (suggested by elevated **FSH**), it offers the highest reduction in blood loss and can remain in situ for up to 5 years. *Tranexamic acid for symptomatic relief* - This is a **non-hormonal** option that reduces fibrinolysis; however, it does not regulate the cycle or address the underlying **proliferative endometrium**. - It is less effective at reducing total blood loss compared to the **LNG-IUS** and provides no **contraceptive** benefit. *Cyclical progestogen therapy days 15-26 of cycle* - While it can help regulate the cycle, it is significantly **less effective** than the LNG-IUS or the combined pill in reducing menstrual blood flow. - It does not consistently provide **contraception** and often has lower patient compliance due to the need for daily dosing. *Combined hormonal contraceptive pill* - The **COCP** is an effective treatment for HMB, but it carries an increased risk of **venous thromboembolism (VTE)** in women over 35, especially those who smoke or have cardiovascular risk factors. - Given the high **FSH of 42 IU/L**, the patient is nearing menopause, and systemic estrogens may not be the ideal initial choice compared to **local delivery** systems. *Total hysterectomy with bilateral salpingo-oophorectomy* - This is an **invasive surgical** option that should only be considered after medical management (like the **LNG-IUS**) has failed or is contraindicated. - Given her **normal biopsy** (no atypia) and normal imaging, initial management must prioritize conservative, **medical therapies**.

Question 80: A 29-year-old nulliparous woman undergoes laparoscopy for left-sided pelvic pain and amenorrhoea of 7 weeks. A 3.5 cm unruptured ectopic pregnancy is identified in the left fallopian tube. The tube appears distended but intact. The right fallopian tube appears normal. She is haemodynamically stable. What is the most appropriate surgical management?

A. Left salpingectomy to minimize risk of recurrent ectopic pregnancy (Correct Answer)
B. Left salpingotomy with postoperative beta-hCG monitoring
C. Bilateral salpingectomy to prevent future ectopic pregnancy
D. Left salpingotomy only if the tube appears severely damaged
E. Right-sided salpingectomy with left salpingotomy

Explanation: ***Left salpingectomy to minimize risk of recurrent ectopic pregnancy***- For a **3.5 cm unruptured ectopic pregnancy** in a **hemodynamically stable** woman with a **normal contralateral tube**, salpingectomy is the preferred surgical management because it definitively removes the affected tube, eliminating the risk of **persistent trophoblastic tissue**.- Evidence indicates that **future intrauterine pregnancy rates** are similar between salpingectomy and salpingotomy when the other fallopian tube appears healthy, making salpingectomy a safe and definitive approach.*Left salpingotomy with postoperative beta-hCG monitoring*- This procedure attempts to preserve the fallopian tube but carries a 15-20% risk of **persistent trophoblast**, requiring close **postoperative beta-hCG monitoring** and potentially further methotrexate or surgery.- Salpingotomy is generally reserved for patients with a **damaged or absent contralateral tube** to maximize fertility potential, which is not the primary indication here given the normal right tube.*Bilateral salpingectomy to prevent future ectopic pregnancy*- This is an **overly aggressive and inappropriate** intervention as it would render the patient **infertile**, necessitating assisted reproductive technologies for any future conception.- Surgical management should only address the **affected tube** (left) when the contralateral tube (right) is normal, preserving the patient's reproductive capacity.*Left salpingotomy only if the tube appears severely damaged*- This statement is contradictory; if a tube is **severely damaged** by an ectopic pregnancy, a **salpingectomy** (removal of the tube) is typically indicated rather than an attempt at preservation.- Salpingotomy is more technically difficult and less successful if the **tubal integrity** is significantly compromised or if the ectopic is large, increasing risks of hemorrhage or retained trophoblast.*Right-sided salpingectomy with left salpingotomy*- This approach involves unnecessarily operating on the **normal-appearing right fallopian tube** (salpingectomy) while attempting a less definitive procedure on the affected left tube.- Performing surgery on a healthy, unaffected tube is medically unjustified and risks the patient's remaining **reproductive capacity** without any therapeutic benefit for the current ectopic pregnancy.

Question 81: A 42-year-old woman presents with heavy menstrual bleeding affecting her quality of life. She has completed her family and requests definitive treatment. Examination reveals a 16-week size irregular uterus. Ultrasound confirms multiple intramural and subserosal fibroids, the largest measuring 8 cm. Her haemoglobin is 89 g/L. She has no significant medical history. After discussion of treatment options, she wishes to avoid major surgery if possible. What is the most appropriate management?

A. Total abdominal hysterectomy after iron replacement
B. Uterine artery embolisation following counselling about risks (Correct Answer)
C. Levonorgestrel intrauterine system insertion
D. GnRH analogue therapy for 6 months then reassess
E. Hysteroscopic myomectomy of accessible fibroids

Explanation: ***Uterine artery embolisation following counselling about risks*** - **Uterine artery embolisation (UAE)** is a minimally invasive alternative for women with **symptomatic fibroids** who wish to avoid **major surgery** (hysterectomy).- It is highly effective for reducing **heavy menstrual bleeding** and is viable here as the patient has completed her family and the uterus is significantly enlarged (**16-week size**).*Total abdominal hysterectomy after iron replacement*- While **hysterectomy** provides a definitive cure for fibroids, it is classified as **major surgery**, which the patient specifically requested to avoid.- It would require significant recovery time and carries risks such as **primary/secondary hemorrhage** and damage to adjacent pelvic organs.*Levonorgestrel intrauterine system insertion*- The **LNG-IUS** is often ineffective in a **grossly enlarged uterus** (16-week size) or when the uterine cavity is distorted by large fibroids.- There is a high risk of **expulsion** or technical difficulty with insertion in the presence of multiple **intramural fibroids**.*GnRH analogue therapy for 6 months then reassess*- **GnRH analogues** are generally used as a temporary measure to **shrink fibroids** and increase hemoglobin levels before surgery, rather than as a definitive treatment.- Symptoms and fibroid size typically return to baseline once the medication is discontinued after the **6-month limit** due to bone density concerns.*Hysteroscopic myomectomy of accessible fibroids*- This procedure is only indicated for **submucosal fibroids** (FIGO type 0, 1, or 2) that distort the uterine cavity.- It is not an appropriate treatment for the **intramural and subserosal** fibroids identified in this patient's ultrasound.

Question 82: A 31-year-old woman with 6 weeks amenorrhoea presents with minimal vaginal spotting. She is asymptomatic otherwise. Transvaginal ultrasound shows an empty uterus with no adnexal masses. Her serum beta-hCG is 1800 IU/L. A repeat beta-hCG after 48 hours is 2100 IU/L. What is the most appropriate classification of this clinical scenario?

A. Failing intrauterine pregnancy requiring evacuation
B. Pregnancy of unknown location requiring further monitoring (Correct Answer)
C. Ectopic pregnancy requiring immediate methotrexate treatment
D. Complete miscarriage with resolving beta-hCG levels
E. Normal early intrauterine pregnancy below discriminatory zone

Explanation: ***Pregnancy of unknown location requiring further monitoring*** - A **Pregnancy of Unknown Location (PUL)** is diagnosed when the woman has a positive pregnancy test but the **transvaginal ultrasound** does not identify an intrauterine or extrauterine pregnancy. - The **hCG rise of only 17%** (from 1800 to 2100 IU/L) over 48 hours is suboptimal, but because the patient is **asymptomatic**, further monitoring with serial hCG and repeat imaging is required before definitive intervention. *Failing intrauterine pregnancy requiring evacuation* - An **intrauterine pregnancy** has not yet been visualized on ultrasound; therefore, it cannot be classified as failing within the uterus. - **Surgical evacuation** is inappropriate unless a non-viable intrauterine pregnancy is confirmed or the patient becomes hemodynamically unstable. *Ectopic pregnancy requiring immediate methotrexate treatment* - While the suboptimal hCG rise increases the suspicion of an **ectopic pregnancy**, immediate treatment is not indicated as the location is still **unconfirmed** and the patient is stable. - **Methotrexate** should only be administered once the diagnosis of ectopic pregnancy is confirmed or a PUL persists with rising hCG levels below the **discriminatory zone**. *Complete miscarriage with resolving beta-hCG levels* - A **complete miscarriage** would typically show a significant drop in **beta-hCG levels** (at least 50%) rather than an increase. - In this case, the hCG is **rising**, which is inconsistent with the resolution of a pregnancy through miscarriage. *Normal early intrauterine pregnancy below discriminatory zone* - The **discriminatory zone** is the hCG level (usually 1500–2000 IU/L) at which a viable **intrauterine sac** should be visible; this patient is at 1800–2100 IU/L with an empty uterus. - A normal pregnancy should show a **minimal hCG increase of 53–63%** over 48 hours; a 17% rise is highly suggestive of an abnormal pregnancy (ectopic or failing).

Question 83: A 45-year-old woman with type 2 diabetes mellitus and body mass index of 32 kg/m² presents with heavy menstrual bleeding of 11 months duration. Her periods occur regularly every 28 days but last 8 days with flooding and clots. Pelvic examination is normal. Transvaginal ultrasound shows a uniformly thickened endometrium measuring 14 mm with no focal lesions. Full blood count shows haemoglobin 98 g/L. What is the most appropriate next step in management?

A. Insert levonorgestrel intrauterine system and review in 6 months
B. Perform endometrial biopsy before initiating treatment (Correct Answer)
C. Commence tranexamic acid therapy and monitor response
D. Arrange hysteroscopy and endometrial ablation
E. Start combined hormonal contraceptive pill

Explanation: ***Perform endometrial biopsy before initiating treatment*** - This patient requires **endometrial sampling** due to her age (≥45 years) and persistent **abnormal uterine bleeding (AUB)**, combined with risk factors like **obesity (BMI 32)** and **type 2 diabetes**, and a significantly **thickened endometrium (14 mm)**. - It is crucial to exclude **endometrial hyperplasia** or **carcinoma** via biopsy before initiating any hormonal or symptomatic treatment that might delay diagnosis. *Insert levonorgestrel intrauterine system and review in 6 months* - The **levonorgestrel intrauterine system (LNG-IUS)** is a treatment for heavy menstrual bleeding, but it is contraindicated as an initial step in a patient with risk factors for **endometrial cancer** until **histological sampling** has ruled out malignancy. - Initiating hormonal treatment without biopsy risks masking a potential **endometrial carcinoma** or **atypical hyperplasia**, critically delaying diagnosis and appropriate management. *Commence tranexamic acid therapy and monitor response* - **Tranexamic acid** provides symptomatic relief for heavy menstrual bleeding by reducing fibrinolysis, but it does not investigate or treat the underlying cause of the bleeding. - Using it in a high-risk patient without an **endometrial biopsy** would delay the diagnosis of a potentially serious **endometrial pathology**, such as hyperplasia or carcinoma. *Arrange hysteroscopy and endometrial ablation* - **Endometrial ablation** is a definitive treatment for heavy menstrual bleeding, but it is **contraindicated** until **endometrial cancer** and **atypical hyperplasia** have been conclusively excluded by histological examination. - Performing ablation without a prior biopsy could destroy malignant tissue, making future diagnosis or staging difficult, and would be an inappropriate first-line intervention in a high-risk patient. *Start combined hormonal contraceptive pill* - Starting a **combined hormonal contraceptive pill** (COCP) in this patient is inappropriate without an **endometrial biopsy** to rule out malignancy, as it could mask symptoms. - Furthermore, a 45-year-old woman with **obesity** and **type 2 diabetes** has increased risks for **thromboembolic events**, making COCP a less ideal choice without careful consideration and screening.

Question 84: A 34-year-old woman presents to the emergency department with 7 weeks amenorrhoea and moderate left-sided abdominal pain. She has a copper intrauterine device in situ. Transvaginal ultrasound shows an empty uterus with a 25 mm left adnexal mass and moderate free fluid in the pelvis. Her serum beta-hCG is 4200 IU/L and haemoglobin is 102 g/L. She is haemodynamically stable with blood pressure 118/75 mmHg and pulse 88 bpm. What is the most appropriate immediate management?

A. Administer intramuscular methotrexate and arrange follow-up in 48 hours
B. Arrange urgent laparoscopy for surgical management (Correct Answer)
C. Remove the intrauterine device and commence expectant management
D. Admit for observation with serial beta-hCG measurements
E. Perform endometrial sampling to exclude intrauterine pregnancy

Explanation: ***Arrange urgent laparoscopy for surgical management*** - The presence of **moderate free fluid** in the pelvis and a slightly low **haemoglobin** (102 g/L) are strong indicators of **intra-abdominal bleeding** from a ruptured or leaking ectopic pregnancy. - Despite current **haemodynamic stability**, the risk of rapid clinical deterioration is high, necessitating urgent **laparoscopy** for definitive surgical management, such as **salpingectomy** or **salpingotomy**. *Administer intramuscular methotrexate and arrange follow-up in 48 hours* - **Methotrexate** is contraindicated due to the high **beta-hCG** level (4200 IU/L) and clear signs of rupture (**moderate free fluid**), which increase the risk of treatment failure and complications. - Medical management is reserved for patients who are asymptomatic, haemodynamically stable, have smaller ectopic pregnancies, and lower **beta-hCG** levels without signs of haemorrhage. *Remove the intrauterine device and commence expectant management* - **Expectant management** is only appropriate for highly selected patients with very low and declining **beta-hCG** levels and no signs of rupture or significant pain. - While the **copper IUD** increases the risk of ectopic pregnancy, simply removing it does not treat the existing and potentially life-threatening **extrauterine gestation**. *Admit for observation with serial beta-hCG measurements* - Serial **beta-hCG** monitoring is primarily for pregnancies of **unknown location (PUL)** or very early, stable ectopic pregnancies without evidence of rupture. - Given the ultrasound findings of an **adnexal mass** and **free fluid**, observation would dangerously delay definitive treatment for a condition with a high risk of **hypovolemic shock**. *Perform endometrial sampling to exclude intrauterine pregnancy* - **Endometrial sampling** is unnecessary because the transvaginal ultrasound already clearly demonstrates an **empty uterus** and a definitive **adnexal mass**, indicating an ectopic pregnancy. - Pursuing such an invasive and time-consuming procedure would lead to a critical delay in the required **surgical intervention** for the ruptured ectopic pregnancy.

Question 85: A 33-year-old nulliparous woman undergoes laparoscopy for a suspected ectopic pregnancy. At surgery, a 2.2cm unruptured ampullary ectopic pregnancy is identified in the right fallopian tube with surrounding oedema. The left fallopian tube appears healthy with no abnormalities. There is no haemoperitoneum. The patient has previously expressed strong desire to preserve her fertility and had declined salpingectomy in pre-operative discussions. The surgeon performs right salpingotomy and achieves complete removal of ectopic tissue with haemostasis. What is the most important aspect of post-operative follow-up for this patient?

A. Serial beta-hCG measurements until levels fall to <5 IU/L (Correct Answer)
B. Hysterosalpingography at 3 months to assess tubal patency
C. Prophylactic intramuscular methotrexate to prevent persistent trophoblast
D. Repeat laparoscopy at 6 weeks to assess tubal healing
E. Serum progesterone measurement to confirm return of ovulation

Explanation: ***Serial beta-hCG measurements until levels fall to <5 IU/L*** - Salpingotomy carries a 4–8% risk of **persistent trophoblast**, requiring serial **beta-hCG monitoring** to ensure all pregnancy tissue has been successfully removed. - Monitoring is typically performed weekly until the level reaches the laboratory's threshold for a **non-pregnant state**, as plateauing or rising levels indicate the need for **methotrexate** or repeat surgery. *Hysterosalpingography at 3 months to assess tubal patency* - While tubal patency is a concern for future fertility, **hysterosalpingography (HSG)** is not a routine part of immediate post-operative care following an ectopic pregnancy. - An HSG may be considered later if the patient struggles with **subfertility**, but it does not address the acute risk of persistent trophoblastic tissue. *Prophylactic intramuscular methotrexate to prevent persistent trophoblast* - **Prophylactic methotrexate** is not routinely recommended after salpingotomy as the majority of cases resolve spontaneously without further intervention. - Medical management is reserved for patients where beta-hCG levels actually **plateau or rise** during the post-operative surveillance period. *Repeat laparoscopy at 6 weeks to assess tubal healing* - **Repeat laparoscopy** is an invasive procedure and is not indicated for routine follow-up of a standard, uncomplicated salpingotomy. - Healing is monitored through clinical symptoms and **biochemical markers** rather than direct visual inspection unless complications like hemorrhage or infection occur. *Serum progesterone measurement to confirm return of ovulation* - **Serum progesterone** levels are used to confirm ovulation in specialized fertility workups, but they have no role in the management of post-ectopic recovery. - The primary safety concern post-salpingotomy is the resolution of the **ectopic pregnancy**, for which beta-hCG is the only reliable marker.

Question 86: A 40-year-old woman presents with heavy menstrual bleeding affecting her daily activities. She reports soaking through ultra-absorbent pads every 1-2 hours on her heaviest days and passing large clots. Her periods last 9 days and occur regularly every 26 days. She has tried tranexamic acid without significant benefit. She has three children and does not wish for more. Pelvic examination reveals a bulky, slightly irregular uterus. Which investigation would be most appropriate to guide further management?

A. Transvaginal ultrasound scan (Correct Answer)
B. Full blood count and serum ferritin
C. Hysteroscopy with endometrial biopsy
D. Serum thyroid function tests
E. MRI pelvis with contrast

Explanation: ***Transvaginal ultrasound scan***- This is the first-line imaging modality for **heavy menstrual bleeding (HMB)** when physical examination reveals a **bulky or irregular uterus**, suggesting structural pathology like **fibroids** or **adenomyosis**.- It guides management by detailing the size, location, and number of fibroids, which is essential since the patient has already failed **tranexamic acid** and may require surgical intervention.*Full blood count and serum ferritin*- These tests are necessary to diagnose **iron-deficiency anemia** resulting from chronic HMB but do not identify the **underlying etiology** or guide structural management.- While important for supportive care, they cannot distinguish between causes like **leiomyoma** or **polyps** indicated by the bulky uterus.*Hysteroscopy with endometrial biopsy*- Usually reserved as a second-line investigation or when **ultrasound** is inconclusive or suggests **endometrial polyps** or submucosal fibroids.- While biopsy is important to rule out **endometrial hyperplasia** or malignancy in specific risk groups, ultrasound is the more appropriate initial step for a bulky, irregular uterus.*Serum thyroid function tests*- Thyroid dysfunction can cause menstrual irregularities, but it is not indicated as a routine investigation for HMB unless **symptoms of hypothyroidism** are present.- In this case, the **physical finding** of an irregular uterus points strongly toward a primary pelvic structural cause rather than systemic endocrine disease.*MRI pelvis with contrast*- **MRI** provides high resolution for preoperative mapping of complex fibroids but is not the first-line diagnostic investigation due to high cost and lower accessibility.- It is generally reserved for cases where **ultrasound** findings are indeterminate or when distinguishing between **adenomyosis** and multiple fibroids is critical for specific surgical planning.

Question 87: A 28-year-old woman is being monitored following single-dose intramuscular methotrexate for an unruptured tubal ectopic pregnancy. Her initial beta-hCG was 2,100 IU/L. On day 4, her beta-hCG is 2,450 IU/L, and on day 7, it is 1,890 IU/L. She remains clinically stable with minimal symptoms. What is the most appropriate management at this stage?

A. Continue expectant monitoring with repeat beta-hCG on day 14 (Correct Answer)
B. Administer second dose of methotrexate 50mg/m² immediately
C. Arrange urgent laparoscopy for surgical management
D. Measure beta-hCG on day 11 to assess ongoing decline
E. Change to multi-dose methotrexate regimen with folinic acid rescue

Explanation: ***Continue expectant monitoring with repeat beta-hCG on day 14*** - In the **single-dose methotrexate protocol**, a successful response is defined by a **decrease in beta-hCG of ≥15%** between Day 4 and Day 7. - The patient's beta-hCG dropped from 2,450 IU/L on Day 4 to 1,890 IU/L on Day 7, which represents a **~22.8% reduction**, confirming the treatment is effective. Expectant monitoring with the next beta-hCG on Day 14 is the appropriate next step until levels are **<5 IU/L**. *Administer second dose of methotrexate 50mg/m² immediately* - A second dose of methotrexate is indicated only if the **beta-hCG decline is less than 15%** between Day 4 and Day 7, or if there is clinical deterioration. - Since a sufficient decline was observed, administering an additional dose now would be premature and increase the risk of **methotrexate-related side effects** without clinical benefit. *Arrange urgent laparoscopy for surgical management* - **Surgical intervention** is reserved for patients who are **hemodynamically unstable**, show signs of **tubal rupture**, or fail medical management. - This patient is **clinically stable** and has shown a biochemical response to methotrexate, making surgical management inappropriate at this stage. *Measure beta-hCG on day 11 to assess ongoing decline* - Standard follow-up after a successful Day 7 beta-hCG decline in single-dose methotrexate protocols involves **weekly monitoring**, meaning the next measurement would typically be on **Day 14**, not Day 11. - Deviation from established **monitoring protocols** can lead to suboptimal management and does not align with evidence-based guidelines. *Change to multi-dose methotrexate regimen with folinic acid rescue* - The **multi-dose regimen** is a distinct protocol or an alternative initial treatment strategy, not typically a switch or rescue for a successfully responding single-dose case. - Since the patient has already achieved the target **15% reduction** in beta-hCG, changing to a more intensive regimen is unnecessary and could lead to increased **toxicity**.

Question 88: A 46-year-old woman presents with a 12-month history of heavy menstrual bleeding significantly affecting her quality of life. She has used maximum-dose tranexamic acid and mefenamic acid without adequate improvement. She declined the levonorgestrel intrauterine system. Examination reveals a mobile, non-tender uterus of approximately 10-week size. Transvaginal ultrasound shows a bulky uterus with adenomyosis and endometrial thickness of 8mm. She has completed her family. What is the most appropriate next management step?

A. Offer endometrial ablation after appropriate counselling (Correct Answer)
B. Prescribe continuous oral progestogen therapy with norethisterone
C. Refer for GnRH analogue therapy with add-back hormone replacement
D. Arrange hysterectomy without further medical management trials
E. Prescribe combined oral contraceptive pill for three months then review

Explanation: ***Offer endometrial ablation after appropriate counselling*** - In patients with **heavy menstrual bleeding (HMB)** who fail or decline pharmaceutical treatments like **LNG-IUS**, **tranexamic acid**, or **mefenamic acid**, surgical options such as **endometrial ablation** are recommended by NICE guidelines. - It is a suitable choice for this patient as she has **completed her family** and has a uterus less than **10-week size**, although she must be counselled that **adenomyosis** may reduce its overall success rate. *Prescribe continuous oral progestogen therapy with norethisterone* - This is generally not considered a long-term first-line solution due to a significant **side-effect profile** and lower efficacy compared to structural or hormonal interventions. - It lacks the high patient satisfaction rates and definitive management benefits provided by **ablation** or **hysterectomy** in cases of failed medical therapy. *Refer for GnRH analogue therapy with add-back hormone replacement* - **GnRH analogues** are typically used as a **temporary measure** to thin the endometrium before surgery or to manage symptoms short-term, rather than as a primary management step. - Their use is limited by concerns over **bone mineral density loss** and the recurrence of symptoms once the medication is discontinued. *Arrange hysterectomy without further medical management trials* - While **hysterectomy** is a definitive option and effective for **adenomyosis**, it is a major surgical procedure with a longer **recovery time** and higher complication risk than ablation. - Guidelines suggest offering **endometrial ablation** as a less invasive alternative before proceeding to major abdominal surgery, unless the patient specifically requests it or ablation is contraindicated. *Prescribe combined oral contraceptive pill for three months then review* - The **combined oral contraceptive pill** is likely to be less effective in a 46-year-old with a **bulky, adenomyotic uterus** and already established failed medical management. - Given her age and clinical history, moving toward a **surgical management** option is more appropriate than continuing to trial oral pharmaceutical agents.

Question 89: A 29-year-old woman presents to the emergency department with 6 weeks amenorrhoea and right lower abdominal pain. She has a history of pelvic inflammatory disease treated 2 years ago. Examination reveals right iliac fossa tenderness without peritonism. She is haemodynamically stable. Serum beta-hCG is 4,200 IU/L. Transvaginal ultrasound shows an empty uterus with endometrial thickness of 9mm, a 28mm right adnexal mass with a hyperechoic ring, and a small amount of free fluid in the pouch of Douglas. What is the most appropriate management?

A. Intramuscular methotrexate with beta-hCG monitoring
B. Emergency laparoscopic salpingectomy (Correct Answer)
C. Expectant management with weekly beta-hCG measurements
D. Laparoscopic salpingotomy with preservation of the tube
E. Diagnostic laparoscopy followed by shared decision-making regarding surgical approach

Explanation: ***Emergency laparoscopic salpingectomy*** - **Surgical intervention** is the gold standard for ectopic pregnancy when **beta-hCG levels exceed 3,000-3,500 IU/L** or when medical management criteria are not met. - **Laparoscopic salpingectomy** is preferred over salpingotomy if the contralateral tube is healthy, as it prevents **persistent trophoblast** and removes a tube likely damaged by prior **pelvic inflammatory disease**. *Intramuscular methotrexate with beta-hCG monitoring* - Medical management is generally reserved for patients with a **beta-hCG <1,500-3,000 IU/L** and no visible fetal heartbeat or significant pain. - This patient’s **beta-hCG of 4,200 IU/L** significantly increases the risk of treatment failure and subsequent **tubal rupture** with methotrexate. *Expectant management with weekly beta-hCG measurements* - This approach is only appropriate for clinically stable patients with very low, **declining beta-hCG levels** (typically <1,000-1,500 IU/L). - High baseline **beta-hCG levels** and the presence of **adnexal pain** make expectant management unsafe and inappropriate. *Laparoscopic salpingotomy with preservation of the tube* - Salpingotomy carries a higher risk of **persistent trophoblastic tissue**, requiring post-operative beta-hCG monitoring and potential methotrexate treatment. - It is usually reserved for patients with a **damaged contralateral tube** who wish to maintain future fertility, which is not indicated as the primary concern here. *Diagnostic laparoscopy followed by shared decision-making regarding surgical approach* - While shared decision-making is important, the definitive diagnosis of **ectopic pregnancy** is already established by the high **beta-hCG and ultrasound findings**. - Delaying the specific procedure for further discussion during surgery is inefficient when **salpingectomy** is the clinically recommended definitive treatment for a damaged tube.

Question 90: What is the primary mechanism by which the levonorgestrel intrauterine system reduces menstrual blood loss in women with heavy menstrual bleeding?

A. Decidualisation and atrophy of the endometrium through local progestogenic effects (Correct Answer)
B. Systemic suppression of follicle-stimulating hormone leading to anovulation
C. Inhibition of prostaglandin synthesis in the endometrium reducing inflammation
D. Thickening of cervical mucus preventing ascending endometrial infection
E. Direct vasoconstriction of spiral arterioles reducing blood flow to endometrium

Explanation: ***Decidualisation and atrophy of the endometrium through local progestogenic effects***- The **LNG-IUS** releases a high local concentration of **levonorgestrel** into the uterine cavity, leading to initial **stromal decidualisation** followed by significant **endometrial atrophy**.- This thinning and inactivity of the **endometrial glands** directly results in a profound reduction in **menstrual blood loss**, often leading to **amenorrhoea**.*Systemic suppression of follicle-stimulating hormone leading to anovulation*- Although some systemic absorption occurs, most users of the **LNG-IUS** continue to have **ovulatory cycles** with normal hormone levels.- Suppression of **FSH** and **ovulation** is not the primary mechanism, occurring in only a minority of cycles during the first year of use.*Inhibition of prostaglandin synthesis in the endometrium reducing inflammation*- Inhibiting **prostaglandin synthesis** is the primary mechanism of **NSAIDs** (like mefenamic acid), which are used to manage heavy bleeding and pain.- While the **LNG-IUS** may have secondary anti-inflammatory effects, its main action is through **progestogenic atrophy** rather than prostaglandin blockade.*Thickening of cervical mucus preventing ascending endometrial infection*- **Cervical mucus thickening** is a key **contraceptive mechanism** as it creates a barrier to sperm penetration.- While important for preventing pregnancy and potentially infection, it does not directly influence the volume of **menstrual blood flow**.*Direct vasoconstriction of spiral arterioles reducing blood flow to endometrium*- **Direct vasoconstriction** and stabilization of clotting are mechanisms associated more with **antifibrinolytics** like **tranexamic acid**.- The **LNG-IUS** works by altering the morphology and thickness of the **endometrium** itself rather than primarily targeting the vascular tone of **spiral arterioles**.

Question 91: A 32-year-old woman with 7 weeks amenorrhoea presents with minimal vaginal bleeding and mild lower abdominal discomfort. Transvaginal ultrasound shows an empty uterus with endometrial thickness of 10mm and a 22mm inhomogeneous adnexal mass adjacent to the ovary. Initial serum beta-hCG is 2,800 IU/L. Repeat beta-hCG 48 hours later is 2,650 IU/L. She is haemodynamically stable and pain-free. She has a history of previous left salpingectomy for ectopic pregnancy. What is the most appropriate management?

A. Emergency laparoscopy with right salpingectomy
B. Intramuscular methotrexate 50mg/m² body surface area (Correct Answer)
C. Expectant management with weekly beta-hCG monitoring
D. Diagnostic laparoscopy to assess tubal patency before treatment decision
E. Repeat beta-hCG in 48 hours and reassess treatment options

Explanation: ***Intramuscular methotrexate 50mg/m² body surface area*** - **Medical management** is indicated because the patient is **haemodynamically stable**, the adnexal mass is **<35mm**, and serum **beta-hCG is <5,000 IU/L** (often <3,000 IU/L for most conservative guidelines). - Given her history of **previous left salpingectomy**, preserving the remaining right fallopian tube with methotrexate is crucial for **future fertility**. *Emergency laparoscopy with right salpingectomy* - This surgical intervention is reserved for patients who are **haemodynamically unstable**, have signs of rupture, severe pain, or when hCG levels are significantly higher (>5,000 IU/L) or rapidly rising. - Removing her only remaining fallopian tube would lead to **permanent sterility**, which is avoidable with medical management in her stable condition. *Expectant management with weekly beta-hCG monitoring* - **Expectant management** is typically considered for highly selected cases with **asymptomatic patients** and very low initial **beta-hCG levels (<1,000-1,500 IU/L)**, which is not the case here. - Although her hCG levels are declining, they are still too high (2,650 IU/L) to safely defer active intervention, given the persistent risk of **tubal rupture**. *Diagnostic laparoscopy to assess tubal patency before treatment decision* - **Diagnostic laparoscopy** is an invasive procedure that is not necessary, as the diagnosis of ectopic pregnancy is already strongly supported by the **ultrasound findings** (empty uterus, adnexal mass) and the **suboptimal hCG trend**. - Assessing **tubal patency** is not a critical step in the acute management of an ectopic pregnancy and would delay definitive treatment. *Repeat beta-hCG in 48 hours and reassess treatment options* - Two beta-hCG readings have already been obtained, showing a **suboptimal decline**, which confirms a non-viable pregnancy that requires intervention, not further observation. - Delaying active management further by repeating hCG increases the risk of **tubal rupture** and other complications without adding significant diagnostic information.

Question 92: A 38-year-old woman with heavy menstrual bleeding has had a levonorgestrel intrauterine system in situ for 8 months. She returns to clinic reporting persistent irregular bleeding and spotting occurring 15-20 days per month. She is finding this unacceptable and wishes to have the LNG-IUS removed. Prior to LNG-IUS insertion, her ultrasound showed a normal uterus with endometrial thickness of 8mm. What is the most appropriate next step in management?

A. Remove LNG-IUS and prescribe tranexamic acid and mefenamic acid (Correct Answer)
B. Reassure that irregular bleeding settles by 6 months and continue for another 4 months
C. Remove LNG-IUS and commence combined oral contraceptive pill
D. Arrange hysteroscopy to exclude endometrial pathology before removing LNG-IUS
E. Remove LNG-IUS and arrange endometrial ablation

Explanation: ***Remove LNG-IUS and prescribe tranexamic acid and mefenamic acid*** - The patient has had the LNG-IUS for **8 months**, which is beyond the typical 3-6 month adaptation period for irregular bleeding. Her reporting of **persistent irregular bleeding** (15-20 days per month) that she finds **unacceptable** necessitates honoring her request for removal due to **patient autonomy**. - After removal, for persistent heavy menstrual bleeding, **tranexamic acid** (an antifibrinolytic) and **mefenamic acid** (an NSAID) are effective **non-hormonal medical treatments** that can be offered as first-line options. *Reassure that irregular bleeding settles by 6 months and continue for another 4 months* - The patient is already at **8 months** of LNG-IUS use, past the typical 3-6 month period where irregular bleeding is expected to settle, making further reassurance without action inappropriate. - The patient explicitly states the bleeding is **unacceptable** and wishes for removal, therefore continued use against her will disregards **patient preference** and quality of life. *Remove LNG-IUS and commence combined oral contraceptive pill* - While the **combined oral contraceptive pill (COCP)** is a valid treatment for heavy menstrual bleeding, the patient's dissatisfaction stems from **hormonal irregular bleeding** with the LNG-IUS, so switching immediately to another hormonal method may not be her preferred choice without exploring non-hormonal options. - A 38-year-old would require a full assessment for **COCP contraindications** (e.g., smoking, migraines with aura, BMI) before initiation. *Arrange hysteroscopy to exclude endometrial pathology before removing LNG-IUS* - The patient had a **normal ultrasound** and a normal **endometrial thickness of 8mm** prior to LNG-IUS insertion, which makes significant underlying endometrial pathology less likely to be the cause of the current irregular bleeding. - **Hysteroscopy** is an invasive procedure generally reserved for cases with abnormal findings on ultrasound, failure of medical management, or new **red flag symptoms**, not as a routine step before removing a device at patient request. *Remove LNG-IUS and arrange endometrial ablation* - **Endometrial ablation** is a **surgical procedure** that is typically considered a **second-line treatment** for heavy menstrual bleeding, offered after medical management has failed or is contraindicated. - It is a permanent procedure requiring **permanent contraception** and extensive counseling, making it an overly aggressive and premature step before trying simpler, less invasive medical options following LNG-IUS removal.

Question 93: A 25-year-old woman is admitted with suspected ruptured ectopic pregnancy. She has sudden onset severe right iliac fossa pain, dizziness, and shoulder tip pain. On examination, she is pale, pulse 118 bpm, blood pressure 95/60 mmHg. Abdominal examination shows generalised tenderness with guarding and rebound. Pregnancy test is positive. Transvaginal ultrasound shows an empty uterus and moderate free fluid in the pelvis. What is the most appropriate immediate management?

A. Commence IV fluid resuscitation, group and save, and proceed to emergency laparoscopy (Correct Answer)
B. Administer intramuscular methotrexate and observe for 24 hours
C. Arrange CT abdomen and pelvis to confirm diagnosis before surgery
D. Perform diagnostic laparoscopy to confirm diagnosis then plan definitive surgery for next day
E. Measure serum beta-hCG level and repeat in 48 hours before intervention

Explanation: ***Commence IV fluid resuscitation, group and save, and proceed to emergency laparoscopy*** - The patient's presentation with **hemodynamic instability** (tachycardia, hypotension), **shoulder tip pain**, and signs of **hemoperitoneum** (abdominal guarding, rebound tenderness, free fluid on ultrasound) is highly indicative of a **ruptured ectopic pregnancy**. - Immediate management requires **aggressive IV fluid resuscitation**, preparing for potential **blood transfusion** (group and save), and urgent **emergency surgery** (laparoscopy or laparotomy) to control the bleeding and remove the ectopic pregnancy. *Administer intramuscular methotrexate and observe for 24 hours* - **Methotrexate** is strictly contraindicated in patients who are **hemodynamically unstable** or have evidence of a **ruptured ectopic pregnancy**, as it does not provide immediate hemostasis and can worsen the patient's condition. - Medical management is only considered for **stable patients** with specific criteria, such as low serum beta-hCG levels, small unruptured ectopic mass, and no fetal cardiac activity. *Arrange CT abdomen and pelvis to confirm diagnosis before surgery* - A **CT scan** would cause an unnecessary and potentially dangerous delay in a patient with a suspected **ruptured ectopic pregnancy** who is hemodynamically unstable. - The diagnosis is already strongly supported by the clinical presentation (sudden pain, hemodynamic instability, shoulder tip pain) and **transvaginal ultrasound findings** (empty uterus, free fluid in the pelvis). *Perform diagnostic laparoscopy to confirm diagnosis then plan definitive surgery for next day* - In a ruptured ectopic pregnancy, the surgical intervention must be **both diagnostic and therapeutic** in the same sitting (e.g., salpingectomy) to achieve immediate hemostasis. - Delaying definitive surgery until the next day for an actively bleeding and unstable patient is **life-threatening** and completely inappropriate. *Measure serum beta-hCG level and repeat in 48 hours before intervention* - While **serial beta-hCG levels** are crucial for diagnosing pregnancies of unknown location in **stable patients**, they have no role in the immediate management of an **acute surgical emergency** like a ruptured ectopic pregnancy. - Waiting for these results would lead to critical delays and further deterioration, risking severe **hypovolemic shock** and potentially death due to ongoing internal hemorrhage.

Question 94: A 44-year-old multiparous woman presents with heavy menstrual bleeding that has not responded to tranexamic acid or mefenamic acid. She has completed her family and does not wish to use hormonal treatments. Examination reveals a 16-week-size uterus with multiple palpable irregular masses. Transvaginal ultrasound confirms multiple intramural and subserosal fibroids, the largest measuring 8cm. She has significant dysmenorrhoea and pressure symptoms including urinary frequency. Haemoglobin is 88 g/L. What is the most appropriate definitive management?

A. Total abdominal hysterectomy (Correct Answer)
B. Uterine artery embolisation
C. Laparoscopic myomectomy
D. Levonorgestrel intrauterine system insertion
E. GnRH analogue therapy for 6 months

Explanation: ***Total abdominal hysterectomy*** - This is the **definitive management** for symptomatic fibroids in a woman who has **completed her family**, has failed medical therapy, and specifically **declines hormonal treatments**. - The **16-week-size uterus** and multiple large fibroids make an **abdominal approach** the most appropriate surgical route to ensure complete removal and address **pressure symptoms** and **anaemia**. *Uterine artery embolisation* - While it is a uterine-sparing option, it is less effective for **very large and multiple fibroids** and has a higher risk of requiring **secondary interventions** compared to hysterectomy. - It may not resolve **pressure symptoms** as effectively as a hysterectomy when the uterine volume is significantly increased, and the patient seeks definitive management. *Laparoscopic myomectomy* - This procedure is primarily considered for women who wish to **preserve fertility** or their uterus, which is not a priority for this patient who has completed her family. - Given the **multiple intramural fibroids** and large uterine size, complete resection would be complex with a high risk of **recurrence** and significant intraoperative bleeding, not offering a definitive solution. *Levonorgestrel intrauterine system insertion* - The patient has specifically stated she **does not wish to use hormonal treatments**, making this an inappropriate choice despite its efficacy in some cases of HMB. - **Cavity distortion** from large intramural fibroids often leads to a high **expulsion rate** of the device and reduced efficacy in controlling bleeding and dysmenorrhoea. *GnRH analogue therapy for 6 months* - These are **temporary measures** often used to shrink fibroids and improve **anaemia** pre-operatively rather than serving as a **definitive treatment**. - Symptoms and fibroid size typically **rebound** rapidly once the medication is discontinued, and long-term use is limited by side effects like **bone mineral density loss**.

Question 95: A 27-year-old nulliparous woman undergoes laparoscopy for suspected ectopic pregnancy. She has 7 weeks amenorrhoea, beta-hCG of 3,500 IU/L, and mild left-sided pain. At surgery, a 3.5cm unruptured left tubal ectopic pregnancy is identified. The left fallopian tube appears dilated but intact, and the right tube appears normal. The patient wishes to preserve her fertility. What is the most appropriate surgical management?

A. Left salpingectomy (Correct Answer)
B. Left salpingotomy with intraoperative methotrexate
C. Left salpingotomy alone
D. Bilateral salpingectomy to reduce future ectopic risk
E. Milking the ectopic pregnancy from the fimbrial end

Explanation: ***Left salpingectomy*** - For women with a **healthy contralateral tube**, salpingectomy is the standard management because it removes the risk of **persistent trophoblastic tissue** and does not significantly reduce future **intrauterine pregnancy** rates. - Current RCOG guidelines recommend salpingectomy over salpingotomy as it reduces the recurrence risk of **ectopic pregnancy** in the same tube and avoids the need for follow-up **beta-hCG monitoring**. *Left salpingotomy with intraoperative methotrexate* - Injecting **methotrexate** into the tube during a salpingotomy has not been proven to significantly lower the risk of **persistent trophoblast**. - This approach is not standard practice and combines the risks of surgery with the potential side effects of **chemotherapy** unnecessarily. *Left salpingotomy alone* - While salpingotomy is considered when there is damage to the **contralateral tube**, it carries an 8% risk of **persistent trophoblastic disease**, requiring further treatment. - It also increases the risk of a **repeat ectopic pregnancy** in the same damaged fallopian tube compared to removal. *Bilateral salpingectomy to reduce future ectopic risk* - This procedure would render the patient permanently **infertile** and reliant on **IVF**, which is inappropriate for a patient wishing to preserve fertility. - Removing a **normal appearing right tube** is clinically contraindicated as it provides the best chance for a future natural conception. *Milking the ectopic pregnancy from the fimbrial end* - This technique, also known as **fimbrial expression**, is associated with a very high rate of **incomplete evacuation** and subsequent bleeding. - It is generally discouraged because it causes higher **persistent trophoblast** rates compared to formal salpingotomy or salpingectomy.

Question 96: A 35-year-old woman with a body mass index of 34 kg/m² presents with a 14-month history of increasingly irregular and heavy menstrual bleeding. Her cycles vary from 21 to 45 days, and bleeding lasts 7-10 days. She has noticed increased facial hair growth over the past year. Pelvic examination is normal. Transvaginal ultrasound shows a bulky uterus with endometrial thickness of 14mm and multiple small peripheral follicles in both ovaries. What is the most important next investigation?

A. Endometrial biopsy (Correct Answer)
B. Serum follicle-stimulating hormone and luteinising hormone levels
C. Hysteroscopy with directed biopsies
D. Serum testosterone and sex hormone-binding globulin
E. MRI pelvis to assess uterine pathology

Explanation: ***Endometrial biopsy*** - This patient presents with significant risk factors for **endometrial hyperplasia or carcinoma**, including **obesity**, **irregular heavy menstrual bleeding** (suggesting chronic anovulation and unopposed estrogen), and clinical features of **PCOS** (hirsutism, ovarian morphology on ultrasound). - An **endometrial thickness of 14mm** in a symptomatic premenopausal woman with these risk factors mandates an immediate **histological assessment** to rule out malignancy, making it the most critical next step. *Serum follicle-stimulating hormone and luteinising hormone levels* - These tests can aid in the diagnostic workup for **PCOS** by evaluating the **LH:FSH ratio**, which is often elevated in this condition. - However, while useful for confirming PCOS, hormonal assessment is secondary to ruling out urgent pathology like **endometrial cancer** in a patient with a significantly thickened endometrium and irregular bleeding. *Hysteroscopy with directed biopsies* - **Hysteroscopy** allows for direct visualization of the uterine cavity and targeted biopsies, which is valuable for focal lesions or failed blind biopsies. - However, a less invasive **blind endometrial biopsy** (e.g., pipelle biopsy) is generally the appropriate initial investigation for diffuse endometrial assessment in the outpatient setting to assess global risk. *Serum testosterone and sex hormone-binding globulin* - These levels are essential for biochemically confirming **hyperandrogenism**, which explains the patient's **hirsutism** and supports the diagnosis of PCOS. - While important for managing the patient's underlying PCOS, these tests do not directly address the immediate and more pressing concern of **endometrial pathology** or the cause of the abnormal bleeding. *MRI pelvis to assess uterine pathology* - **MRI** is not a first-line investigation for evaluating abnormal uterine bleeding or thickened endometrium, especially after a **transvaginal ultrasound** has been performed. - It cannot provide a **histological diagnosis**, which is paramount for differentiating benign endometrial changes from **hyperplasia** or **malignancy**, making it unsuitable as the most important next step.

Question 97: A 30-year-old woman presents to the emergency department with 6 weeks amenorrhoea, mild right-sided abdominal pain, and minimal vaginal spotting. She is haemodynamically stable. Transvaginal ultrasound shows an empty uterus with endometrial thickness of 12mm and a 15mm adnexal mass with a hyperechoic ring. There is no free fluid in the pouch of Douglas. Serum beta-hCG is 1,200 IU/L. She has no significant past medical history and takes no regular medications. What is the most appropriate next step in management?

A. Repeat beta-hCG in 48 hours to assess rate of change (Correct Answer)
B. Administer intramuscular methotrexate 50mg/m² immediately
C. Arrange emergency laparoscopy for salpingectomy
D. Commence expectant management with weekly beta-hCG monitoring
E. Perform diagnostic uterine curettage to exclude miscarriage

Explanation: ***Repeat beta-hCG in 48 hours to assess rate of change*** - Since the serum **beta-hCG is 1,200 IU/L** (below the typical **discriminatory zone** of 1,500–2,000 IU/L), an intrauterine pregnancy (IUP) may not yet be visible on ultrasound. - Monitoring the **rate of change** helps differentiate between a viable IUP (expected rise >63%), an **ectopic pregnancy** (plateau or suboptimal rise), or a failing pregnancy. *Administer intramuscular methotrexate 50mg/m² immediately* - **Methotrexate** is contraindicated until a viable IUP has been definitively excluded, as it is highly **teratogenic**. - The patient is currently **clinically stable**, allowing time to confirm the diagnosis through serial biochemical monitoring. *Arrange emergency laparoscopy for salpingectomy* - Surgical intervention is reserved for patients who are **haemodynamically unstable**, have signs of **peritoneal irritation**, or have a large adnexal mass (>35mm). - This patient is stable with no **free fluid** in the pouch of Douglas, making immediate surgery unnecessary and potentially premature. *Commence expectant management with weekly beta-hCG monitoring* - **Expectant management** for a confirmed ectopic pregnancy typically requires the beta-hCG to be **initially falling** and often <1,000 IU/L. - Weekly monitoring is inappropriate at this stage because the diagnosis of a **pregnancy of unknown location (PUL)** has not yet been resolved. *Perform diagnostic uterine curettage to exclude miscarriage* - **Uterine curettage** is an invasive procedure that carries the risk of terminating a **viable early intrauterine pregnancy**. - It is only considered in cases of PUL where the pregnancy is confirmed to be **non-viable** (via serial hCG) and the location remains uncertain.

Question 98: A 42-year-old woman with heavy menstrual bleeding is assessed in the gynaecology clinic. She reports flooding through night-time protection and passing clots larger than a 50-pence coin. Her menstrual cycle is regular at 28 days, with bleeding lasting 8 days. Abdominal and pelvic examination are unremarkable. Full blood count shows haemoglobin 95 g/L and ferritin 8 μg/L. Transvaginal ultrasound demonstrates a normal uterus with endometrial thickness of 7mm. What is the most appropriate first-line medical treatment?

A. Levonorgestrel intrauterine system (Correct Answer)
B. Combined oral contraceptive pill
C. Oral norethisterone 5mg three times daily from days 5-26 of cycle
D. Tranexamic acid 1g three times daily during menstruation
E. Intramuscular medroxyprogesterone acetate 150mg every 12 weeks

Explanation: ***Levonorgestrel intrauterine system***- According to **NICE guidelines**, the **LNG-IUS** is the first-line treatment for heavy menstrual bleeding (HMB) in women with no identified uterine pathology.- It is highly effective in reducing blood loss, provides **long-term contraception**, and helps in the management of associated **iron-deficiency anemia** by reducing menstrual blood loss.*Combined oral contraceptive pill*- The COCP is an effective treatment for HMB but is usually considered a **second-line option** if the LNG-IUS is declined or unsuitable.- It carries more potential systemic **side effects** and **contraindications** compared to the LNG-IUS, such as an increased risk of venous thromboembolism.*Oral norethisterone 5mg three times daily from days 5-26 of cycle*- **Cyclical oral progestogens** are generally less effective at reducing menstrual blood loss compared to the LNG-IUS.- High-dose norethisterone can be associated with significant **side effects** like mood changes, bloating, and weight gain.*Tranexamic acid 1g three times daily during menstruation*- **Tranexamic acid** is a non-hormonal option and can be used for HMB, but it is typically less effective than the LNG-IUS for substantial, long-term blood loss reduction.- It only reduces bleeding during menstruation and **does not provide contraception** or directly improve iron deficiency beyond reducing blood flow.*Intramuscular medroxyprogesterone acetate 150mg every 12 weeks*- **Injectable progestogens** are not a primary first-line treatment for heavy menstrual bleeding, particularly when other more effective and less impactful options exist.- Long-term use is associated with potential concerns regarding **bone mineral density** and a variable return to fertility after discontinuation.

Question 99: A 39-year-old nulliparous woman presents with heavy menstrual bleeding for 14 months. She reports flooding and clots, requiring time off work. Examination reveals a 16-week size irregular uterus. Ultrasound confirms multiple fibroids, with the largest (8cm) being intramural and distorting the endometrial cavity. Endometrial biopsy shows proliferative endometrium with no atypia. She strongly wishes to preserve her fertility. What is the most appropriate management option to discuss?

A. Levonorgestrel intrauterine system insertion
B. Uterine artery embolization
C. GnRH agonist therapy for 6 months followed by myomectomy (Correct Answer)
D. Hysteroscopic fibroid resection
E. Ulipristal acetate 5mg daily for 3 months

Explanation: ***GnRH agonist therapy for 6 months followed by myomectomy*** - **Myomectomy** is the gold standard surgical approach for women with symptomatic **intramural fibroids** who strongly desire to preserve their **fertility**, particularly when the fibroid distorts the endometrial cavity. - Pre-operative **GnRH agonists** are used to reduce fibroid size and **vascularity**, which decreases intraoperative blood loss and allows time to correct any associated **anemia** before surgery. *Levonorgestrel intrauterine system insertion* - The effectiveness and suitability of a **levonorgestrel intrauterine system** (LNG-IUS) are significantly compromised when there is marked **endometrial cavity distortion** by a large fibroid, like an 8cm intramural fibroid. - While effective for managing **heavy menstrual bleeding**, it does not address the **mass effect** of the fibroid or its impact on uterine structure, which is crucial for fertility preservation. *Uterine artery embolization* - **Uterine artery embolization (UAE)** is generally not recommended for women who desire future **pregnancy** due to potential risks of **ovarian compromise** and adverse obstetric outcomes, including higher rates of miscarriage, preterm birth, and placental complications. - Although it can reduce fibroid size and symptoms, its long-term impact on **fertility** makes it a less appropriate choice in this clinical scenario. *Hysteroscopic fibroid resection* - **Hysteroscopic fibroid resection** is primarily indicated for **submucosal fibroids** (Type 0, 1, or 2) that project into the uterine cavity, and are typically smaller in size. - An 8cm **intramural fibroid** cannot be safely or completely resected via a **hysteroscopic** approach as it is embedded within the myometrial wall. *Ulipristal acetate 5mg daily for 3 months* - The use of **Ulipristal acetate** for fibroid treatment has been largely restricted or withdrawn in many regions due to concerns about a risk of **serious liver injury**. - While it can reduce bleeding and fibroid volume, its safety profile and the availability of more established and safer preoperative options like **GnRH agonists** make it less favorable.

Question 100: A 41-year-old woman presents with increasingly heavy menstrual bleeding over 18 months. Transvaginal ultrasound shows multiple intramural fibroids, the largest measuring 6cm, and a uniformly thickened endometrium of 11mm in the secretory phase. She has dysmenorrhoea and deep dyspareunia. She has completed her family. Examination reveals a bulky, tender uterus. What additional diagnosis should be considered alongside the fibroids?

A. Endometrial hyperplasia
B. Endometriosis
C. Adenomyosis (Correct Answer)
D. Chronic pelvic inflammatory disease
E. Endometrial polyp

Explanation: ***Adenomyosis***- The presence of a **bulky, tender uterus** on examination is a classic sign of adenomyosis; fibroids typically present as a non-tender enlarged uterus unless undergoing degeneration.- Clinical features such as **heavy menstrual bleeding**, **progressive dysmenorrhea**, and **deep dyspareunia** often occur together when adenomyosis coexists with fibroids.*Endometrial hyperplasia*- While it causes heavy bleeding, an **endometrial thickness of 11mm** is considered within the **normal range** for the secretory phase (7-16mm).- Hyperplasia would not typically explain a **tender, bulky uterus** or significant **deep dyspareunia**.*Endometriosis*- While associated with dysmenorrhea and dyspareunia, it involves ectopic tissue **outside the uterus**, which usually does not cause the uterus itself to be **bulky**.- Uterine tenderness in endometriosis is often related to **fixed retroversion** or pelvic nodules rather than global uterine enlargement.*Chronic pelvic inflammatory disease*- This usually presents with **chronic pelvic pain**, adnexal tenderness, and a history of infection rather than isolated heavy menstrual bleeding and a **bulky uterus**.- Ultrasound would more likely show **hydrosalpinx** or tubo-ovarian complexes rather than intramural fibroids and uniform thickening.*Endometrial polyp*- Polyps are more commonly associated with **intermenstrual bleeding** or postmenopausal bleeding rather than progressive global uterine tenderness.- A polyp would usually appear as a **focal echogenic mass** within the endometrial cavity on ultrasound, rather than a uniformly thickened endometrium.

Question 101: A 28-year-old woman is being monitored for a pregnancy of unknown location following one dose of intramuscular methotrexate given 6 days ago for a presumed ectopic pregnancy. Her initial beta-hCG was 1,650 IU/L. She now presents to the emergency department with worsening right-sided abdominal pain and shoulder tip pain. She is tachycardic at 110 bpm with blood pressure 100/65 mmHg. What is the most appropriate interpretation and management?

A. This represents separation pain; manage with analgesia and reassess in 24 hours
B. Arrange urgent beta-hCG to assess treatment response before deciding on management
C. This suggests methotrexate treatment failure; administer second dose of methotrexate
D. This indicates possible tubal rupture; arrange emergency laparoscopy (Correct Answer)
E. Perform urgent transvaginal ultrasound to visualize ectopic pregnancy location

Explanation: ***This indicates possible tubal rupture; arrange emergency laparoscopy*** - The patient exhibits classic signs of **ruptured ectopic pregnancy**, including **shoulder tip pain** (suggestive of diaphragmatic irritation from blood) and **hemodynamic instability** (tachycardia and hypotension). - While medical management with **methotrexate** was initiated, its risk of treatment failure and subsequent **tubal rupture** necessitates immediate surgical intervention when clinical deterioration occurs. *This represents separation pain; manage with analgesia and reassess in 24 hours* - **Separation pain** (occurring 3-7 days after treatment) is typically milder and not associated with **hemodynamic compromise** or **shoulder tip pain**. - Dismissing these red-flag symptoms as benign could lead to a life-threatening **hemoperitoneum** and maternal collapse. *Arrange urgent beta-hCG to assess treatment response before deciding on management* - While **beta-hCG levels** are monitored on days 4 and 7 post-methotrexate, clinical stability always takes precedence over biochemical trends. - Waiting for lab results in a patient showing signs of **internal hemorrhage** unnecessarily delays life-saving **operative management**. *This suggests methotrexate treatment failure; administer second dose of methotrexate* - A **second dose of methotrexate** is only considered if beta-hCG does not drop by >15% between days 4 and 7, and only if the patient remains **hemodynamically stable**. - Administering further medical therapy in the face of a suspected **tubal rupture** is strictly contraindicated. *Perform urgent transvaginal ultrasound to visualize ectopic pregnancy location* - While **transvaginal ultrasound** could show free fluid, it should not delay the transfer to theater in a patient with clear clinical signs of **peritoneal irritation** and tachycardia. - **Surgical exploration** via laparoscopy is the definitive diagnostic and therapeutic step for suspected **ruptured ectopic pregnancy**.

Question 102: A 35-year-old woman with von Willebrand disease presents with heavy menstrual bleeding that significantly affects her quality of life. She uses 16 super-absorbent tampons per period and has haemoglobin of 88 g/L. She wishes to avoid hormonal contraception due to a family history of breast cancer. What is the most appropriate initial pharmacological management?

A. Tranexamic acid 1g three times daily during menstruation
B. Desmopressin (DDAVP) administered intranasally at the onset of menstruation
C. Combined tranexamic acid and desmopressin therapy (Correct Answer)
D. Mefenamic acid 500mg three times daily during menstruation
E. Factor VIII concentrate infusion before each menstrual period

Explanation: ***Combined tranexamic acid and desmopressin therapy*** - For patients with **von Willebrand disease (vWD)** and severe menorrhagia (indicated by heavy tampon use and **anemia**), combined therapy is the most effective non-hormonal approach as it addresses both **clot formation** and **clot stability**. - **Desmopressin (DDAVP)** increases endogenous levels of vWF and Factor VIII, while **tranexamic acid** prevents the breakdown of clots within the endometrial lining, offering a synergistic effect. *Tranexamic acid 1g three times daily during menstruation* - While it is a potent **antifibrinolytic** that reduces menstrual blood loss by stabilizing clots, it does not correct the underlying **vWF deficiency**. - In the context of known vWD with significant **iron deficiency anemia**, monotherapy is often insufficient for optimal control compared to dual therapy. *Desmopressin (DDAVP) administered intranasally at the onset of menstruation* - DDAVP helps release **vWF and Factor VIII** stores, but its effect is temporary and may not provide sustained control throughout the entire menstrual period, especially in severe cases. - Used alone, it is generally less effective for **heavy menstrual bleeding** due to vWD than when paired with an antifibrinolytic agent like tranexamic acid. *Mefenamic acid 500mg three times daily during menstruation* - **Mefenamic acid** is an NSAID that reduces prostaglandin levels, thereby decreasing menstrual flow, but it is significantly less effective than tranexamic acid for treating **coagulopathy-related bleeding**. - It also carries a theoretical risk of interfering with **platelet aggregation**, which could potentially worsen bleeding tendencies in a patient with vWD. *Factor VIII concentrate infusion before each menstrual period* - **Factor VIII or vWF concentrates** are usually reserved for surgical prophylaxis, severe bleeding episodes, or life-threatening bleeds rather than routine management of **menorrhagia**. - This treatment is invasive, expensive, and not considered **first-line pharmacological management** for chronic menstrual control in vWD when other options are available.

Question 103: A 46-year-old woman presents with a 7-month history of heavy irregular bleeding. She reports cycles varying from 18 to 45 days with unpredictable heavy flow. She experiences hot flushes and night sweats. Haemoglobin is 108 g/L, TSH is normal. Transvaginal ultrasound shows a 6mm endometrium and normal ovaries. What is the most appropriate management approach?

A. Reassure and manage conservatively with iron supplementation
B. Commence cyclical oral progestogen therapy
C. Arrange outpatient hysteroscopy and endometrial biopsy (Correct Answer)
D. Start combined oral contraceptive pill
E. Prescribe tranexamic acid for heavy days only

Explanation: ***Arrange outpatient hysteroscopy and endometrial biopsy*** - In women aged **≥45 years** presenting with persistent **heavy irregular bleeding** or a significant change in pattern, international guidelines recommend **endometrial sampling** to rule out **endometrial hyperplasia** or **carcinoma**. - Although the **endometrial thickness of 6mm** is within a benign range for postmenopausal women on HRT, it does not reliably exclude focal **endometrial pathology** or **atypia** in the context of persistent, irregular perimenopausal bleeding, making a biopsy essential. *Reassure and manage conservatively with iron supplementation* - While **iron supplementation** is necessary to address the **anaemia** (Hb 108 g/L), this approach fails to investigate the underlying cause of the **heavy irregular bleeding**. - Reassurance alone is inappropriate and potentially dangerous for a 46-year-old with such symptoms, as it could delay the diagnosis of serious **endometrial pathology**. *Commence cyclical oral progestogen therapy* - **Cyclical oral progestogens** can help regulate bleeding in perimenopause, but they should not be initiated as a primary treatment before **endometrial sampling** in a woman over 45 with persistent abnormal uterine bleeding. - Starting hormonal therapy without a biopsy risks masking symptoms and delaying the diagnosis of conditions like **endometrial hyperplasia** or **cancer**. *Start combined oral contraceptive pill* - The **combined oral contraceptive pill (COCP)** can effectively manage both bleeding and perimenopausal symptoms but is contraindicated as a first step before **endometrial investigation** in this age group and clinical scenario. - Prescribing a COCP without excluding **endometrial pathology** could obscure a significant diagnosis and delay appropriate management. *Prescribe tranexamic acid for heavy days only* - **Tranexamic acid** is an effective non-hormonal treatment for reducing **heavy menstrual bleeding**, but it does not address the **irregularity** of the cycles or the underlying diagnostic requirement. - This treatment is purely symptomatic and does not investigate the crucial **7-month history** of unpredictable bleeding in a woman over 45, which mandates histological assessment.

Question 104: A 22-year-old woman presents with sudden onset severe right-sided pelvic pain and vaginal bleeding. She has a copper intrauterine device in situ for contraception. Her LMP was 8 weeks ago. Urine pregnancy test is positive. She is haemodynamically stable. Transvaginal ultrasound shows an empty uterus with the IUD correctly positioned and a 25mm right adnexal mass with a hyperechoic ring. Free fluid is visible in the pouch of Douglas. Beta-hCG is 3,200 IU/L. What does this clinical scenario illustrate about contraceptive failure?

A. The copper IUD increases the risk of ectopic pregnancy compared to no contraception
B. When pregnancy occurs with an IUD in situ, the relative risk of it being ectopic is increased (Correct Answer)
C. IUDs prevent intrauterine pregnancies but provide no protection against ectopic pregnancies
D. The IUD should be removed immediately to reduce ectopic pregnancy risk
E. Copper IUDs are less effective at preventing ectopic pregnancy than hormonal IUDs

Explanation: ***When pregnancy occurs with an IUD in situ, the relative risk of it being ectopic is increased*** - While IUDs significantly lower the **overall risk** of pregnancy, they are more effective at preventing **intrauterine implantation** than extrauterine implantation. - Because of this differential efficacy, if a patient becomes pregnant with an IUD in situ, there is a much higher **proportion (relative risk)** that the pregnancy will be **ectopic** compared to the general population. *The copper IUD increases the risk of ectopic pregnancy compared to no contraception* - This is false because any form of effective contraception, including the **copper IUD**, reduces the **absolute risk** of ectopic pregnancy by preventing fertilization. - A woman using an IUD has a lower total chance of having an **ectopic pregnancy** than a woman using no contraception at all. *IUDs prevent intrauterine pregnancies but provide no protection against ectopic pregnancies* - IUDs do provide protection against **ectopic pregnancies** by acting as a contraceptive and preventing the initial **conception** from occurring. - However, the protection is simply less complete than its protection against **intrauterine pregnancies**, leading to the observed shift in relative frequency. *The IUD should be removed immediately to reduce ectopic pregnancy risk* - Once an **ectopic pregnancy** is already established and visualized on **ultrasound**, removing the IUD does not treat or resolve the ectopic gestation. - Management should focus on the **adnexal mass** (surgical or medical with methotrexate) rather than the **intrauterine** contraceptive device location. *Copper IUDs are less effective at preventing ectopic pregnancy than hormonal IUDs* - Both the **copper IUD** and the **levonorgestrel-releasing intrauterine system (LNG-IUS)** are highly effective at preventing both types of pregnancy. - There is no clinical evidence provided in this scenario to suggest a superiority of **hormonal IUDs** over copper ones specifically regarding **ectopic pregnancy** prevention rates.

Question 105: A 31-year-old woman undergoes laparoscopy for suspected ectopic pregnancy. At surgery, a 3.5cm unruptured left tubal ectopic pregnancy is identified. The left tube appears damaged, but the right tube appears healthy with no abnormality. She has one child and wishes to have more children in the future. What is the most appropriate surgical management?

A. Left salpingotomy with conservation of the tube
B. Left salpingectomy (Correct Answer)
C. Bilateral salpingectomy
D. Left salpingectomy and right salpingostomy
E. Segmental resection of the affected portion with tubal anastomosis

Explanation: ***Left salpingectomy*** - **Salpingectomy** is the preferred surgical treatment when the **contralateral tube** is healthy and the affected tube is significantly **damaged**, as seen here. - Given the **3.5 cm unruptured ectopic pregnancy** and a **damaged left tube**, salpingectomy reduces the risk of **persistent trophoblastic disease** and offers similar future **intrauterine pregnancy** rates compared to conservative approaches. *Left salpingotomy with conservation of the tube* - This conservative approach is generally reserved for cases where the tube is less damaged, the ectopic pregnancy is smaller, or when the **contralateral tube** is compromised, to preserve fertility. - Given the **damaged left tube** and 3.5 cm size, **salpingotomy** carries a higher risk of **persistent trophoblastic disease** and **recurrent ectopic pregnancy** in the same tube. *Bilateral salpingectomy* - Performing a **bilateral salpingectomy** would render the patient unable to conceive naturally, which contradicts her desire for more children. - The **right tube** was identified as **healthy** with no abnormalities, making its removal medically unnecessary and against the patient's reproductive wishes. *Left salpingectomy and right salpingostomy* - There is no clinical indication for any surgical intervention on the **right tube**, as it was found to be **healthy** and without abnormality during the laparoscopy. - A **right salpingostomy** would unnecessarily introduce trauma and potential scarring to a healthy tube, potentially impairing its future function. *Segmental resection of the affected portion with tubal anastomosis* - **Segmental resection with tubal anastomosis** is not a primary acute management for ectopic pregnancy, especially given the emergency context and desire for future fertility. - This complex procedure is typically considered in a non-acute setting for specific tubal reconstruction or reversal of sterilization, not for immediate ectopic pregnancy removal.

Question 106: A 37-year-old woman with heavy menstrual bleeding has tried tranexamic acid and mefenamic acid with minimal improvement. She has completed her family and does not wish to use hormonal treatments. Pelvic examination and ultrasound are normal with no structural abnormality. Her haemoglobin is 102 g/L. She is significantly bothered by the heavy bleeding. What is the most appropriate next management option?

A. Offer endometrial ablation (Correct Answer)
B. Commence oral norethisterone (5mg three times daily) days 5-26 of cycle
C. Arrange hysterectomy
D. Trial of combined oral contraceptive pill despite her preference
E. Refer for uterine artery embolization

Explanation: ***Offer endometrial ablation*** - For women who have **completed their family** and find medical management unsuccessful or undesirable, **endometrial ablation** is a recommended surgical option for heavy menstrual bleeding without structural pathology. - It is less invasive than a hysterectomy and is suitable for patients, like this woman, who have specifically **declined hormonal treatments**. *Commence oral norethisterone (5mg three times daily) days 5-26 of cycle* - This is a **progestogen-based hormonal treatment** which the patient has already stated she does not wish to use. - While effective for cycle control, it does not address her preference for **non-hormonal** management. *Arrange hysterectomy* - **Hysterectomy** is a definitive surgical treatment but is more invasive and associated with longer **recovery times** and higher complication rates. - It is usually considered if **endometrial ablation** has failed, is contraindicated, or if the patient expresses a specific preference for it after discussing other surgical options. *Trial of combined oral contraceptive pill despite her preference* - Medical ethics and **NICE guidelines** emphasize the importance of respecting **patient preference**; offering a hormonal treatment she has explicitly declined is inappropriate. - The **combined oral contraceptive pill** is a hormonal method which she has excluded from her chosen management path. *Refer for uterine artery embolization* - **Uterine artery embolization (UAE)** is primarily indicated for the treatment of **heavy menstrual bleeding** associated with **large fibroids**. - Since this patient has a **normal ultrasound** with no structural abnormalities, UAE is not an appropriate clinical intervention.

Question 107: A 26-year-old woman presents with sudden onset severe left iliac fossa pain and syncope. She has missed her last period and her LMP was 7 weeks ago. On examination, she is tachycardic at 115 bpm, blood pressure 95/60 mmHg, and has generalized abdominal tenderness with guarding. Bedside urine pregnancy test is positive. What is the most appropriate immediate management?

A. Arrange urgent transvaginal ultrasound scan
B. Obtain serum beta-hCG level before any intervention
C. Insert two large-bore IV cannulae, commence fluid resuscitation, and arrange emergency laparoscopy (Correct Answer)
D. Administer intramuscular methotrexate
E. Perform culdocentesis to confirm haemoperitoneum

Explanation: ***Insert two large-bore IV cannulae, commence fluid resuscitation, and arrange emergency laparoscopy*** - The patient's presentation with **sudden severe abdominal pain**, **syncope**, **tachycardia**, **hypotension**, and **generalized abdominal tenderness** strongly indicates a **ruptured ectopic pregnancy** with **hypovolemic shock**. - Immediate management involves stabilizing the patient with **fluid resuscitation** and urgent surgical intervention (typically **laparoscopy**) to control the internal hemorrhage and remove the ectopic pregnancy. *Arrange urgent transvaginal ultrasound scan* - While an ultrasound is crucial for diagnosing ectopic pregnancy in **stable patients**, it should not delay life-saving surgical intervention in a patient exhibiting signs of **hemodynamic instability** and **hemoperitoneum**. - The priority is to address the **shock** and stop the bleeding, not to confirm the diagnosis with imaging when the clinical picture is clear. *Obtain serum beta-hCG level before any intervention* - A **positive bedside urine pregnancy test** is sufficient to confirm pregnancy in an emergency setting. Waiting for quantitative serum beta-hCG levels would dangerously delay crucial **resuscitation** and surgical management in a patient in **shock**. - Management of an unstable patient with suspected ruptured ectopic pregnancy is based on clinical presentation and immediate stabilization, not on specific **hCG values**. *Administer intramuscular methotrexate* - **Methotrexate** is a medical treatment reserved for **stable patients** with small, unruptured ectopic pregnancies and specific criteria (e.g., low hCG levels, no fetal cardiac activity). - It is absolutely **contraindicated** in patients with signs of **tubal rupture**, **hemodynamic instability**, or **active bleeding**, as seen in this patient. *Perform culdocentesis to confirm haemoperitoneum* - **Culdocentesis** is an outdated and largely **obsolete diagnostic procedure** that has been replaced by more modern and efficient methods like **FAST scan** or direct surgical exploration in unstable patients. - Performing this procedure would waste precious time that should be dedicated to initiating **fluid resuscitation** and preparing for **emergency laparoscopy** to control the bleeding.

Question 108: What is the mechanism by which mefenamic acid reduces menstrual blood loss in women with heavy menstrual bleeding?

A. Inhibition of fibrinolysis in the endometrium
B. Reduction in endometrial prostaglandin synthesis (Correct Answer)
C. Suppression of gonadotrophin release
D. Induction of endometrial atrophy
E. Enhancement of platelet aggregation

Explanation: ***Reduction in endometrial prostaglandin synthesis***- **Mefenamic acid** is an **NSAID** that inhibits **cyclooxygenase (COX) enzymes**, leading to decreased production of **prostaglandins** (PGE2, PGF2α) in the endometrium.- Excess prostaglandins cause **vasodilation** and increased blood loss during menstruation, so reducing their synthesis helps to decrease heavy menstrual bleeding.*Inhibition of fibrinolysis in the endometrium*- This is the primary mechanism of action for **tranexamic acid**, an **antifibrinolytic agent**, which works by preventing the breakdown of existing blood clots.- Mefenamic acid does not directly inhibit the **fibrinolytic system** in the endometrium.*Suppression of gonadotrophin release*- This mechanism is characteristic of **hormonal treatments** such as combined oral contraceptives or GnRH agonists, which act on the **hypothalamic-pituitary-ovarian axis**.- Mefenamic acid's action is localized to the endometrium, affecting prostaglandin pathways rather than systemic hormonal regulation.*Induction of endometrial atrophy*- This effect is typically achieved by **progestogen-releasing intrauterine systems** (e.g., LNG-IUS) or continuous progestogen therapy, which thin the endometrial lining.- Mefenamic acid does not cause structural changes or **atrophy** of the endometrium; it primarily modulates biochemical pathways.*Enhancement of platelet aggregation*- Mefenamic acid, like other NSAIDs, generally has a mild **inhibitory effect on platelet function** by suppressing thromboxane A2, rather than enhancing it.- Therefore, enhancing platelet aggregation is not the mechanism by which mefenamic acid reduces menstrual blood loss.

Question 109: A 44-year-old woman with heavy menstrual bleeding has had a levonorgestrel intrauterine system in situ for 18 months. She reports significant improvement initially, but now her periods have become heavy again over the past 3 months. Examination reveals a bulky uterus. What is the most appropriate initial investigation?

A. Serum beta-hCG to exclude pregnancy
B. Transvaginal ultrasound to check LNG-IUS position and assess uterine pathology (Correct Answer)
C. Endometrial biopsy to exclude malignancy
D. Hysteroscopy and LNG-IUS removal
E. Full blood count and coagulation screen

Explanation: ***Transvaginal ultrasound to check LNG-IUS position and assess uterine pathology*** - The return of heavy bleeding after 18 months of efficacy suggests **LNG-IUS displacement** or the development of structural pathology like **fibroids or adenomyosis**. - A **transvaginal ultrasound** is the gold standard for verifying correct device placement and evaluating the **bulky uterus** for underlying pathology. *Serum beta-hCG to exclude pregnancy* - While **pregnancy** should be considered in women of reproductive age, it is less likely to present as a return of heavy menstrual patterns compared to structural issues. - It does not address the physical finding of a **bulky uterus** or investigate the primary cause of system failure. *Endometrial biopsy to exclude malignancy* - While age 44 is near the threshold for **endometrial cancer** screening, clinical suspicion points first to mechanical failure or structural changes. - **Endometrial biopsy** is usually performed after ultrasound results confirm an increased **endometrial thickness** or other risk factors. *Hysteroscopy and LNG-IUS removal* - **Hysteroscopy** is an invasive procedure and should not be the first-line investigation when imaging can non-invasively detect **device displacement**. - Removal of the device is premature before confirming it is the cause of the issue; it might still be salvageable or need targeted replacement. *Full blood count and coagulation screen* - A **full blood count** is helpful to assess the degree of **anemia** caused by bleeding, but it does not diagnose the underlying cause of treatment failure. - **Coagulation screens** are typically indicated if heavy bleeding has been lifelong or if there is a strong family history, not for sudden recurrence with a **bulky uterus**.

Question 110: A 33-year-old woman is being treated with intramuscular methotrexate for an unruptured tubal ectopic pregnancy. Her initial beta-hCG was 1,850 IU/L. On day 4 post-methotrexate, she develops increased right-sided abdominal pain with guarding but remains haemodynamically stable. Beta-hCG on day 4 is 2,100 IU/L. What is the most likely explanation for her symptoms?

A. Tubal rupture requiring immediate laparoscopy
B. Methotrexate treatment failure requiring second dose
C. Separation pain from tubal abortion (Correct Answer)
D. Methotrexate-induced gastritis
E. Urinary tract infection

Explanation: ***Separation pain from tubal abortion***- This phenomenon typically occurs **3-7 days** after methotrexate administration as the pregnancy detaches from the tubal wall, causing **tubal distension**.- The patient remains **haemodynamically stable** despite symptoms of guarding or peritonism, and an initial **hCG rise** on day 4 is a common, non-diagnostic finding.*Tubal rupture requiring immediate laparoscopy*- Rupture is usually associated with significant **haemodynamic instability** (tachycardia, hypotension) and signs of **intra-abdominal hemorrhage**.- While pain and guarding are present, the stability of this patient and the timing post-injection make separation pain more statistically likely in the absence of shock.*Methotrexate treatment failure requiring second dose*- Treatment failure is defined by a **less than 15% fall** in beta-hCG between **day 4 and day 7** of treatment.- It is impossible to diagnose failure on day 4 alone because a transient **initial rise** in hCG is expected as trophoblastic cells die and release the hormone.*Methotrexate-induced gastritis*- Although methotrexate can cause gastrointestinal side effects, it typically manifests as **nausea** or **stomatitis** rather than focal lower abdominal pain with guarding.- The location of the pain in the **right-sided lower abdomen** is more consistent with the site of the ectopic pregnancy than gastric irritation.*Urinary tract infection*- A **UTI** would typically present with **dysuria**, frequency, or suprapubic tenderness rather than guarding in the adnexal region.- Clinical suspicion should remain on the known **ectopic pregnancy** given the recent medical management and the specific timeline of the abdominal symptoms.

Question 111: A 48-year-old woman presents with heavy menstrual bleeding lasting 10 days each cycle. She has passed large clots and experiences flooding. Blood tests show haemoglobin 95 g/L, ferritin 8 ng/mL, and TSH 2.1 mU/L. Transvaginal ultrasound reveals a uniformly enlarged uterus measuring 14cm with heterogeneous myometrium but no discrete masses. Endometrial thickness is 8mm. What is the most likely diagnosis?

A. Endometrial hyperplasia
B. Adenomyosis (Correct Answer)
C. Multiple small intramural fibroids
D. Endometrial polyp
E. Endometrial carcinoma

Explanation: ***Adenomyosis***- The ultrasound finding of a **uniformly enlarged uterus** with **heterogeneous myometrium** but no discrete masses is highly characteristic of adenomyosis.- It commonly presents in women in their 40s with **heavy menstrual bleeding**, **iron-deficiency anaemia**, and a "globular" uterus on examination.*Endometrial hyperplasia*- This condition typically presents with a significantly **thickened endometrial stripe** (usually >14mm in premenopausal women), whereas this patient's thickness is 8mm.- While it causes heavy bleeding, it does not typically cause a **uniformly enlarged, heterogeneous myometrium**.*Multiple small intramural fibroids*- Fibroids (leiomyomas) usually appear as **discrete, well-circumscribed, hypoechoic masses** on ultrasound rather than diffuse heterogeneity.- While they cause uterine enlargement, the enlargement is often **irregular or nodular** rather than uniform.*Endometrial polyp*- A polyp would appear as a **focal echogenic mass** within the endometrial cavity, often with a visible vascular pedicle on Doppler.- Polyps cause intermenstrual or heavy bleeding but do not lead to **diffuse uterine enlargement** or myometrial changes.*Endometrial carcinoma*- This diagnosis usually presents with a **thickened, irregular endometrium** or a distinct intrauterine mass, especially in a postmenopausal setting.- Although the patient is 48, her **endometrial thickness of 8mm** and the specific myometrial findings make adenomyosis much more likely.

Question 112: A 29-year-old woman presents with 6 weeks amenorrhoea and right lower abdominal pain. Beta-hCG is 2,400 IU/L. Transvaginal ultrasound shows an empty uterus with 15mm endometrial thickness and no adnexal mass visible. She is haemodynamically stable with minimal pain. A repeat beta-hCG 48 hours later is 2,550 IU/L. What is the most appropriate next step in management?

A. Arrange diagnostic laparoscopy (Correct Answer)
B. Administer intramuscular methotrexate
C. Commence expectant management with weekly beta-hCG monitoring
D. Repeat transvaginal ultrasound in 48-72 hours
E. Perform uterine evacuation for presumed miscarriage

Explanation: ***Arrange diagnostic laparoscopy***- The patient has a **pregnancy of unknown location (PUL)** with a **beta-hCG level (2,400-2,550 IU/L)** well above the **discriminatory zone** (usually 1,500-2,000 IU/L), where an intrauterine pregnancy should be visible on ultrasound.- A **suboptimal rise in beta-hCG** (less than 35-53% in 48 hours) without a visible uterine pregnancy is highly concerning for **ectopic pregnancy**, making laparoscopy the gold standard for definitive diagnosis and treatment.*Administer intramuscular methotrexate*- Medical management with **methotrexate** typically requires a confirmed diagnosis of ectopic pregnancy or a high clinical suspicion where an **adnexal mass** is visible.- It is generally contraindicated if the diagnosis is uncertain and the patient is stable enough for a **laparoscopic evaluation** to find the exact location of the pregnancy.*Commence expectant management with weekly beta-hCG monitoring*- Expectant management is reserved for patients where **beta-hCG levels are falling** or are very low (<1,000 IU/L), suggesting a self-limiting miscarriage or resolving ectopic.- In this patient, the **rising beta-hCG** (even if suboptimal) indicates continuing trophoblastic activity, posing a high risk of rupture if left unmanaged.*Repeat transvaginal ultrasound in 48-72 hours*- Repeating ultrasound is indicated when the initial **beta-hCG is below the discriminatory zone** and the patient is asymptomatic.- Given the current level is **2,550 IU/L**, a viable intrauterine pregnancy would already be visible; further delay in surgical assessment increases the risk of **tubal rupture**.*Perform uterine evacuation for presumed miscarriage*- Uterine evacuation or **manual vacuum aspiration (MVA)** is used to confirm the absence of products of conception but carries the risk of delaying the diagnosis of an **extra-uterine pregnancy**.- This step might only be considered if a **non-viable intrauterine pregnancy** was suspected, but it does not address the primary concern of a potential ectopic pregnancy in the adnexa.

Question 113: A 34-year-old woman with polycystic ovary syndrome presents with a 15-month history of oligomenorrhoea with occasional very heavy bleeding episodes. She experiences a period approximately every 3-4 months, lasting 10-12 days with flooding and clots. BMI is 32 kg/m². She is not sexually active. Pelvic examination is normal. What is the underlying pathophysiological mechanism most likely responsible for her heavy menstrual bleeding?

A. Anovulatory cycles causing prolonged unopposed oestrogen stimulation of endometrium (Correct Answer)
B. Increased endometrial prostaglandin production causing impaired haemostasis
C. Hyperinsulinaemia causing increased endometrial vascular permeability
D. Elevated LH:FSH ratio causing deficient endometrial maturation
E. Androgen excess causing endometrial hyperplasia and abnormal angiogenesis

Explanation: ***Anovulatory cycles causing prolonged unopposed oestrogen stimulation of endometrium*** - In **Polycystic Ovary Syndrome (PCOS)**, the absence of **ovulation** means no **corpus luteum** forms, leading to a persistent lack of **progesterone**. - This results in **unopposed oestrogen** stimulation, causing continuous **endometrial proliferation** and thickening. The lack of structured shedding leads to **irregular, heavy, and prolonged bleeding** when the unstable endometrium eventually sloughs. *Increased endometrial prostaglandin production causing impaired haemostasis* - This mechanism primarily explains heavy menstrual bleeding (HMB) in **ovulatory cycles**, where there's a prostaglandin imbalance (e.g., increased PGF2α/PGE2 ratio) leading to vasodilation and impaired platelet aggregation. - The patient's presentation of **oligomenorrhoea** and **irregular, heavy bleeding** strongly points to anovulation, not primarily a prostaglandin issue in regularly ovulating cycles. *Hyperinsulinaemia causing increased endometrial vascular permeability* - **Hyperinsulinaemia** is a common feature of PCOS and contributes to its metabolic and androgenic manifestations, but it is not the direct cause of heavy menstrual bleeding. - While insulin can influence various tissues, **increased endometrial vascular permeability** is not the primary pathophysiological mechanism for the heavy, irregular bleeding seen in anovulatory cycles. *Elevated LH:FSH ratio causing deficient endometrial maturation* - An elevated **LH:FSH ratio** is characteristic of PCOS and contributes to **follicular arrest** and anovulation. - However, it is the *consequence* of anovulation, specifically the **lack of progesterone**, that directly leads to the abnormal endometrial development and heavy bleeding, rather than the LH:FSH ratio itself causing deficient endometrial maturation in a direct sense. *Androgen excess causing endometrial hyperplasia and abnormal angiogenesis* - While **androgen excess** is a hallmark of PCOS, it primarily contributes to hirsutism, acne, and is often peripherally converted to oestrogen, which then acts on the endometrium. - High levels of **androgens** themselves often have an inhibitory effect on the endometrium; the bleeding is specifically due to the **progesterone deficiency** and resulting estrogen-driven hyperplasia rather than direct abnormal angiogenesis from androgens.

Question 114: A 47-year-old woman with a 10-month history of heavy menstrual bleeding has been using a levonorgestrel intrauterine system for 5 months. Initially her bleeding improved, but for the last 6 weeks she has experienced persistent irregular bleeding occurring every 10-14 days. Transvaginal ultrasound confirms the LNG-IUS is correctly positioned in the uterine cavity. Endometrial thickness is 4 mm. There are no fibroids or polyps. What is the most appropriate management?

A. Remove LNG-IUS and arrange hysteroscopy
B. Reassure and continue with LNG-IUS for 3 more months (Correct Answer)
C. Add cyclical norethisterone for 3 months
D. Remove LNG-IUS and start combined oral contraceptive
E. Remove LNG-IUS and arrange endometrial ablation

Explanation: ***Reassure and continue with LNG-IUS for 3 more months*** - **Irregular bleeding or spotting** is a common side effect during the first **3 to 6 months** of LNG-IUS use, affecting a majority of patients as the endometrium adjusts. - Given the **ultrasound confirms correct positioning** and a thin **4 mm endometrium** without structural pathology, the most appropriate step is to allow more time for the bleeding pattern to stabilize. *Remove LNG-IUS and arrange hysteroscopy* - There are no **red flags** or ultrasound findings (like a thickened endometrium or polyps) to justify an invasive **hysteroscopy** at this stage. - The LNG-IUS remains the **first-line treatment** for heavy menstrual bleeding, and premature removal should be avoided unless pathology is suspected. *Add cyclical norethisterone for 3 months* - Adding **progestogens** like norethisterone is not a standard recommendation for managing initial breakthrough bleeding with an LNG-IUS. - This intervention may introduce additional side effects without addressing the underlying **endometrial thinning** caused by the IUS itself. *Remove LNG-IUS and start combined oral contraceptive* - Removing a correctly placed and effective device for a **well-known transient side effect** ignores clinical guidelines advocating for a 6-month trial period. - The patient previously had **heavy menstrual bleeding**, and the LNG-IUS typically offers better long-term management of this condition than the **COCP**. *Remove LNG-IUS and arrange endometrial ablation* - **Endometrial ablation** is an irreversible surgical procedure that should only be considered after medical management, like the **LNG-IUS**, has been given an adequate trial. - Five months is insufficient to declare **treatment failure**, especially when structural abnormalities have already been ruled out via **transvaginal ultrasound**.

Question 115: A 25-year-old woman undergoes laparoscopy for suspected ectopic pregnancy. At laparoscopy, both fallopian tubes appear normal. There is a 3 cm haemorrhagic cyst on the right ovary. The uterus appears normal-sized with no obvious pathology. Serum beta-hCG pre-operatively was 1,800 IU/L. Transvaginal ultrasound showed an empty uterus. What is the most likely diagnosis?

A. Early intrauterine pregnancy not yet visible on ultrasound
B. Completed spontaneous miscarriage
C. Ovarian ectopic pregnancy
D. Cornual ectopic pregnancy (Correct Answer)
E. Persistent corpus luteum of failed intrauterine pregnancy

Explanation: ***Cornual ectopic pregnancy*** - A **cornual (interstitial) pregnancy** implants within the myometrium of the uterine horn, which often prevents it from being visible during a standard **laparoscopic inspection** of the fallopian tubes. - With a **serum beta-hCG of 1,800 IU/L**, an intrauterine pregnancy should be visible on ultrasound (discriminatory zone >1,500 IU/L); its absence alongside normal-looking tubes strongly suggests a hidden **interstitial implantation**. *Early intrauterine pregnancy not yet visible on ultrasound* - A visible gestational sac is typically expected on **transvaginal ultrasound** once the **beta-hCG** levels exceed **1,500 IU/L**. - Since the uterus appeared empty at this level, an early viable **intrauterine pregnancy** is highly unlikely. *Completed spontaneous miscarriage* - Following a **completed miscarriage**, the uterus should appear empty, but the **beta-hCG levels** would be rapidly declining rather than remaining at a high level like 1,800 IU/L. - Clinical presentation usually involves a history of **heavy vaginal bleeding** and passing of tissue, which is not mentioned here. *Ovarian ectopic pregnancy* - **Ovarian ectopics** typically present as a suspicious mass on the ovary during laparoscopy, following widespread **Spiegelberg criteria**. - While a 3 cm **haemorrhagic cyst** is present, this is more statistically likely to be a **corpus luteum**, which supports any pregnancy regardless of site. *Persistent corpus luteum of failed intrauterine pregnancy* - A **corpus luteum** is a normal finding in early pregnancy and not a diagnosis for the **location** of the pregnancy itself. - It does not explain the high **beta-hCG** of 1,800 IU/L in the absence of an **intrauterine sac** or visible tubal pathology.

Question 116: A 43-year-old woman presents with intermenstrual bleeding and postcoital bleeding for 4 months. Her periods are regular and normal in volume. Her last cervical screening 2 years ago was negative for high-risk HPV. On speculum examination, the cervix appears healthy with no visible lesions. What is the most appropriate initial management?

A. Repeat cervical screening with HPV testing and cytology (Correct Answer)
B. Transvaginal ultrasound scan
C. Reassure and review in 3 months
D. Hysteroscopy and endometrial biopsy
E. Empirical treatment with norethisterone

Explanation: ***Repeat cervical screening with HPV testing and cytology*** - **Postcoital bleeding (PCB)** and **intermenstrual bleeding** are red flags for **cervical pathology**, including **cervical cancer**, even if the cervix appears healthy on speculum examination and previous screening was negative. - The most appropriate initial step is to repeat **cervical screening** with **HPV testing** and **cytology** to rule out high-risk HPV infection or early dysplastic changes that might have developed or been missed. *Transvaginal ultrasound scan* - While a **transvaginal ultrasound** is useful for assessing uterine and ovarian pathology (like fibroids or polyps), it is not the primary investigation for **postcoital bleeding** as it does not directly evaluate cervical lesions. - This scan would be more appropriate if cervical causes were ruled out and suspicion for **intracavitary uterine pathology** or ovarian issues remained. *Reassure and review in 3 months* - **Postcoital bleeding** is a concerning symptom that warrants thorough investigation to exclude **cervical malignancy** (up to 3%) or **cervical intraepithelial neoplasia (CIN)** (up to 9%). - Reassurance without investigation could lead to a **delayed diagnosis** of a potentially serious condition, which is medically inappropriate. *Hysteroscopy and endometrial biopsy* - **Hysteroscopy** and **endometrial biopsy** are indicated when there is a strong suspicion of **endometrial pathology**, such as in cases of **postmenopausal bleeding** or persistent heavy menstrual bleeding. - Given the patient's symptoms are primarily **intermenstrual** and **postcoital bleeding**, with regular normal volume periods, a cervical cause is more likely than an endometrial one as the initial focus. *Empirical treatment with norethisterone* - **Empirical hormonal treatment** like **norethisterone** can mask the symptoms of **underlying pathology**, particularly **cervical cancer**, leading to a delay in diagnosis and treatment. - Hormonal therapy is typically reserved for **dysfunctional uterine bleeding** after structural and malignant causes have been comprehensively excluded.

Question 117: A 29-year-old woman with a confirmed tubal ectopic pregnancy receives single-dose methotrexate (50 mg/m²) on day 0. Her initial beta-hCG was 2,400 IU/L. On day 4, she complains of increased lower abdominal pain without signs of rupture. On examination, she has mild right iliac fossa tenderness but is haemodynamically stable with no peritonism. Beta-hCG on day 4 is 2,650 IU/L. What is the most appropriate management?

A. Emergency laparoscopy for presumed rupture
B. Immediate second dose of methotrexate
C. Reassurance and continue monitoring with day 7 beta-hCG (Correct Answer)
D. Admit for observation and repeat ultrasound
E. Switch to two-dose methotrexate regimen

Explanation: ***Reassurance and continue monitoring with day 7 beta-hCG***- It is expected and common for **beta-hCG levels to rise** between day 0 and day 4 of methotrexate treatment; the critical therapeutic evaluation occurs by comparing **day 4 and day 7** levels.- The patient is likely experiencing **separation pain**, a transient increase in abdominal pain typically occurring 3–7 days after methotrexate due to tubal abortion or hematoma formation in a **hemodynamically stable** patient.*Emergency laparoscopy for presumed rupture*- This patient lacks clinical signs of **hemodynamic instability**, severe peritonism, or shoulder-tip pain that would indicate an **ectopic rupture**.- Surgical intervention is reserved for patients who fail medical management or show signs of **acute hemoperitoneum**.*Immediate second dose of methotrexate*- A second dose is only considered if the **beta-hCG level** fails to drop by at least **15% between day 4 and day 7**.- Giving a second dose on day 4 is premature as the initial dose's effectiveness cannot be accurately assessed until the **day 7 measurement**.*Admit for observation and repeat ultrasound*- While monitoring is necessary, this patient is **stable** and exhibiting a physiological response to treatment that can usually be managed with **outpatient follow-up**.- An ultrasound is often unhelpful at this stage as it may show a transient increase in the size of the **ectopic mass** due to hemorrhage, which does not necessarily indicate failure.*Switch to two-dose methotrexate regimen*- The choice between single-dose and multi-dose regimens is made at **treatment initiation** based on baseline hCG levels and mass size.- Once a **single-dose protocol** has started, the standard of care is to follow the set monitoring schedule rather than switching mid-cycle due to expected day 4 hCG rises.

Question 118: A 36-year-old nulliparous woman presents with heavy menstrual bleeding for 12 months. She reports using 16 pads per day for 8 days each cycle. Haemoglobin is 78 g/L. Transvaginal ultrasound shows a 4 cm subserosal fibroid on the posterior uterine wall and otherwise normal appearances. She strongly wishes to maintain her fertility. What is the most appropriate management?

A. Levonorgestrel intrauterine system insertion
B. Tranexamic acid and iron supplementation (Correct Answer)
C. Laparoscopic myomectomy
D. GnRH analogue therapy for 6 months
E. Combined oral contraceptive pill

Explanation: ***Tranexamic acid and iron supplementation*** - The patient has severe **anaemia (Hb 78 g/L)** due to heavy menstrual bleeding; initial management must include **iron replacement** and medical control of bleeding. - A **subserosal fibroid** does not distort the uterine cavity and is rarely the cause of heavy bleeding, making medical management more appropriate than surgery. *Levonorgestrel intrauterine system insertion* - This is a first-line treatment for heavy bleeding but provides **contraception**, which may not be ideal if she is currently trying to conceive. - While effective, the patient's immediate need is the correction of **acute severe anaemia** and stabilization of bleeding. *Laparoscopic myomectomy* - Surgical removal is generally reserved for **symptomatic fibroids** (e.g., pressure symptoms or infertility) or those distorting the cavity (submucosal). - **Subserosal fibroids** are unlikely to be causing the heavy bleeding, so removing them would not resolve her primary complaint and carries unnecessary surgical risk. *GnRH analogue therapy for 6 months* - These are typically used to **shrink fibroids** pre-operatively or as a short-term bridge to menopause, not as a long-term strategy for women wishing to retain fertility. - Symptoms recur rapidly after discontinuation, and long-term use is limited by **bone mineral density** loss. *Combined oral contraceptive pill* - While the COCP can reduce menstrual flow, it is a **contraceptive**, which conflicts with the patient's desire to maintain her fertility options. - **Tranexamic acid** is more suitable for women seeking pregnancy as it is taken only during menstruation and does not inhibit ovulation.

Question 119: A 32-year-old woman presents with 7 weeks amenorrhoea and mild abdominal discomfort. Transvaginal ultrasound shows an empty uterus and a 30mm left adnexal mass. Initial serum beta-hCG is 1,200 IU/L. She is haemodynamically stable. A repeat beta-hCG 48 hours later is 1,450 IU/L. She meets all other criteria for expectant management and wishes to avoid intervention if possible. What is the most appropriate management?

A. Continue expectant management with weekly beta-hCG monitoring (Correct Answer)
B. Repeat beta-hCG after another 48 hours
C. Proceed with single-dose methotrexate therapy
D. Arrange urgent laparoscopy
E. Perform endometrial curettage to exclude miscarriage

Explanation: ***Continue expectant management with weekly beta-hCG monitoring*** - The patient is **haemodynamically stable** with a beta-hCG level that is low (<1500 IU/L) and an adnexal mass <35mm, meeting criteria for **expectant management** despite the slight rise in hCG, especially given her preference to avoid intervention. - Continued **weekly beta-hCG monitoring** is the standard approach for expectant management to ensure resolution or detect the need for alternative treatment if levels plateau or rise significantly. *Repeat beta-hCG after another 48 hours* - The initial 48-hour beta-hCG repeat has already provided the necessary trend information to confirm a likely ectopic pregnancy and assess suitability for expectant management. - Once expectant management is chosen, short-interval (48-hour) monitoring is generally replaced by **weekly monitoring** to track the resolution of the ectopic, rather than repeating diagnostic-phase tests. *Proceed with single-dose methotrexate therapy* - While methotrexate is an option for stable ectopic pregnancies, the patient explicitly **wishes to avoid intervention**, and expectant management is a suitable first-line approach in this scenario. - Methotrexate carries side effects and requires close follow-up; given the favorable criteria for expectant management and patient preference, it is not the most appropriate immediate next step. *Arrange urgent laparoscopy* - **Urgent laparoscopy** is indicated for haemodynamically unstable patients, those with signs of rupture (e.g., severe pain, significant bleeding), or very high hCG levels (typically >5,000 IU/L). - This patient is **haemodynamically stable** with mild discomfort and a low hCG level, thus not warranting immediate surgical intervention. *Perform endometrial curettage to exclude miscarriage* - **Endometrial curettage** is primarily used to differentiate a non-viable intrauterine pregnancy from a pregnancy of unknown location (PUL) when hCG levels are falling and no adnexal mass is clearly visualized. - In this case, a **left adnexal mass** is present, strongly suggesting an ectopic pregnancy, and curettage would not treat the ectopic or align with the patient's desire to avoid intervention.

Question 120: What is the primary cellular mechanism by which the levonorgestrel intrauterine system reduces menstrual blood loss in women with heavy menstrual bleeding?

A. Suppression of ovulation leading to reduced progesterone production
B. Increased endometrial stromal decidualisation with glandular atrophy (Correct Answer)
C. Direct vasoconstriction of spiral arterioles in the endometrium
D. Enhanced platelet aggregation at the endometrial-myometrial interface
E. Inhibition of prostaglandin synthesis in endometrial tissue

Explanation: ***Increased endometrial stromal decidualisation with glandular atrophy*** - The **LNG-IUS** releases levonorgestrel directly into the uterine cavity, leading to high local concentrations that cause **profound endometrial suppression**. - This results in **decidualisation** of the stroma and progressive **glandular atrophy**, creating a thin, inactive endometrium that significantly reduces menstrual volume. *Suppression of ovulation leading to reduced progesterone production* - While the **LNG-IUS** may suppress **ovulation** in a small subset of users, most women continue to have regular ovulatory cycles. - The reduction in bleeding is primarily a **local endometrial effect** rather than a systemic endocrine change in progesterone levels. *Direct vasoconstriction of spiral arterioles in the endometrium* - Levonorgestrel does not act as a primary **vasoconstrictor**; its effect is mediated through cellular changes in the endometrial layers. - **Vasoconstriction** is more characteristic of pharmacological agents like ergometrine used in acute postpartum hemorrhage. *Enhanced platelet aggregation at the endometrial-myometrial interface* - The system does not primarily target **hemostatic pathways** or the coagulation cascade to control bleeding. - Mechanisms like enhanced clotting or platelet function are more relevant to therapies like **tranexamic acid**, which inhibits fibrinolysis. *Inhibition of prostaglandin synthesis in endometrial tissue* - Although progestogens can influence the local environment, the primary mechanism of **LNG-IUS** is structural atrophy rather than enzymatic inhibition. - **Prostaglandin synthesis inhibition** is the specific primary mechanism of **NSAIDs** used to treat heavy menstrual bleeding and dysmenorrhea.

Question 121: A 27-year-old woman undergoes emergency laparoscopy for a ruptured left tubal ectopic pregnancy. Intraoperatively, there is approximately 800 mL of haemoperitoneum. The left fallopian tube is disrupted with active bleeding. The right fallopian tube appears normal. She has no children but wishes to preserve fertility. What is the most appropriate surgical management?

A. Left salpingectomy (Correct Answer)
B. Left salpingotomy with tube preservation
C. Bilateral salpingectomy
D. Left salpingectomy with right prophylactic salpingectomy
E. Segmental resection with end-to-end anastomosis

Explanation: ***Left salpingectomy***- For a **ruptured ectopic pregnancy** with significant **haemoperitoneum** and extensive tubal damage, salpingectomy is the gold-standard treatment to achieve **haemostasis** and prevent recurrence.- While fertility preservation is important, a **normal contralateral tube** means the patient still has a high chance of future spontaneous pregnancy without the risks associated with a damaged site.*Left salpingotomy with tube preservation*- This procedure is generally indicated for **unruptured ectopic pregnancies** in women who have risk factors for infertility, such as a damaged **contralateral tube**.- In the presence of **active bleeding** and a **disrupted fallopian tube**, salpingotomy is contraindicated due to the high risk of persistent trophoblastic tissue and secondary haemorrhage.*Bilateral salpingectomy*- There is no clinical indication to remove the **healthy right fallopian tube**, which is essential for preserving the patient's **future fertility** aspirations.- Removing both tubes would render the patient **permanently infertile** (barring IVF), which directly contradicts her expressed wishes.*Left salpingectomy with right prophylactic salpingectomy*- **Prophylactic removal** of a healthy fallopian tube is not standard practice in emergency management and unnecessarily compromises reproductive potential.- Surgical management should be focused on treating the **acute pathology** and the source of **haemoperitoneum** while minimizing harm to healthy pelvic structures.*Segmental resection with end-to-end anastomosis*- This technique is not performed in an **emergency setting** for a ruptured tube because it is technically difficult and carries a high risk of **tubal stricture**.- Current clinical guidelines recommend **salpingectomy** over resection because it more reliably resolves the pathology and has superior outcomes compared to acute reconstructive attempts.

Question 122: A 51-year-old woman presents with irregular heavy bleeding over 9 months. She describes cycles varying from 18 to 45 days with flooding for 7-10 days. Her last cervical smear 18 months ago was normal. BMI is 34 kg/m². Pelvic examination is normal. Transvaginal ultrasound shows an endometrial thickness of 18 mm with a normal-sized uterus and ovaries. What is the most important next investigation?

A. MRI pelvis
B. Hysteroscopy with endometrial biopsy (Correct Answer)
C. Repeat transvaginal ultrasound in 3 months
D. Saline infusion sonography
E. CA-125 measurement

Explanation: ***Hysteroscopy with endometrial biopsy***- This 51-year-old perimenopausal woman presents with **abnormal uterine bleeding** and a significantly thickened endometrium of **18 mm**, which necessitates tissue sampling to rule out **endometrial hyperplasia** or **malignancy**.- Her **obesity (BMI 34 kg/m²)** is a strong risk factor for endometrial cancer due to unopposed estrogen, making an immediate histological diagnosis critical.*MRI pelvis*- MRI is typically used for **staging** known pelvic malignancies or for characterizing complex adnexal masses, rather than for the initial diagnosis of abnormal uterine bleeding.- It cannot provide the crucial **histological diagnosis** required to differentiate between benign endometrial changes and carcinoma in this high-risk patient.*Repeat transvaginal ultrasound in 3 months*- Delaying further investigation with a repeat ultrasound is inappropriate given the patient's age, persistent **abnormal uterine bleeding**, and a pathological **endometrial thickness** of 18 mm.- This delay could lead to a missed or later diagnosis of **endometrial cancer**, which has a better prognosis when detected early.*Saline infusion sonography*- While effective for identifying **focal intracavitary lesions** such as polyps or submucosal fibroids, saline infusion sonography (SIS) does not provide tissue for **histological analysis**.- In this context of diffuse endometrial thickening and significant risk factors for malignancy, a definitive tissue diagnosis is required.*CA-125 measurement*- **CA-125** is a tumor marker primarily used in the workup and monitoring of **ovarian cancer** and certain benign gynecological conditions.- It has no established role in the primary investigation of **abnormal uterine bleeding** or in the evaluation of endometrial pathology due to its low specificity for endometrial cancer.

Question 123: A 41-year-old woman with heavy menstrual bleeding has tried the levonorgestrel intrauterine system for 8 months but continues to have unacceptable bleeding. Transvaginal ultrasound shows a bulky uterus measuring 14 cm in length with multiple intramural fibroids, the largest measuring 6 cm. She has completed her family and wishes to avoid major surgery if possible. What is the most appropriate next management option?

A. Uterine artery embolisation (Correct Answer)
B. Total abdominal hysterectomy
C. Endometrial ablation
D. GnRH analogue therapy
E. Myomectomy

Explanation: ***Uterine artery embolisation***- **Uterine artery embolisation (UAE)** is a highly effective second-line option for symptomatic **fibroids** in patients who wish to avoid **major surgery** and have failed medical management.- It is suitable for a **bulky uterus** and multiple intramural fibroids, providing high success rates for symptom control while being less invasive than a hysterectomy.*Total abdominal hysterectomy*- While a **hysterectomy** provides a definitive cure for heavy menstrual bleeding and fibroids, it is classified as **major surgery** with significant recovery time.- The patient specifically expressed a desire to avoid **major surgery**, making this an inappropriate next step until less invasive options are exhausted.*Endometrial ablation*- **Endometrial ablation** is generally contraindicated or has high failure rates in the presence of fibroids larger than **3 cm** or a uterine cavity larger than **10-12 cm**.- Since this patient has a **6 cm fibroid** and a uterus measuring **14 cm**, this procedure is technically unsuitable and likely to fail.*GnRH analogue therapy*- **GnRH analogues** are typically used as a short-term measure to shrink fibroids **pre-operatively** rather than as a long-term management solution.- Use is restricted by significant side effects, such as **bone mineral density loss**, and symptoms usually recur rapidly once treatment is discontinued.*Myomectomy*- **Myomectomy** is an invasive surgical procedure primarily reserved for women who wish to **preserve fertility** or their uterus while removing specific fibroids.- Given the patient has **completed her family** and seeks to avoid major surgery, UAE is a preferred, less invasive alternative.

Question 124: A 28-year-old woman presents with 6 weeks amenorrhoea and right-sided pelvic pain. Transvaginal ultrasound shows an empty uterus with normal endometrial thickness and a 25mm right adnexal mass with a hyperechoic ring (blob sign). There is minimal free fluid in the pouch of Douglas. Serum beta-hCG is 2,800 IU/L. She is haemodynamically stable and pain is controlled with oral analgesia. What is the most appropriate management?

A. Expectant management with serial beta-hCG monitoring
B. Single-dose intramuscular methotrexate 50 mg/m² (Correct Answer)
C. Two-dose intramuscular methotrexate regimen
D. Laparoscopic salpingectomy
E. Laparoscopic salpingotomy

Explanation: ***Single-dose intramuscular methotrexate 50 mg/m²*** - Medical management with **methotrexate** is indicated as the patient is **haemodynamically stable**, has **minimal pain**, no fetal heartbeat, and a **beta-hCG < 3,000 IU/L** (2,800 IU/L in this case). - The adnexal mass size of **25mm** (which is < 35mm) and lack of significant abdominal fluid make her an ideal candidate for this **non-surgical** approach. *Expectant management with serial beta-hCG monitoring* - This approach is typically reserved for clinically stable patients where the initial **beta-hCG is < 1,500 IU/L** and levels are already declining. - With a beta-hCG of **2,800 IU/L**, the risk of **tubal rupture** is too high for simple observation without active intervention. *Two-dose intramuscular methotrexate regimen* - The **two-dose regimen** is generally reserved for patients with higher initial beta-hCG levels or those who do not respond adequately to the first dose. - Current guidelines recommend starting with a **single-dose regimen** for patients meeting the criteria, as it has a lower side-effect profile. *Laparoscopic salpingectomy* - **Salpingectomy** (removal of the tube) is the gold standard for **ruptured ectopic pregnancy** or when the patient is haemodynamically unstable. - Surgical intervention is less desirable here because the patient is stable and meets the criteria for **organ-preserving medical therapy**. *Laparoscopic salpingotomy* - **Salpingotomy** (incising the tube to remove the pregnancy) is considered if the patient has risk factors for **infertility**, such as damage to the contralateral tube. - It carries a risk of **persistent trophoblastic tissue** and is not the first-line choice when medical management with **methotrexate** is appropriate and available.

Question 125: A 45-year-old woman presents to her GP with heavy menstrual bleeding for 8 months. She reports flooding through pads every 2 hours and passing large clots. Her haemoglobin is 92 g/L. Physical examination including bimanual pelvic examination is unremarkable. According to NICE guidelines for the management of heavy menstrual bleeding, what is the most appropriate initial investigation?

A. Full blood count and ferritin levels (Correct Answer)
B. Transvaginal ultrasound scan
C. Pelvic MRI scan
D. Endometrial biopsy
E. Hysteroscopy

Explanation: ***Full blood count and ferritin levels***- According to **NICE guidelines (NG88)**, for heavy menstrual bleeding with an **unremarkable physical examination**, the initial laboratory assessment must include a **Full Blood Count** to screen for anaemia.- This patient already shows a low haemoglobin (92 g/L); assessing **ferritin** further evaluates **iron stores**, which is critical for managing systemic effects of persistent bleeding and guiding iron supplementation.*Transvaginal ultrasound scan*- This is the first-line **imaging** modality but is typically reserved for cases where there is a **palpable mass**, clinical suspicion of structural pathology (like fibroids), or if initial medical treatment fails.- As this patient's bimanual examination is **unremarkable** and the focus is on initial *investigation* for the consequences of bleeding, immediate imaging is not the *first* step before blood work.*Pelvic MRI scan*- MRI is not a routine initial investigation for heavy menstrual bleeding and is generally used for complex cases such as **adenomyosis** or surgical planning for large **fibroids**, after other investigations.- It is far more expensive and less accessible than the required initial blood tests or ultrasound, making it unsuitable as the *most appropriate initial* investigation.*Endometrial biopsy*- Indicated primarily in women over **45 years old** with persistent bleeding or those with risk factors for **endometrial hyperplasia** or malignancy.- While this patient is 45 and has persistent bleeding, the NICE guidance prioritizes initial assessment of systemic impacts (anaemia) and general structural screening via ultrasound or hysteroscopy before tissue sampling, unless specific red-flag risks are strongly present.*Hysteroscopy*- This is recommended if the history suggests **submucous fibroids**, polyps, or if ultrasound is inconclusive/unavailable and structural pathology is still suspected.- It is an an invasive procedure and is not the indicated **initial** step for a woman with a normal pelvic examination and no immediate red-flag symptoms requiring direct visualization.

Question 126: A 33-year-old woman presents to the emergency department with sudden onset severe right-sided abdominal pain and syncope. She has a history of 7 weeks amenorrhoea. On examination, she is pale, cold and clammy with a heart rate of 115 bpm and blood pressure of 85/55 mmHg. Abdominal examination reveals generalised tenderness with guarding and rebound. A urine pregnancy test is positive. What is the most appropriate immediate management?

A. Urgent transvaginal ultrasound scan
B. Serum beta-hCG measurement
C. Emergency laparotomy
D. IV fluid resuscitation and arrange emergency laparoscopy (Correct Answer)
E. Intramuscular methotrexate

Explanation: ***IV fluid resuscitation and arrange emergency laparoscopy*** - The patient presents with clinical signs of **haemorrhagic shock** (hypotension, tachycardia, pallor, syncope) and a positive pregnancy test after amenorrhoea, strongly indicating a **ruptured ectopic pregnancy**. - Immediate management requires **aggressive IV fluid resuscitation** to stabilize the patient while simultaneously arranging for **emergency laparoscopy** to definitively stop the internal bleeding. *Urgent transvaginal ultrasound scan* - Delaying treatment for imaging in a patient with clear signs of **haemoperitoneum** and **shock** can lead to rapid clinical deterioration and death. - The clinical diagnosis of a **ruptured ectopic pregnancy** with hemodynamic instability is sufficient for emergency surgical intervention without prior imaging. *Serum beta-hCG measurement* - Quantitative beta-hCG is primarily used for diagnosing **pregnancy of unknown location** in stable patients but is inappropriate in an emergency setting with active haemorrhage. - Waiting for lab results would cause critical delays in the **immediate surgical management** required for acute abdominal hemorrhage and shock. *Emergency laparotomy* - While **laparotomy** is indicated for critically unstable patients who cannot tolerate a pneumoperitoneum, this option lacks the vital first step of **IV fluid resuscitation** to address shock. - **Laparoscopy** is generally the preferred surgical approach for a ruptured ectopic pregnancy due to its minimally invasive nature, provided the patient is stable enough and the surgical team is experienced. *Intramuscular methotrexate* - Methotrexate is a **medical management** option reserved for stable, **unruptured ectopic pregnancies** with specific criteria (e.g., small size, low hCG levels). - It is strictly **contraindicated** in cases of rupture, hemodynamic instability, or evidence of significant **haemoperitoneum**, as it will not stop active bleeding.

Question 127: A 49-year-old woman presents with a 4-month history of irregular heavy bleeding. She reports cycles ranging from 18 to 60 days. Her BMI is 38 kg/m² and she has type 2 diabetes controlled with metformin. Transvaginal ultrasound shows endometrial thickness of 22mm with a bulky uterus but no focal lesions. Endometrial biopsy shows complex endometrial hyperplasia without atypia. She has completed her family. What is the most appropriate management?

A. Total hysterectomy with bilateral salpingo-oophorectomy
B. Continuous oral progestogen therapy for 6 months then re-biopsy
C. Cyclical oral progestogen therapy
D. Insert levonorgestrel intrauterine system and re-biopsy at 6 months (Correct Answer)
E. Repeat endometrial biopsy in 3 months

Explanation: ***Insert levonorgestrel intrauterine system and re-biopsy at 6 months*** - For **complex endometrial hyperplasia without atypia**, the **levonorgestrel intrauterine system (LNG-IUS)** is the first-line treatment, delivering high local progestogen concentrations that are more effective at causing regression than oral therapies. - A **repeat endometrial biopsy at 6 months** is essential to confirm the resolution of hyperplasia and monitor for any persistence or progression, which is crucial given the patient's risk factors. *Total hysterectomy with bilateral salpingo-oophorectomy* - **Hysterectomy** is generally reserved for patients with **atypical endometrial hyperplasia** or those with non-atypical hyperplasia who fail conservative medical management. - This patient's **high BMI** and **diabetes** increase surgical and anesthetic risks, making a less invasive initial treatment more appropriate. *Continuous oral progestogen therapy for 6 months then re-biopsy* - While an acceptable alternative, **continuous oral progestogens** are considered second-line due to **lower efficacy** and a higher incidence of **systemic side effects** compared to the localized delivery of the LNG-IUS. - Adherence to daily oral medication can be challenging, potentially leading to suboptimal regression rates of the **hyperplastic endometrium**. *Cyclical oral progestogen therapy* - **Cyclical progestogens** are significantly **less effective** than continuous therapy and are not recommended for the treatment of **endometrial hyperplasia**. - Continuous exposure to progestogen is required to effectively counteract the **unopposed estrogen** driving endometrial proliferation and induce atrophy. *Repeat endometrial biopsy in 3 months* - Simply observing with a **repeat biopsy** without active treatment is inappropriate for symptomatic **endometrial hyperplasia without atypia**, especially with significant risk factors like **obesity** and **diabetes**. - This approach delays necessary intervention and increases the risk of the condition persisting or potentially progressing, although the immediate risk of malignancy without atypia is low.

Question 128: A 38-year-old woman presents with a 9-month history of progressively worsening heavy menstrual bleeding and pressure symptoms. Transvaginal ultrasound shows a 9 cm subserosal fibroid arising from the posterior uterine wall. She has completed her family but wishes to retain her uterus. She has no significant medical history. Which factor would most strongly favour recommending myomectomy over uterine artery embolisation in this patient?

A. Age under 40 years
B. Completed family size
C. Presence of pressure symptoms
D. Single large fibroid location (Correct Answer)
E. Size of fibroid greater than 8 cm

Explanation: ***Single large fibroid location***- A **subserosal pedunculated fibroid**, especially one with a narrow stalk, is a relative contraindication for **uterine artery embolisation (UAE)** due to the high risk of **stalk necrosis**, detachment, and subsequent peritonitis or infection.- **Myomectomy** is the preferred surgical approach for a single, accessible subserosal fibroid, providing definitive removal with a lower risk of post-procedural complications and allowing for pathological assessment compared to UAE in this specific anatomical location.*Age under 40 years*- While **myomectomy** is often preferred in younger women who desire future fertility, age under 40 years itself does not strictly dictate the choice between surgery and UAE when both options for **uterine preservation** are available and fertility is not a primary concern.- Both procedures are viable for a 38-year-old; the decision often hinges on fibroid characteristics and patient preference, not solely age.*Completed family size*- This factor typically broadens treatment options to include **hysterectomy** or makes **UAE** more acceptable, as the primary concern for future pregnancy is removed.- Since the patient specifically wishes to **retain her uterus**, this factor does not inherently favor myomectomy over UAE; both techniques satisfy her request for uterine preservation.*Presence of pressure symptoms*- Both **myomectomy** and **UAE** are effective at reducing the volume of fibroids and alleviating **bulk symptoms** and pelvic pressure.- While myomectomy provides immediate physical removal, UAE leads to progressive shrinkage, meaning this symptom alone does not strongly favor one over the other.*Size of fibroid greater than 8 cm*- A **9 cm fibroid** is considered large but can be managed by both UAE and myomectomy; however, very large fibroids (e.g., >10 cm) may have a higher failure rate or slower symptom resolution with UAE.- Size alone is less of a deciding factor than the **subserosal pedunculated** nature of the fibroid, which carries specific embolization risks and makes myomectomy more advantageous for definitive removal.

Question 129: A 21-year-old woman presents with sudden onset severe left-sided abdominal pain and vaginal spotting. She has a history of pelvic inflammatory disease 2 years ago. She is sexually active and uses condoms inconsistently. Her last menstrual period was 5 weeks ago. On examination, she is pale, blood pressure 85/50 mmHg, heart rate 115 bpm. She has generalised abdominal tenderness with guarding and rebound. A bedside pregnancy test is positive. What is the single most important immediate step in management?

A. Arrange emergency laparoscopy
B. Commence intravenous fluids and cross-match blood (Correct Answer)
C. Obtain consent for blood transfusion
D. Perform transvaginal ultrasound
E. Request serum beta-hCG level

Explanation: ***Commence intravenous fluids and cross-match blood*** - The patient presents with classic signs of **haemorrhagic shock** (pallor, hypotension, tachycardia) and **peritonism** in early pregnancy, highly suggestive of a **ruptured ectopic pregnancy**. - The single most important immediate step is to follow the **ABC (Airway, Breathing, Circulation)** approach, prioritizing **circulatory support** through large-bore intravenous access, rapid fluid resuscitation, and preparing blood for transfusion by cross-matching. *Arrange emergency laparoscopy* - While an **emergency laparoscopy** is the definitive treatment for a ruptured ectopic pregnancy, it cannot be safely undertaken until the patient's **hemodynamic stability** is initiated through aggressive resuscitation. - Surgical intervention requires the patient to be as stable as possible; attempting surgery without prior **volume replacement** significantly increases risk. *Obtain consent for blood transfusion* - **Consent** for blood transfusion is crucial but is an administrative step that can occur concurrently with or immediately after initiating life-saving **resuscitation**. - The absolute priority is to *begin* fluid and blood product preparation (**cross-matching**) and administration, rather than just obtaining consent for future administration. *Perform transvaginal ultrasound* - In a **hemodynamically unstable** patient with clear clinical signs of a ruptured ectopic pregnancy (shock, peritonism, positive pregnancy test), performing a **transvaginal ultrasound** would cause a dangerous and potentially fatal delay. - The diagnosis is **clinical** in this emergent situation; ultrasound is reserved for *stable* patients where the diagnosis is less certain. *Request serum beta-hCG level* - A **bedside urine pregnancy test** is already positive, confirming pregnancy. Requesting a quantitative **serum beta-hCG** level provides no additional immediate management benefit in a patient in shock. - Waiting for **laboratory results** for a confirmed pregnancy in a crashing patient delays crucial **resuscitation** and surgical preparation without changing the immediate management plan.

Question 130: A 30-year-old woman presents with 7 weeks amenorrhoea and light vaginal bleeding. Transvaginal ultrasound shows an empty uterus with endometrial thickness of 8mm and a heterogeneous adnexal mass measuring 22mm. Serum beta-hCG is 1850 IU/L. A repeat scan 48 hours later shows the same findings and beta-hCG is now 1920 IU/L. She is clinically stable. What is the most likely diagnosis?

A. Complete miscarriage
B. Ectopic pregnancy (Correct Answer)
C. Incomplete miscarriage
D. Intrauterine pregnancy too early to visualise
E. Pregnancy of unknown location

Explanation: ***Ectopic pregnancy*** - The presence of an **empty uterus** despite a serum **beta-hCG** level above the **discriminatory zone** (typically 1500-2000 IU/L) along with a **heterogeneous adnexal mass** strongly indicates an ectopic pregnancy. - The **suboptimal rise in beta-hCG** over 48 hours (from 1850 to 1920 IU/L, far less than the expected 66% increase for a viable intrauterine pregnancy) further confirms an abnormal pregnancy, consistent with an ectopic location. *Complete miscarriage* - In a **complete miscarriage**, serum **beta-hCG levels** would be expected to **fall significantly** (typically >50% within 48 hours), not remain plateaued or slightly increase. - An ultrasound would show an **empty uterus** without the presence of an associated **adnexal mass**. *Incomplete miscarriage* - An **incomplete miscarriage** is characterized by the presence of **retained products of conception** within the uterine cavity, which would be visible on ultrasound, contradicting the finding of an **empty uterus**. - Clinical presentation often includes **heavier bleeding** and an **open cervical os**, which is not the case here (light bleeding, clinically stable). *Intrauterine pregnancy too early to visualise* - For a **beta-hCG level** of 1850-1920 IU/L, a gestational sac should be clearly visible via **transvaginal ultrasound** if the pregnancy were intrauterine, as this is above the standard **discriminatory zone**. - The presence of a **heterogeneous adnexal mass** in conjunction with an empty uterus rules out a viable early intrauterine pregnancy and points to an extrauterine location. *Pregnancy of unknown location* - **Pregnancy of unknown location (PUL)** is a provisional diagnosis used when transvaginal ultrasound does not identify either an intrauterine pregnancy or an extrauterine pregnancy. - In this case, a **heterogeneous adnexal mass** was identified in the adnexa, which localizes the pregnancy and allows for a more specific diagnosis of **ectopic pregnancy**.

Question 131: A 42-year-old woman presents with a 1-year history of heavy menstrual bleeding. She reports using 8-10 pads per day for 6 days each cycle. Examination reveals a 16-week size uterus with irregular contour. Transvaginal ultrasound confirms multiple intramural fibroids, the largest measuring 7 cm. Haemoglobin is 95 g/L. She wishes to avoid hysterectomy if possible. She has completed her family. Which treatment option provides the best long-term symptom control while avoiding major surgery?

A. Endometrial ablation
B. Gonadotrophin-releasing hormone analogues
C. Levonorgestrel intrauterine system
D. Uterine artery embolisation (Correct Answer)
E. Ulipristal acetate

Explanation: ***Uterine artery embolisation*** - **Uterine artery embolisation (UAE)** is a minimally invasive procedure that effectively treats multiple large fibroids by obstructing blood supply, reducing volume, and significantly improving **heavy menstrual bleeding**. - It is the best long-term non-surgical option for a patient with a **16-week size uterus** who has completed her family and wishes to avoid major surgery like a hysterectomy. *Endometrial ablation* - This procedure is generally **contraindicated** when the uterus is enlarged beyond **10-12 weeks size** or when intramural fibroids are larger than 3 cm. - It only treats the **endometrial lining** and does not address the underlying pathology of large, multiple **intramural fibroids**. *Gonadotrophin-releasing hormone analogues* - **GnRH analogues** are typically used for **short-term** management (usually <6 months) to shrink fibroids before surgery or to treat anemia. - Symptoms recur rapidly after discontinuation, and long-term use is restricted due to risks of **bone mineral density loss** and menopausal side effects. *Levonorgestrel intrauterine system* - The **LNG-IUS** is less likely to be effective or stay in place (increased risk of **expulsion**) when the uterine cavity is significantly distorted by large fibroids. - A **16-week size uterus** and irregular contour suggest a degree of cavity distortion that limits the utility of this hormonal treatment. *Ulipristal acetate* - **Ulipristal acetate**, a selective progesterone receptor modulator, has significant restrictions due to concerns regarding **rare but serious liver toxicity**. - It is no longer considered a first-line long-term management strategy for fibroids and requires rigorous **liver function monitoring** if used.

Question 132: A 26-year-old woman is being monitored for an ectopic pregnancy with expectant management. Her initial beta-hCG was 450 IU/L. At day 4, it has risen to 520 IU/L. At day 7, it is 480 IU/L. She remains asymptomatic and haemodynamically stable. Repeat ultrasound shows no significant change in the 12mm adnexal mass and no free fluid. What is the most appropriate management?

A. Continue expectant management with repeat beta-hCG in 7 days (Correct Answer)
B. Immediate laparoscopy
C. Intramuscular methotrexate
D. Uterine curettage to exclude pregnancy of unknown location
E. Admit for observation

Explanation: ***Continue expectant management with repeat beta-hCG in 7 days***- **Expectant management** is appropriate for patients who are **asymptomatic**, hemodynamically stable, and have a low initial **beta-hCG** (<1,000-1,500 IU/L) with a small adnexal mass.- While the levels fluctuated slightly, the **decline from Day 4 to Day 7** suggests the ectopic pregnancy is resolving spontaneously, requiring only continued weekly monitoring.*Immediate laparoscopy*- **Surgical intervention** is indicated for patients who are hemodynamically unstable, have signs of **tubal rupture**, or have a large adnexal mass (>35mm).- This patient is **clinically stable** and asymptomatic, making invasive surgery unnecessary at this stage.*Intramuscular methotrexate*- **Medical management** with methotrexate is usually considered if beta-hCG levels **plateau or rise** significantly during expectant management.- Since her beta-hCG has started to **decrease**, she is likely to resolve without the potential side effects of **folate antagonism**.*Uterine curettage to exclude pregnancy of unknown location*- This procedure is used to differentiate between a **non-viable intrauterine pregnancy** and an ectopic pregnancy when the location is unclear.- An **adnexal mass** has already been identified on ultrasound, confirming the diagnosis of an ectopic pregnancy and making curettage inappropriate.*Admit for observation*- **Inpatient admission** is reserved for patients with increasing pain, suspected rupture, or those unable to comply with **outpatient follow-up**.- This patient remains **hemodynamically stable** and can be safely monitored through serial outpatient **biochemical assessments**.

Question 133: A 35-year-old woman presents with heavy menstrual bleeding. Her periods last 9 days with flooding for the first 4 days. She has dysmenorrhoea requiring regular analgesia. Transvaginal ultrasound shows a bulky uterus measuring 11 cm with heterogeneous myometrium consistent with adenomyosis. She has two children and does not wish for more. She has tried the LNG-IUS but had it removed after 8 months due to persistent irregular bleeding. What is the most appropriate definitive management?

A. Endometrial ablation
B. GnRH analogues for 6 months
C. High-dose progestogens
D. Trial of combined oral contraceptive pill
E. Total hysterectomy with ovarian conservation (Correct Answer)

Explanation: ***Total hysterectomy with ovarian conservation***- **Hysterectomy** is the only **definitive management** for **adenomyosis**, as it completely removes the ectopic endometrial tissue embedded within the **myometrium**.- Since the patient has completed her family, failed **conservative management** (LNG-IUS), and suffers from severe symptoms, this surgical approach provides a permanent cure while maintaining **hormonal function** through ovarian conservation.*Endometrial ablation*- This procedure is often ineffective for **adenomyosis** because it only targets the superficial endometrial lining, leaving deeper **myometrial disease** untreated.- It has a high **failure rate** in women with bulky uteri or extensive adenomyosis, often leading to subsequent need for surgery.*GnRH analogues for 6 months*- These provide only a **temporary solution** by inducing a hypoestrogenic state and are generally used as a bridge to surgery rather than definitive treatment.- Use is limited to 6 months due to risks of **bone mineral density loss** and vasomotor symptoms, and symptoms typically recur once treatment stops.*High-dose progestogens*- These are unlikely to succeed given that the **LNG-IUS**, which provides a high local dose of progestogen, has already failed to control the **irregular bleeding** and pain.- Side effects of systemic high-dose progestogens, such as weight gain and mood changes, often result in poor **patient compliance**.*Trial of combined oral contraceptive pill*- The **combined oral contraceptive pill** is considered a first-line medical therapy but is frequently insufficient for the severe **dysmenorrhea** and flooding associated with structural adenomyosis.- Given the failure of the more potent **LNG-IUS**, a trial of COCP is unlikely to provide the definitive relief requested by a patient with significant quality-of-life impairment.

Question 134: A 29-year-old nulliparous woman undergoes laparoscopy for suspected ectopic pregnancy. A 3.5 cm unruptured left tubal ectopic pregnancy is identified. The tube appears distended but intact. The right fallopian tube appears normal. She has no history of pelvic inflammatory disease or previous ectopic pregnancy. What is the most appropriate surgical management that balances her fertility preservation with recurrence risk?

A. Left salpingotomy
B. Bilateral salpingectomy
C. Left salpingectomy (Correct Answer)
D. Left salpingectomy with right tubal assessment
E. Left salpingotomy with right prophylactic salpingectomy

Explanation: ***Left salpingectomy*** - This approach removes the **affected tube**, significantly reducing the risk of **recurrent ectopic pregnancy** and **persistent trophoblastic disease** while preserving the healthy contralateral tube. - For patients with a **normal contralateral tube**, salpingectomy offers better outcomes regarding recurrence rates without negatively impacting overall future **fertility rates** compared to salpingotomy.*Left salpingotomy* - This procedure carries a **4-15% risk of persistent trophoblast**, requiring serial **beta-hCG monitoring** and potentially systemic treatment with methotrexate. - While it preserves the tube, it is generally reserved for patients with a **diseased contralateral tube** where preserving the affected tube is crucial for natural fertility, which is not the case here.*Bilateral salpingectomy* - This is an **overly aggressive** and inappropriate approach since the **right fallopian tube** is explicitly described as normal. - It would result in permanent **sterility**, making **In Vitro Fertilization (IVF)** the only option for future pregnancy, which is not desired given the focus on fertility preservation.*Left salpingectomy with right tubal assessment* - The initial laparoscopy already includes a thorough **pelvic assessment**, and the right fallopian tube has already been identified as **normal**. - Therefore, an explicit additional "right tubal assessment" step is **redundant** and does not change the management plan.*Left salpingotomy with right prophylactic salpingectomy* - This option combines the **higher recurrence risk** associated with salpingotomy with the **iatrogenic infertility** caused by prophylactic removal of a **healthy contralateral tube**. - It is medically **unethical** and entirely counterproductive to the goal of **fertility preservation**.

Question 135: A 40-year-old woman with heavy menstrual bleeding has been using a levonorgestrel intrauterine system for 2 years. She now presents with continuous light bleeding for 6 weeks. She is otherwise well with no abdominal pain. The IUS threads are visible on speculum examination. Bimanual examination is unremarkable. What is the most appropriate initial management?

A. Commence oral tranexamic acid
B. Hysteroscopy and endometrial biopsy
C. Reassure and review in 3 months
D. Remove the IUS and insert a new one
E. Transvaginal ultrasound to check IUS position (Correct Answer)

Explanation: ***Transvaginal ultrasound to check IUS position*** - A **sudden change** in bleeding pattern after 2 years of stability in a patient with a **Levonorgestrel-IUS** warrants investigation to exclude **malposition** or structural pathology. - The **transvaginal ultrasound (TVUS)** is the most appropriate initial tool to confirm the device is correctly located within the uterine cavity and to assess the **endometrial profile**. *Commence oral tranexamic acid* - **Tranexamic acid** is used for heavy bleeding, not typically for the **light, continuous spotting** described in this scenario. - Medical management of symptoms without investigating the **underlying cause** of a new bleeding pattern is inappropriate. *Hysteroscopy and endometrial biopsy* - While used to exclude **endometrial pathology**, these are more invasive and typically reserved for when initial imaging is inconclusive or if the patient is at high risk for **malignancy**. - In a 40-year-old with an IUS already in place, confirming **device position** via ultrasound is the standard first-line step. *Reassure and review in 3 months* - **Reassurance** is only appropriate in the first 6 months after insertion when **irregular spotting** is a common and expected side effect. - A new onset of continuous bleeding after being **established on the IUS** for 2 years requires active investigation rather than watchful waiting. *Remove the IUS and insert a new one* - Removal is premature without first confirming the current device's **position** or identifying the cause of the bleeding. - If the IUS is located correctly, simply replacing it is unlikely to resolve the issue and may expose the patient to unnecessary **procedural risks**.

Question 136: A 24-year-old woman presents to the emergency department with 6 weeks amenorrhoea, right-sided pelvic pain, and vaginal spotting. She has a copper IUD in situ. Vital signs show blood pressure 105/65 mmHg, heart rate 92 bpm, temperature 37.1°C. Abdominal examination reveals right iliac fossa tenderness without guarding. Pregnancy test is positive. Transvaginal ultrasound shows an empty uterus, 25mm right adnexal mass, and minimal free fluid in the pouch of Douglas. Serum beta-hCG is 2100 IU/L. What is the most appropriate immediate management?

A. Admit for observation and repeat beta-hCG in 48 hours
B. Arrange laparoscopy for ectopic pregnancy (Correct Answer)
C. Intramuscular methotrexate and remove IUD
D. Remove IUD and arrange outpatient follow-up
E. Remove IUD and commence methotrexate

Explanation: ***Arrange laparoscopy for ectopic pregnancy*** - Surgical intervention via **laparoscopy** is the most appropriate immediate management due to the patient's symptomatic presentation (pelvic pain, spotting), a **positive beta-hCG** (2100 IU/L), an **adnexal mass** (25mm), and **minimal free fluid** in the pouch of Douglas, all highly suggestive of an unruptured or potentially rupturing ectopic pregnancy. - The presence of a **copper IUD** in situ is also a relative contraindication to medical management with methotrexate and increases the risk of ectopic pregnancy, making surgical removal of the ectopic gestation the most definitive and safest option to prevent **tubal rupture** and **hemorrhage**.*Admit for observation and repeat beta-hCG in 48 hours* - **Expectant management** or observation is generally reserved for hemodynamically stable patients with very low or declining **beta-hCG levels** (<1000 IU/L) and no evidence of rupture or significant adnexal mass. - This patient's **beta-hCG of 2100 IU/L**, combined with significant symptoms and ultrasound findings, indicates an active and potentially unstable ectopic pregnancy, making observation risky.*Intramuscular methotrexate and remove IUD* - **Methotrexate** is contraindicated or has a higher failure rate in the presence of an **IUD**, and its effectiveness is reduced with **beta-hCG levels >1500-2000 IU/L** or the presence of significant free fluid. - The patient's **pelvic pain** and **free fluid** suggest possible ongoing rupture or impending rupture, which are absolute contraindications for medical management.*Remove IUD and arrange outpatient follow-up* - Removing the IUD alone does not resolve the **ectopic pregnancy**, and arranging outpatient follow-up for a patient with symptomatic ectopic pregnancy puts them at extremely high risk for **tubal rupture** and **life-threatening hemorrhage**. - This approach is medically unsafe and would delay crucial definitive treatment for a potentially unstable condition.*Remove IUD and commence methotrexate* - While removing the IUD might be considered, initiating **methotrexate** is still problematic due to the **high beta-hCG (2100 IU/L)**, the presence of an **adnexal mass**, and clinical symptoms suggesting an active ectopic. - **Surgical management** is preferred when the diagnosis of ectopic pregnancy is clear, the patient is symptomatic, and there are ultrasound findings such as an adnexal mass, to ensure definitive treatment and prevent complications.

Question 137: What is the primary mechanism of action of tranexamic acid in treating heavy menstrual bleeding?

A. Decreasing prostaglandin synthesis
B. Inhibiting fibrinolysis by blocking plasminogen activation (Correct Answer)
C. Reducing endometrial proliferation
D. Stimulating platelet aggregation
E. Vasoconstriction of endometrial blood vessels

Explanation: ***Inhibiting fibrinolysis by blocking plasminogen activation***- Tranexamic acid is an **antifibrinolytic** agent that works by competitively inhibiting the activation of **plasminogen to plasmin**, which prevents the degradation of fibrin clots.- In heavy menstrual bleeding, endometrial **fibrinolytic activity** is often increased; by stabilizing clots, this medication reduces blood loss by approximately 40-50%.*Decreasing prostaglandin synthesis*- This is the primary mechanism of **NSAIDs** like mefenamic acid, which are used to reduce both menstrual blood flow and **dysmenorrhea**.- While effective for mild heavy bleeding, NSAIDs target **cyclooxygenase (COX)** enzymes rather than the fibrinolytic pathway.*Reducing endometrial proliferation*- This mechanism is characteristic of **hormonal treatments** such as the levonorgestrel intrauterine system (LNG-IUS) or **combined oral contraceptives**.- These agents cause thinning of the **endometrial lining** over time, whereas tranexamic acid is a non-hormonal treatment taken only during menses.*Stimulating platelet aggregation*- Tranexamic acid does not directly affect **platelet count** or the initial activation and **aggregation** of platelets at the site of vascular injury.- Its therapeutic benefit is derived strictly from preventing the dissolution of the **hemostatic plug** once it has already formed.*Vasoconstriction of endometrial blood vessels*- Vasoconstriction is a physiological response to endothelin or certain **prostaglandins**, but it is not the pharmacological effect of tranexamic acid.- Unlike some ergot alkaloids or specific hormones, this drug does not alter the **vascular tone** of the uterine arteries or endometrial vessels.

Question 138: A 46-year-old woman presents with a 6-month history of irregular heavy bleeding. She reports cycles varying from 21 to 45 days with heavy bleeding lasting 7-10 days. Her BMI is 34 kg/m². Transvaginal ultrasound shows endometrial thickness of 18mm and a normal-sized uterus with no fibroids. What is the most appropriate next investigation?

A. Endometrial biopsy (Correct Answer)
B. Hysteroscopy
C. MRI pelvis
D. Repeat ultrasound in 3 months
E. Serum CA-125

Explanation: ***Endometrial biopsy*** - A **transvaginal ultrasound** showing an **endometrial thickness of 18mm** in a 46-year-old woman with **abnormal uterine bleeding (AUB)** and risk factors like **obesity (BMI 34)** warrants **endometrial sampling** to rule out **endometrial hyperplasia** or **malignancy**. - **Endometrial biopsy** is the most appropriate initial investigation as it provides a **histopathological diagnosis**, which is crucial for definitive management. *Hysteroscopy* - While useful for direct visualization and targeted biopsy, **hysteroscopy** is generally performed after an initial endometrial biopsy, or if the biopsy is inconclusive, or if focal lesions like polyps are highly suspected and missed by initial sampling. - It is a more **invasive** procedure and not typically the *first* diagnostic step for diffuse endometrial pathology in the absence of a specific focal lesion identified by ultrasound. *MRI pelvis* - **MRI pelvis** is primarily used for **staging** known endometrial cancers, assessing myometrial invasion, or characterizing complex pelvic masses, rather than for the initial diagnosis of endometrial pathology causing AUB. - It is an imaging modality and does not provide a **histopathological diagnosis**, which is essential to definitively exclude hyperplasia or cancer. *Repeat ultrasound in 3 months* - Given the patient's age (46 years), **obesity (BMI 34)**, persistent **abnormal uterine bleeding**, and a significantly thickened endometrium of **18mm**, delaying investigation with a repeat ultrasound is **inappropriate** and potentially dangerous. - There is a clear indication for **prompt histological evaluation** to exclude **endometrial hyperplasia with atypia** or **endometrial carcinoma**. *Serum CA-125* - **Serum CA-125** is a tumor marker primarily associated with **ovarian cancer** and some other conditions like endometriosis or fibroids, but it is **not used for the initial investigation of abnormal uterine bleeding** or endometrial pathology. - It is a **non-specific marker** and does not provide information about the histological status of the endometrium, which is the primary concern here.

Question 139: A 37-year-old woman presents with heavy menstrual bleeding affecting her quality of life. She reports flooding and passing clots, requiring pad changes every 2 hours. Her cycles are regular at 28 days and last 8 days. She has completed her family. Pelvic examination is unremarkable and transvaginal ultrasound shows a normal-sized uterus with 12mm endometrial thickness and no structural abnormalities. Full blood count shows haemoglobin 102 g/L. What is the most appropriate first-line management?

A. Combined oral contraceptive pill
B. Endometrial ablation
C. Levonorgestrel intrauterine system (Correct Answer)
D. Oral tranexamic acid
E. Total abdominal hysterectomy

Explanation: ***Levonorgestrel intrauterine system*** - For women with **heavy menstrual bleeding (HMB)** and no identified **structural abnormalities**, the **levonorgestrel intrauterine system (LNG-IUS)** is the recommended first-line treatment according to **NICE guidelines**. - It is highly effective, reducing menstrual blood loss significantly, and is particularly suitable since the patient has **completed her family**, as it also provides contraception. *Combined oral contraceptive pill* - While **COCPs** can reduce menstrual blood loss and regulate cycles, they are generally considered less effective than the **LNG-IUS** for significant HMB. - They also carry risks like **thromboembolism** and require daily adherence, which may not be ideal for long-term management of heavy bleeding. *Endometrial ablation* - This is a **surgical procedure** that ablates the endometrial lining, reserved for women who have completed their family and failed medical management. - It is not considered a **first-line management** option when effective medical treatments like **LNG-IUS** have not yet been tried. *Oral tranexamic acid* - **Tranexamic acid** is an **antifibrinolytic** taken only during menstruation to reduce blood loss, offering symptomatic relief but not addressing the underlying cause hormonally. - It is less effective for long-term reduction of flow compared to the **LNG-IUS** and does not offer **contraceptive benefits** or sustained endometrial suppression. *Total abdominal hysterectomy* - **Hysterectomy** is a **definitive surgical treatment** for HMB but is a major, irreversible procedure, only considered after all other medical and less invasive surgical options have failed. - It is inappropriate as a **first-line** intervention given the availability of highly effective and less invasive treatments.

Question 140: A 33-year-old woman presents with 7 weeks amenorrhoea and mild left-sided abdominal discomfort. She has had one previous ectopic pregnancy treated with salpingectomy. Transvaginal ultrasound shows an empty uterus and a 15mm adnexal mass with no free fluid. Serum beta-hCG is 850 IU/L. She is haemodynamically stable and wishes to preserve her fertility. What is the most appropriate initial management?

A. Emergency laparoscopy with salpingectomy
B. Expectant management with serial beta-hCG monitoring
C. Intramuscular methotrexate 50 mg/m² single dose (Correct Answer)
D. Laparoscopic salpingotomy
E. Repeat transvaginal ultrasound in 48 hours

Explanation: ***Intramuscular methotrexate 50 mg/m² single dose*** - Medical management with **methotrexate** is indicated because the patient is **hemodynamically stable**, has a **beta-hCG of 850 IU/L** (meeting criteria typically < 5000 IU/L), and the adnexal mass size is **15mm** (< 35mm). - This approach is ideal for women wishing to **preserve fertility** and avoids the risks associated with surgery when specific clinical criteria are met, especially given her previous salpingectomy. *Emergency laparoscopy with salpingectomy* - **Emergency surgery** is reserved for patients who are **hemodynamically unstable** or have signs of **tubal rupture**, neither of which is present in this stable patient. - **Salpingectomy** involves removing the tube, which is undesirable given her desire to **preserve fertility** and her history of a previous salpingectomy. *Expectant management with serial beta-hCG monitoring* - **Expectant management** is typically reserved for patients with very low and **decreasing beta-hCG levels** (often < 200-1000 IU/L), or a confirmed resolving ectopic. - Given the clinical presentation and hCG level of 850 IU/L with a confirmed adnexal mass, active medical intervention is generally preferred to ensure resolution of the **ectopic pregnancy**. *Laparoscopic salpingotomy* - While **salpingotomy** preserves the tube, it is a surgical procedure that carries risks and is typically considered if **medical management** with methotrexate is contraindicated or fails. - Since the patient meets the criteria for **methotrexate**, a non-invasive medical approach is the most appropriate first-line treatment, aligning with her fertility preservation wishes. *Repeat transvaginal ultrasound in 48 hours* - Repeating the **ultrasound** in 48 hours is more relevant for a **pregnancy of unknown location (PUL)** where the diagnosis is not yet confirmed. - In this case, an **adnexal mass** has already been identified, confirming the diagnosis of ectopic pregnancy and necessitating active management rather than delay.

Question 141: A 50-year-old woman presents with postcoital bleeding and intermenstrual bleeding for 3 months. She had a normal cervical screening test 18 months ago. Speculum examination reveals a healthy-appearing cervix with no visible lesions or contact bleeding. She is perimenopausal with irregular periods occurring every 35-60 days. Transvaginal ultrasound shows an endometrial thickness of 18 mm with heterogeneous appearance and a normal-sized uterus. What is the single most important investigation required before initiating treatment?

A. Repeat cervical cytology
B. Endometrial biopsy
C. Colposcopy
D. Hysteroscopy with targeted biopsies (Correct Answer)
E. Serum CA-125 level

Explanation: ***Hysteroscopy with targeted biopsies*** - The patient presents with **abnormal uterine bleeding** (postcoital and intermenstrual) and a significantly **thickened, heterogeneous endometrium (18 mm)**, which is highly suspicious for **endometrial hyperplasia or malignancy**. - **Hysteroscopy** is the gold standard as it allows direct visualization of the cavity and ensures **targeted sampling** of focal lesions that might be missed by a blind biopsy. *Repeat cervical cytology* - The patient had a **normal cervical screening** 18 months ago and has a **healthy-appearing cervix** on examination, making primary cervical pathology less likely than endometrial issues. - Cytology is a screening tool for **cervical intraepithelial neoplasia** and is not the diagnostic test of choice for investigating thickened endometrium or intermenstrual bleeding. *Endometrial biopsy* - While an endometrial biopsy (like a **Pipelle**) is often used as a first-line screening tool, it is a **blind procedure** with a false-negative rate of up to 15% for focal lesions. - Given the **heterogeneous appearance** on ultrasound, a targeted biopsy via hysteroscopy is preferred to ensure a more accurate histological diagnosis. *Colposcopy* - This procedure is used to examine the **cervix, vagina, and vulva** under magnification, typically following abnormal cervical cytology results. - Since the cervix appears normal and the pathology is clearly **intrauterine** based on the ultrasound findings, colposcopy is not the primary investigation required. *Serum CA-125 level* - **CA-125** is a non-specific tumor marker primarily used in the evaluation of **ovarian cancer** or for monitoring response to treatment. - It has no diagnostic value in the initial workup of suspected **endometrial cancer** or hyperplasia and cannot replace histological tissue sampling.

Question 142: A 31-year-old woman undergoes laparoscopic salpingotomy for a 2.5 cm unruptured left tubal ectopic pregnancy. Her pre-operative serum beta-hCG was 2100 IU/L. The procedure is completed successfully. What is the most important aspect of post-operative follow-up specific to salpingotomy compared to salpingectomy?

A. Weekly serum beta-hCG monitoring until undetectable (Correct Answer)
B. Repeat transvaginal ultrasound at 1 week post-operatively
C. Prescription of prophylactic methotrexate
D. Routine hysterosalpingography at 6 weeks
E. Daily measurement of urinary beta-hCG for 2 weeks

Explanation: ***Weekly serum beta-hCG monitoring until undetectable*** - **Salpingotomy** is a conservative surgical approach that leaves the fallopian tube intact, creating a risk (5-20%) of **persistent trophoblastic tissue** remaining in the tube. - **Serial quantitative serum beta-hCG** monitoring is crucial to ensure levels steadily decline to zero, as a plateau or rise indicates **persistent ectopic pregnancy** requiring further intervention (e.g., methotrexate or repeat surgery). *Repeat transvaginal ultrasound at 1 week post-operatively* - While ultrasound may be used to assess for complications like hematoma, it is **not sensitive** enough to reliably detect microscopic **persistent trophoblast** when hCG levels are low after salpingotomy. - The primary follow-up for persistent trophoblastic disease relies on **biochemical monitoring** of beta-hCG levels, rather than imaging. *Prescription of prophylactic methotrexate* - **Prophylactic methotrexate** is not routinely given after salpingotomy; it is typically reserved for cases where **beta-hCG levels** fail to decline appropriately, indicating **persistent disease**. - Administering methotrexate prophylactically to all patients is unwarranted due to potential **side effects** and the fact that most patients will not develop persistent disease. *Routine hysterosalpingography at 6 weeks* - **Hysterosalpingography (HSG)** is primarily used to assess **tubal patency** and uterine cavity integrity for future fertility planning, usually performed several months post-procedure. - Performing HSG at 6 weeks post-salpingotomy is too early to evaluate long-term tubal function and does not provide information about the resolution of **trophoblastic tissue**. *Daily measurement of urinary beta-hCG for 2 weeks* - **Urinary beta-hCG tests** are typically qualitative or semi-quantitative and lack the necessary precision to accurately monitor the **rate of decline** in hCG levels. - **Quantitative serum beta-hCG** measurement is essential for detecting subtle changes, such as a plateau or rise, which are indicative of **persistent trophoblastic activity**.

Question 143: A 44-year-old woman presents with heavy prolonged menstrual bleeding for 8 months. She experiences periods lasting 10-12 days every 24-26 days. Her haemoglobin is 91 g/L with a mean corpuscular volume of 68 fL. Transvaginal ultrasound shows multiple small intramural fibroids (largest 3 cm), a bulky uterus of 11 cm length, and endometrial thickness of 9 mm on day 7 of cycle. She declines surgical management. After endometrial sampling shows benign endometrium, what is the most appropriate medical management?

A. Tranexamic acid and mefenamic acid combination
B. Levonorgestrel-releasing intrauterine system (Correct Answer)
C. Cyclical oral progestogens (days 15-26 of cycle)
D. Combined oral contraceptive pill
E. Gonadotropin-releasing hormone agonist

Explanation: ***Levonorgestrel-releasing intrauterine system*** - The **LNG-IUS** is the first-line medical recommendation for **heavy menstrual bleeding (HMB)** and is effective for patients with small **fibroids (<3 cm)** that do not distort the uterine cavity. - It provides a superior reduction in menstrual blood loss (up to 94%), which is critical here given the patient's **iron deficiency anaemia** (Hb 91 g/L). *Tranexamic acid and mefenamic acid combination* - While these reduce blood loss by approximately 20-50%, they are considered less effective than the **LNG-IUS** and are typically used intermittently during menses. - They do not provide the continuous endometrial suppression needed to optimally manage severe **menorrhagia** and allow iron stores to fully recover. *Cyclical oral progestogens (days 15-26 of cycle)* - This regimen is largely ineffective for **heavy menstrual bleeding** and is no longer recommended as it does not significantly reduce blood loss. - High-dose **progestogens** must be taken from day 5 to 26 of the cycle to be effective, but even then, they remain second-line to the **LNG-IUS**. *Combined oral contraceptive pill* - The **COCP** is an option for HMB, but it carries higher risks (e.g., **venous thromboembolism**) in women over 35, especially if other cardiovascular risk factors exist. - It is generally less effective than the **LNG-IUS** in controlling bleeding and managing symptoms associated with a **bulky uterus**. *Gonadotropin-releasing hormone agonist* - **GnRH agonists** are primarily used for short-term management to shrink fibroids before surgery rather than long-term maintenance. - They induce a **hypoestrogenic state** leading to side effects like bone density loss and menopausal symptoms, making them unsuitable for chronic use.

Question 144: A 23-year-old woman presents to the emergency department with sudden onset severe left-sided abdominal pain. She has a 4-week history of amenorrhoea. Urine pregnancy test is positive. Transvaginal ultrasound shows an empty uterus, a 3 cm left adnexal mass, and a moderate amount of free fluid in the pouch of Douglas. Her serum beta-hCG is 4500 IU/L. Observations: blood pressure 100/65 mmHg, heart rate 105 bpm. She reports the pain is severe but stable. What is the most appropriate management?

A. Immediate laparotomy
B. Laparoscopic salpingectomy (Correct Answer)
C. Intramuscular methotrexate
D. Expectant management with close monitoring
E. Laparoscopic salpingotomy

Explanation: ***Laparoscopic salpingectomy*** - **Surgical intervention** is the definitive treatment for ectopic pregnancies with signs of rupture (moderate free fluid in the pouch of Douglas) and a high **beta-hCG level** (4500 IU/L), even if haemodynamically borderline stable. - **Salpingectomy** (removal of the fallopian tube) is preferred over salpingotomy when the tube is significantly damaged or there is a higher risk of **persistent trophoblastic disease**, which is more likely with higher hCG levels and free fluid. *Immediate laparotomy* - This open surgical approach is typically reserved for patients who are **haemodynamically unstable** (e.g., severe hypotension, shock) or where laparoscopic surgery is contraindicated or not feasible. - Although the patient's vitals are borderline, she is not in overt shock, allowing for a less invasive **laparoscopic** approach which offers faster recovery. *Intramuscular methotrexate* - Medical management with methotrexate is contraindicated in this patient due to her high **beta-hCG level** (4500 IU/L, typically >3000-5000 IU/L is a contraindication) and evidence of significant intra-abdominal bleeding (moderate free fluid). - It also requires the patient to be clinically stable and typically have an unruptured ectopic pregnancy, which is not the case here given the severe pain and free fluid. *Expectant management with close monitoring* - Expectant management is appropriate only for very carefully selected, asymptomatic patients with small ectopic pregnancies, no free fluid, and a low and **decreasing beta-hCG level** (typically <1000 IU/L). - This patient has severe pain, a 3 cm mass, moderate free fluid, and a high beta-hCG, indicating a high risk of imminent or ongoing **tubal rupture** and internal haemorrhage. *Laparoscopic salpingotomy* - While a laparoscopic approach is suitable, **salpingotomy** involves incising the tube to remove the pregnancy, aiming to preserve fertility. However, it carries a higher risk of **persistent ectopic pregnancy**. - Given the high hCG level and signs of significant bleeding (free fluid), there's an increased risk of complications with tube preservation, making **salpingectomy** a safer and more definitive option.

Question 145: A 39-year-old woman with heavy menstrual bleeding has been using a levonorgestrel-releasing intrauterine system for 18 months with good symptom control. She now presents with a 6-week history of persistent irregular vaginal bleeding and lower abdominal discomfort. Clinical examination reveals a 12-week size uterus. Transvaginal ultrasound shows the intrauterine system in situ with appropriate positioning, an endometrial thickness of 15 mm, and increased vascularity on Doppler. What is the most appropriate next step?

A. Remove and reinsert a new levonorgestrel-releasing intrauterine system
B. Commence oral progestogens
C. Perform endometrial biopsy (Correct Answer)
D. Prescribe additional tranexamic acid
E. Reassure and review in 3 months

Explanation: ***Perform endometrial biopsy*** - The presence of an **endometrial thickness of 15 mm** while using a **levonorgestrel-releasing intrauterine system (LNG-IUS)** is highly abnormal, as the device typically causes **endometrial atrophy**. - New-onset **persistent irregular bleeding** and increased **vascularity** on Doppler necessitate histopathological evaluation to rule out **endometrial hyperplasia** or **endometrial carcinoma**. *Remove and reinsert a new levonorgestrel-releasing intrauterine system* - The current device is **appropriately positioned** and has only been in situ for 18 months, indicating that device failure/expiry is not the issue. - Replacing the device without investigating the **thickened endometrium** would dangerously delay the diagnosis of potential malignancy. *Commence oral progestogens* - Adding systemic progestogens is an appropriate treatment for certain types of bleeding, but it does not serve as a **diagnostic tool** for the suspicious ultrasound findings. - You must first exclude **atypical hyperplasia** or **carcinoma** through biopsy before determining if hormonal management is safe or sufficient. *Prescribe additional tranexamic acid* - Tranexamic acid is used for the symptomatic relief of **heavy menstrual bleeding**, but it does not address the **irregular bleeding pattern** or the physical ultrasound findings. - Using it here would be **symptomatic management** only, failing to investigate the underlying cause of the thickened, vascular endometrium. *Reassure and review in 3 months* - Reassurance is contraindicated when a patient develops a **change in bleeding pattern** alongside suspicious imaging findings (**15 mm endometrial thickness**). - A 3-month delay risks the **progression of pathology**, as these features are red flags that warrant immediate investigation regardless of the patient's age.

Question 146: A 27-year-old woman with a known ectopic pregnancy is being treated with methotrexate. On day 5 post-administration, she presents to the emergency department with severe abdominal pain and vomiting. Her observations show: blood pressure 110/70 mmHg, heart rate 88 bpm, temperature 37.2°C. Abdominal examination reveals generalised tenderness but no guarding or rebound. Her initial beta-hCG was 1800 IU/L on day 0. What is the most likely diagnosis?

A. Ruptured ectopic pregnancy requiring emergency surgery
B. Methotrexate treatment failure
C. Methotrexate-induced side effects (separation pain) (Correct Answer)
D. Acute gastroenteritis
E. Developing tubo-ovarian abscess

Explanation: ***Methotrexate-induced side effects (separation pain)*** - This occurs in **15-20%** of patients, typically **3-7 days** after methotrexate, due to tubal distension as the pregnancy separates from the tubal wall. - The patient remains **haemodynamically stable** with no signs of peritonism (no guarding or rebound), distinguishing it from clinical rupture. *Ruptured ectopic pregnancy requiring emergency surgery* - While a major concern, it is less likely here given the **normal blood pressure** (110/70 mmHg) and **heart rate** (88 bpm). - Rupture typically presents with **signs of shock** and surgical abdomen features like **guarding or rebound tenderness**, which are absent in this case. *Methotrexate treatment failure* - Failure is defined by an **inadequate fall in beta-hCG** (less than 15% decrease) between **days 4 and 7**, not primarily by clinical pain on day 5. - Pain alone does not indicate failure, as long as the patient remains **clinically stable** and the biochemical markers follow the expected trend. *Acute gastroenteritis* - While vomiting is present, the context of a known ectopic pregnancy and **generalised abdominal tenderness** points more toward a gynecological etiology. - Gastroenteritis would typically involve **diarrhea** and hyperactive bowel sounds, rather than isolated pain following **methotrexate administration**. *Developing tubo-ovarian abscess* - This typically presents with **fever**, purulent vaginal discharge, and persistent pelvic pain rather than acute onset after medical therapy for ectopic pregnancy. - The patient is **afebrile** (37.2°C), and there is no mention of inflammatory markers or history suggestive of **pelvic inflammatory disease**.

Question 147: A 47-year-old woman presents with a 9-month history of heavy menstrual bleeding. She reports flooding and passing clots, requiring double protection. Her periods occur regularly every 28 days and last 8 days. Pelvic examination is unremarkable. Haemoglobin is 102 g/L. Transvaginal ultrasound shows a normal-sized uterus with homogeneous myometrium and endometrial thickness of 7 mm on day 6 of cycle. She has tried tranexamic acid with minimal benefit. What is the most appropriate next management step?

A. Refer for endometrial ablation
B. Prescribe combined oral contraceptive pill
C. Arrange endometrial biopsy before further treatment (Correct Answer)
D. Insert levonorgestrel-releasing intrauterine system
E. Prescribe mefenamic acid

Explanation: ***Arrange endometrial biopsy before further treatment*** - For women aged **45 and over** presenting with **heavy menstrual bleeding (HMB)**, clinical guidelines recommend performing **endometrial sampling** to exclude **endometrial hyperplasia** or **malignancy**. - Although her **transvaginal ultrasound** is relatively reassuring, her age and persistent symptoms (heavy bleeding, clots, and anemia) necessitate ruling out pathology before starting definitive long-term therapy.*Prescribe combined oral contraceptive pill* - This medication is used for **heavy menstrual bleeding** but should not be the first step in a 47-year-old before excluding serious **endometrial pathology**. - At age 47, the **combined oral contraceptive pill** requires a careful assessment of **cardiovascular risk factors** and may be contraindicated if she smokes or has other comorbidities.*Insert levonorgestrel-releasing intrauterine system* - The **LNG-IUS (Mirena)** is the first-line medical treatment for HMB; however, in a patient over 45, it should only be inserted after **endometrial biopsy** has confirmed the absence of cancer. - Inserting the device before sampling could delay the diagnosis of **endometrial cancer** and complicate later histological evaluation.*Prescribe mefenamic acid* - **Mefenamic acid** is an NSAID that reduces blood loss by inhibiting prostaglandins, but it is generally less effective than **tranexamic acid**, which has already failed for this patient. - This approach treats only the symptoms and fails to address the requirement for **diagnostic sampling** in a woman over the age of 45.*Refer for endometrial ablation* - **Endometrial ablation** is an effective surgical option for HMB, but it is reserved for patients where medical management has failed or is declined, and **endometrial pathology** has been ruled out. - It is crucial that **endometrial sampling** is performed prior to ablation to ensure there is no **pre-malignant** or **malignant** condition that would be masked or missed by the procedure.

Question 148: A 30-year-old woman presents with 5 weeks amenorrhoea and minimal vaginal spotting. Transvaginal ultrasound shows an empty uterus and a 2.5 cm adnexal mass adjacent to the right ovary with a hyperechoic ring. There is no free fluid in the pouch of Douglas. Her serum beta-hCG is 2200 IU/L. She is haemodynamically stable and reports mild right-sided pelvic discomfort. What is the most appropriate initial management?

A. Repeat beta-hCG in 48 hours to confirm ectopic pregnancy
B. Emergency laparoscopic salpingectomy
C. Administer intramuscular methotrexate (Correct Answer)
D. Expectant management with weekly beta-hCG monitoring
E. Diagnostic laparoscopy to confirm diagnosis

Explanation: ***Administer intramuscular methotrexate*** - The patient is **haemodynamically stable** with a serum **beta-hCG <5000 IU/L** (2200 IU/L) and an adnexal mass **<3.5 cm** (2.5 cm) without a fetal heartbeat, which are the primary criteria for medical management of ectopic pregnancy. - **Methotrexate** is a folic acid antagonist that stops the growth of the trophoblastic tissue, leading to the resolution of the ectopic pregnancy and often preserving the fallopian tube, avoiding surgical risks. *Repeat beta-hCG in 48 hours to confirm ectopic pregnancy* - Repeating the beta-hCG is unnecessary because the current **beta-hCG is above the discriminatory zone** (>1500-2000 IU/L) and **transvaginal ultrasound** has already confirmed an **adnexal mass** and **empty uterus**, strongly indicative of ectopic pregnancy. - Delaying definitive treatment for a confirmed ectopic pregnancy increases the risk of **tubal rupture** and significant hemorrhage, especially with a beta-hCG of 2200 IU/L. *Emergency laparoscopic salpingectomy* - Surgical intervention like **laparoscopic salpingectomy** is typically reserved for patients who are **haemodynamically unstable**, experiencing severe pain, or have signs of **tubal rupture** (e.g., free fluid in the pouch of Douglas, larger mass). - This patient is stable with a small, unruptured ectopic pregnancy, making medical management a suitable and less invasive initial approach that also helps **preserve fertility**. *Expectant management with weekly beta-hCG monitoring* - **Expectant management** is generally considered only when initial **beta-hCG levels are very low (<1000-1500 IU/L)** and are already declining spontaneously, with no fetal cardiac activity or significant adnexal mass. - With a beta-hCG of **2200 IU/L**, the risk of rupture is too high to simply monitor without active medical or surgical intervention; it falls outside the accepted criteria for expectant management. *Diagnostic laparoscopy to confirm diagnosis* - **Diagnostic laparoscopy** is an invasive surgical procedure that is not required in this case, as the diagnosis of ectopic pregnancy is clearly established by the combination of **transvaginal ultrasound findings** (empty uterus, adnexal mass with hyperechoic ring) and the **serum beta-hCG level**. - Modern imaging and biochemical markers are usually sufficient for diagnosis, and proceeding directly to medical treatment avoids unnecessary surgical risks and costs.

Question 149: What is the minimum fall in serum beta-hCG expected between days 0 and 7 following successful treatment of ectopic pregnancy with a single dose of intramuscular methotrexate?

A. At least 10% decrease from day 0 to day 7
B. At least 15% decrease from day 4 to day 7 (Correct Answer)
C. At least 25% decrease from day 0 to day 7
D. At least 50% decrease from day 0 to day 7
E. Return to undetectable levels by day 7

Explanation: ***At least 15% decrease from day 4 to day 7*** - In the single-dose **methotrexate** protocol for ectopic pregnancy, success is defined by a decrease of **15% or more** in **beta-hCG** levels between **day 4 and day 7**. - This specific measurement interval is used because hCG levels often **initially rise** between day 0 (day of administration) and day 4 due to the drug's mechanism of action. *At least 10% decrease from day 0 to day 7* - This is an incorrect threshold; clinical protocols specifically require a **15% drop** to determine if the medical management is effective. - Measuring the percentage decrease from **day 0** is unreliable because hCG levels commonly **increase** in the first **96 hours** (up to day 4) after methotrexate administration. *At least 25% decrease from day 0 to day 7* - While a greater drop is desirable for a faster resolution, a **15% reduction** between day 4 and 7 is the established minimum criterion for initial success with a single dose to avoid a **second dose** or surgical intervention. - As previously mentioned, measuring from **day 0** is not the standard for initial assessment of success due to the potential for an initial rise in hCG. *At least 50% decrease from day 0 to day 7* - A **50% decrease** in beta-hCG is not the specific criterion for assessing successful single-dose methotrexate treatment within the first week, and it's an overly ambitious expectation for this timeframe. - If the **15% drop** between day 4 and 7 is not met, further management, such as a **second dose of methotrexate** or **surgical intervention**, is usually considered. *Return to undetectable levels by day 7* - It is physiologically impossible for **beta-hCG** to reach **undetectable levels** (typically <5 IU/L) within just one week of initiating methotrexate treatment for ectopic pregnancy. - Complete resolution and a return to undetectable hCG levels usually take **2 to 8 weeks**, requiring consistent **weekly follow-up** until the hormone is fully cleared.

Question 150: A 43-year-old woman presents with heavy menstrual bleeding and is found to have a haemoglobin of 87 g/L. Transvaginal ultrasound reveals a 7 cm intramural fibroid and an endometrial thickness of 6 mm on day 4 of her cycle. She wishes to preserve her fertility. Which treatment option is most likely to preserve fertility while effectively managing her symptoms?

A. Levonorgestrel-releasing intrauterine system
B. Uterine artery embolisation
C. Myomectomy (Correct Answer)
D. Ulipristal acetate
E. Gonadotropin-releasing hormone agonist

Explanation: ***Myomectomy***- **Myomectomy** is the gold standard surgical intervention for **symptomatic fibroids** in patients who wish to **preserve fertility**, as it removes the leiomyoma while keeping the uterus intact.- For a large **7 cm intramural fibroid** causing severe **anaemia**, this procedure effectively resolves mechanical and bleeding symptoms while maintaining the potential for future pregnancy.*Levonorgestrel-releasing intrauterine system*- While the **LNG-IUS** is first-line for heavy menstrual bleeding, its efficacy and retention are significantly reduced in the presence of a large **intramural fibroid** exceeding 3 cm.- Significant **uterine distortion** by large fibroids can make the insertion technically difficult and increases the risk of **expulsion**.*Uterine artery embolisation*- **UAE** is a minimally invasive treatment for fibroids but is generally **not recommended** for women primary wishing to **conceive** due to potential risks to placental blood flow.- It has been associated with an increased risk of **miscarriage**, preterm birth, and potential impairment of **ovarian reserve**.*Ulipristal acetate*- This selective progesterone receptor modulator was used for fibroid management but is now restricted or **withdrawn** in many regions due to the risk of rare but serious **hepatotoxicity**.- Even when used, it is typically a short-term management option rather than a definitive treatment for high-volume fibroid disease.*Gonadotropin-releasing hormone agonist*- **GnRH agonists** are primarily used as **pre-operative** therapy to reduce fibroid volume and improve **haemoglobin levels** before surgery.- They are not a long-term fertility-preserving solution because symptoms and fibroid size rapidly **recur** once the medication is discontinued.

Question 151: A 36-year-old woman is being monitored for a tubal ectopic pregnancy with expectant management. Her initial serum beta-hCG was 450 IU/L. She is clinically stable with minimal pain and no vaginal bleeding. A repeat beta-hCG measurement 48 hours later shows a level of 520 IU/L. What is the most appropriate next step in management?

A. Continue expectant management and repeat beta-hCG in 48 hours
B. Administer intramuscular methotrexate (Correct Answer)
C. Arrange transvaginal ultrasound scan
D. Discharge with safety-netting advice
E. Arrange urgent laparoscopic salpingectomy

Explanation: ***Administer intramuscular methotrexate*** - The patient's **beta-hCG has risen** from 450 to 520 IU/L, indicating the ectopic pregnancy is not resolving spontaneously, thus failing the criteria for continued **expectant management**.- **Methotrexate** is the appropriate medical treatment for a **clinically stable** patient with an **unruptured ectopic pregnancy** and rising or plateauing beta-hCG levels, especially when the initial level is below 3000-5000 IU/L.*Continue expectant management and repeat beta-hCG in 48 hours*- **Expectant management** is only suitable for ectopic pregnancies when **beta-hCG levels are low and spontaneously declining**, signifying resolution.- Continuing expectant management despite rising beta-hCG levels increases the risk of **tubal rupture** and severe complications, requiring prompt intervention.*Arrange transvaginal ultrasound scan*- While **transvaginal ultrasound** is crucial for diagnosing an ectopic pregnancy, the diagnosis is already established, and the rising **beta-hCG** biochemically confirms ongoing active trophoblastic growth.- A repeat ultrasound at this stage would not change the immediate need for intervention, as the biochemical trend already dictates the change in management.*Discharge with safety-netting advice*- Discharging a patient with an **actively growing ectopic pregnancy** (indicated by rising hCG) is unsafe and could lead to severe, life-threatening complications such as **tubal rupture** and hemorrhage.- Active medical intervention is required, not passive observation, to manage the progression of the ectopic pregnancy safely.*Arrange urgent laparoscopic salpingectomy*- **Surgical management** like **laparoscopic salpingectomy** is usually reserved for patients who are **hemodynamically unstable**, have severe pain, show signs of rupture, or have high beta-hCG levels (typically >5000 IU/L).- Given that the patient is **clinically stable** with minimal pain and a relatively low beta-hCG, **methotrexate** offers a less invasive and appropriate first-line treatment.

Question 152: A 25-year-old woman attends her GP with a 3-month history of intermenstrual bleeding. She has been taking the combined oral contraceptive pill reliably for 2 years. She is sexually active with one partner and reports no dyspareunia or pelvic pain. Speculum examination shows a healthy-looking cervix with no visible lesions. What is the most appropriate next investigation?

A. Transvaginal ultrasound scan
B. Cervical smear test if due
C. Endometrial biopsy
D. High vaginal and endocervical swabs for infection screen (Correct Answer)
E. Serum follicle-stimulating hormone and luteinising hormone levels

Explanation: ***High vaginal and endocervical swabs for infection screen***- In a young, sexually active woman presenting with **intermenstrual bleeding**, the most appropriate initial step is to exclude a **Sexually Transmitted Infection (STI)** such as **Chlamydia trachomatis**, which is a common cause of cervicitis and irregular bleeding.- Despite a healthy-looking cervix and no other symptoms like **pelvic pain** or **dyspareunia**, **STI screening** is paramount before considering more invasive or complex investigations. *Transvaginal ultrasound scan*- This investigation is primarily used to identify **structural abnormalities** such as **fibroids**, **polyps**, or assess **endometrial thickness**.- It is not the first-line investigation in a young woman with a normal speculum exam, as infectious causes are more prevalent in this demographic and should be ruled out first. *Cervical smear test if due*- A **cervical smear test** is a screening tool for **cervical pre-malignant** and **malignant changes**, not a diagnostic tool for acute symptomatic bleeding.- While important for routine health, it does not directly address the immediate cause of **intermenstrual bleeding** and does not replace the need for an **infection screen**. *Endometrial biopsy*- This invasive procedure is typically reserved for women **over 45 years old** or those with significant risk factors for **endometrial hyperplasia** or **malignancy**, especially in cases of persistent abnormal uterine bleeding.- In a 25-year-old woman on the **combined oral contraceptive pill (COCP)**, the risk of endometrial pathology is very low, making this an inappropriate initial investigation. *Serum follicle-stimulating hormone and luteinising hormone levels*- These hormone levels are assessed to investigate conditions related to **ovarian function**, such as **amenorrhea**, **infertility**, or suspected **menopause**.- The patient is reliably taking the **combined oral contraceptive pill**, which **suppresses endogenous FSH and LH production**, rendering these test results uninformative in this context.

Question 153: A 41-year-old multiparous woman presents with increasingly heavy menstrual bleeding over the past year. Her periods last 9 days and she passes large clots. Her haemoglobin is 98 g/L. She has completed her family and desires definitive treatment. Transvaginal ultrasound shows a uniformly enlarged uterus measuring 14 cm with no focal lesions and an endometrial thickness of 8 mm on day 5 of her cycle. What is the most appropriate definitive management option?

A. Levonorgestrel-releasing intrauterine system
B. Endometrial ablation
C. Total hysterectomy (Correct Answer)
D. Uterine artery embolisation
E. Combined oral contraceptive pill

Explanation: ***Total hysterectomy*** - A **total hysterectomy** is the only **definitive treatment** for symptomatic **adenomyosis**, which is strongly suggested by a **uniformly enlarged uterus** (14 cm) with heavy menstrual bleeding and no focal lesions. - Since the patient has **completed her family** and specifically desires a permanent solution for her **anemia** (Hb 98 g/L) and severe symptoms, this surgical option offers a complete and lasting cure. *Levonorgestrel-releasing intrauterine system* - While the **LNG-IUS (Mirena)** is an effective first-line medical management for **heavy menstrual bleeding**, it is not considered **definitive** as symptoms can recur if removed or if it fails. - Its efficacy can be reduced in a significantly **enlarged uterus** (14 cm), potentially leading to a higher risk of **displacement** or expulsion and inadequate symptom control. *Endometrial ablation* - **Endometrial ablation** is generally unsuccessful in **adenomyosis** because the disease involves the deep **myometrium**, which ablation techniques cannot adequately reach or treat. - It is often contraindicated or less effective when the **uterine cavity** length or overall uterine size is significantly increased, such as in this case with a 14 cm uterus. *Uterine artery embolisation* - **Uterine artery embolisation (UAE)** is primarily indicated for **uterine fibroids**; while it can be used for adenomyosis, success rates for long-term symptom relief are lower and less predictable compared to hysterectomy. - UAE is a uterine-sparing procedure and does not provide the **definitive surgical cure** that the patient is requesting, particularly given her completed family. *Combined oral contraceptive pill* - The **COCP** offers hormonal management for menstrual bleeding but is not a **definitive treatment** and does not address the underlying **adenomyosis pathology** in a permanent way. - It is unlikely to provide sufficient and lasting symptom control for a patient with **significant anemia** and severe bleeding, especially when a definitive solution is desired.

Question 154: A 34-year-old woman presents to the emergency department with severe right iliac fossa pain and vaginal bleeding. Her last menstrual period was 7 weeks ago. She appears pale and clammy. Her observations are: blood pressure 85/50 mmHg, heart rate 125 bpm, temperature 36.8°C. Abdominal examination reveals generalised tenderness with guarding and rebound tenderness. A urine pregnancy test is positive. What is the most appropriate immediate management?

A. Arrange urgent transvaginal ultrasound scan
B. Administer intramuscular methotrexate
C. Commence intravenous resuscitation and arrange emergency laparoscopy (Correct Answer)
D. Measure serum beta-hCG level
E. Perform diagnostic laparoscopy under local anaesthetic

Explanation: ***Commence intravenous resuscitation and arrange emergency laparoscopy*** - The patient exhibits **haemodynamic instability** (tachycardia, hypotension) and signs of **peritonitis** (rebound tenderness), indicating a **ruptured ectopic pregnancy** which is a surgical emergency. - Immediate management involves **fluid resuscitation** with large-bore access and urgent surgical intervention to control **intra-abdominal haemorrhage**.*Arrange urgent transvaginal ultrasound scan* - While ultrasound is the gold standard for diagnosing ectopic pregnancy, it should not delay surgery in a **haemodynamically unstable** patient with clear clinical signs of rupture. - Clinical diagnosis of **haemoperitoneum** in a pregnant patient is sufficient to proceed directly to the operating theatre.*Administer intramuscular methotrexate* - **Methotrexate** is a medical management option reserved for stable patients with low beta-hCG levels and no signs of rupture. - It is strictly **contraindicated** in this scenario due to the patient's acute collapse and requirement for immediate surgical haemostasis.*Measure serum beta-hCG level* - Serial or single **beta-hCG measurements** are useful for diagnosing pregnancy of unknown location (PUL) in stable patients. - In an unstable patient with signs of shock, waiting for laboratory results causes **life-threatening delays**.*Perform diagnostic laparoscopy under local anaesthetic* - Surgical management of an ectopic pregnancy requires **general anaesthesia** to allow for adequate relaxation, pneumoperitoneum, and potential conversion to laparotomy. - **Local anaesthetic** is insufficient for managing the complex surgical needs and physiological stress of a ruptured ectopic pregnancy.

Question 155: A 40-year-old woman with heavy menstrual bleeding has been treated with tranexamic acid for 6 months with partial improvement. She is currently using condoms for contraception and has completed her family. Her uterus is normal size on examination and transvaginal ultrasound shows no structural abnormalities with endometrial thickness of 8mm. Her haemoglobin is 108 g/L. She declines hormonal treatments. What is the most appropriate next management step?

A. Increase dose of tranexamic acid
B. Arrange hysteroscopy
C. Refer for endometrial ablation (Correct Answer)
D. Refer for hysterectomy
E. Prescribe mefenamic acid

Explanation: ***Refer for endometrial ablation*** - This patient has failed **medical management** with non-hormonal agents (tranexamic acid) and has **declined hormonal treatments**, making a surgical intervention the appropriate next step. - **Endometrial ablation** is suitable as she has **completed her family**, has a normal-sized uterus with no structural abnormalities on ultrasound, and is a less invasive option than hysterectomy. *Increase dose of tranexamic acid* - She has already undergone a **6-month trial** with only partial improvement, indicating that increasing the dose is unlikely to provide adequate symptom control or resolve her **anaemia**. - Moving to a more definitive intervention is warranted given the failure of sustained improvement with current medical therapy. *Arrange hysteroscopy* - A **transvaginal ultrasound** has already shown a **normal uterus** with no structural abnormalities and an 8mm endometrial thickness, making significant focal intrauterine pathology unlikely. - **Hysteroscopy** is generally indicated when ultrasound is inconclusive or there's a high suspicion of a focal lesion not identified by imaging, which is not the case here. *Refer for hysterectomy* - While **hysterectomy** is a definitive cure for heavy menstrual bleeding, it is a **major surgical procedure** with associated higher risks and longer recovery compared to endometrial ablation. - Given the absence of structural pathology and her completed family, **less invasive surgical options** like ablation should be considered first before proceeding to hysterectomy. *Prescribe mefenamic acid* - **Mefenamic acid** is another non-hormonal medical treatment for heavy menstrual bleeding, often used alongside or instead of tranexamic acid. - However, the patient has already shown **partial improvement only** with 6 months of tranexamic acid, making it unlikely that another medical agent alone will provide sufficient relief or address her **anaemia**.

Question 156: A 31-year-old woman presents with sudden onset left-sided pelvic pain. She has had IVF treatment and is 7 weeks pregnant with a singleton intrauterine pregnancy confirmed on scan 5 days ago. Today's transvaginal ultrasound shows the viable intrauterine pregnancy and a new 35mm left adnexal complex mass. Beta-hCG is 48,000 IU/L. She is haemodynamically stable. Free fluid is present in the pelvis. What is the most likely diagnosis?

A. Corpus luteum cyst rupture
B. Ovarian torsion
C. Heterotopic pregnancy (Correct Answer)
D. Tubo-ovarian abscess
E. Haemorrhagic ovarian cyst

Explanation: ***Heterotopic pregnancy*** - This patient's history of **IVF treatment** significantly increases the risk of **heterotopic pregnancy** (simultaneous intrauterine and ectopic pregnancies), which explains the **viable intrauterine pregnancy** and the **new 35mm left adnexal complex mass**. - The sudden onset of **pelvic pain** along with the **adnexal mass** and **free fluid** suggests rupture of the ectopic component, which is a common presentation of heterotopic pregnancy. *Corpus luteum cyst rupture* - While corpus luteum cysts are common in early pregnancy and can rupture causing pain and free fluid, the presence of a distinct **new 35mm complex adnexal mass** in the context of IVF strongly points towards an ectopic component rather than a simple cyst rupture. - A ruptured corpus luteum cyst often shows a collapsing or irregular cyst rather than a well-defined complex mass, and while it causes symptoms, the IVF history raises the suspicion for heterotopic pregnancy higher. *Ovarian torsion* - Ovarian torsion typically presents with **severe, acute pain** but classic ultrasound findings include an **enlarged, edematous ovary** and often altered or absent Doppler flow, rather than a discrete complex mass. - While severe pain is present, the specific description of a **new complex mass** alongside a confirmed intrauterine pregnancy makes heterotopic pregnancy a more direct fit given the significant risk factor of IVF. *Tubo-ovarian abscess* - Tubo-ovarian abscess (TOA) is an inflammatory process usually associated with **pelvic inflammatory disease (PID)**, and typically presents with fever, elevated inflammatory markers, and possibly vaginal discharge, none of which are mentioned here. - The patient is described as **haemodynamically stable** and lacks systemic signs of infection, making TOA an unlikely diagnosis in this early pregnancy. *Haemorrhagic ovarian cyst* - Haemorrhagic ovarian cysts can present as complex masses and cause pain, often showing a characteristic **reticular internal echo pattern** on ultrasound. - However, the combination of **IVF treatment**, a confirmed **intrauterine pregnancy**, and a **new adnexal complex mass** with **free fluid** necessitates a higher suspicion for **heterotopic pregnancy** due to its potentially life-threatening nature if ruptured.

Question 157: A 48-year-old woman presents with menorrhagia and dysmenorrhoea. Transvaginal ultrasound shows a bulky uterus with asymmetrical myometrial thickening and small myometrial cysts. The endometrium is 7mm thick. What is the most likely diagnosis?

A. Endometrial hyperplasia
B. Adenomyosis (Correct Answer)
C. Multiple small fibroids
D. Endometrial polyp
E. Endometrial carcinoma

Explanation: ***Adenomyosis***- Characteristic ultrasound findings include an **asymmetrically thickened myometrium**, a **bulky uterus**, and the presence of **small myometrial cysts**, which represent ectopic endometrial tissue.- It classically presents in multiparous women in their 40s with a triad of **menorrhagia**, **dysmenorrhea**, and a **globular, tender uterus** on examination.*Endometrial hyperplasia*- This condition is primarily characterized by **excessive proliferation** of the endometrial glands, resulting in an **endometrial thickness** usually exceeding normal limits (e.g., >14mm in premenopausal women).- It does not cause **myometrial cysts** or **asymmetrical myometrial thickening**, as the pathology is confined to the uterine lining.*Multiple small fibroids*- Fibroids (leiomyomas) appear as **discrete, well-circumscribed, hypoechoic masses** on ultrasound, often with posterior acoustic shadowing.- While they cause a bulky uterus, they lack the **diffuse, cystic appearance** within the myometrium that is seen in adenomyosis.*Endometrial polyp*- A polyp is a **focal overgrowth** of the endometrial stroma and glands that projects into the **uterine cavity**.- Ultrasound usually identifies a polyp as a **hyperechoic lesion** within the endometrium, often with a visible **vascular feeding vessel** on Doppler, rather than myometrial changes.*Endometrial carcinoma*- This malignancy typically presents as **irregular endometrial thickening** or a focal mass, often associated with a disrupted endo-myometrial junction.- The **7mm endometrial thickness** in this premenopausal patient is within normal limits and the symptoms are better explained by the **myometrial pathology**.

Question 158: A 29-year-old woman is diagnosed with a tubal ectopic pregnancy. Serum beta-hCG is 2,800 IU/L. She is clinically stable with minimal pain. The ectopic mass measures 38 mm on transvaginal ultrasound with no visible fetal heartbeat. She has no contraindications to medical management and strongly wishes to avoid surgery. What is the most appropriate management?

A. Administer single-dose methotrexate regimen
B. Administer two-dose methotrexate regimen
C. Recommend laparoscopic salpingotomy (Correct Answer)
D. Recommend expectant management
E. Administer multi-dose methotrexate regimen

Explanation: ***Recommend laparoscopic salpingotomy***- Medical management with methotrexate is generally reserved for ectopic masses **<35 mm**; since this mass is **38 mm**, surgical intervention is the preferred definitive treatment.- **Salpingotomy** (preserving the tube) is appropriate for women who wish to maintain future fertility, provided the contralateral tube is healthy and the patient is **haemodynamically stable**.*Administer single-dose methotrexate regimen*- The **mass size of 38 mm** exceeds the commonly accepted threshold of **35 mm**, which significantly increases the risk of therapy failure and **tubal rupture**.- While her **beta-hCG** is within the treatable range (<5,000 IU/L), the size of the adnexal mass makes medical management less reliable.*Administer two-dose methotrexate regimen*- Two-dose regimens are sometimes used for higher hCG levels, but they do not mitigate the physical risk associated with an **ectopic mass diameter** exceeding **35 mm**.- Failure rates and the risk of **emergency surgery** remain higher when the initial mass size is large, regardless of the dose count.*Recommend expectant management*- This approach is only considered when **beta-hCG** levels are very low (typically **<1,500 IU/L**) and demonstrably **declining**.- With an hCG of **2,800 IU/L** and a large mass, the risk of rupture is too high to justify monitoring without active intervention.*Administer multi-dose methotrexate regimen*- **Multi-dose methotrexate** involves more side effects and is typically reserved for complex cases or specific hCG protocols, not to overcome **mass size** contraindications.- Consistent with other medical options, the **38 mm size** remains the primary factor necessitating a recommendation for **surgical management**.

Question 159: A 35-year-old woman presents with heavy menstrual bleeding. She reports using 12 pads per day during her periods, passing large clots, and flooding through to her clothes. Her periods last 8 days and occur regularly every 28 days. She has two children and may wish for more in the future. Examination is unremarkable. Which investigation is most important to perform first?

A. Transvaginal ultrasound scan
B. Thyroid function tests
C. Full blood count (Correct Answer)
D. Coagulation screen
E. Serum ferritin

Explanation: ***Full blood count***- According to clinical guidelines, an **FBC** should be performed for all women with **heavy menstrual bleeding (HMB)** to identify **iron-deficiency anaemia**.- This patient's symptoms of **flooding**, passing **large clots**, and using 12 pads per day objectively indicate significant blood loss that prioritizes the assessment of **haemoglobin levels**.*Transvaginal ultrasound scan*- A **TVUS** is indicated to identify structural pathologies like **fibroids** or **adenomyosis**, but it is generally performed after or alongside initial blood tests.- While important for diagnosis, it does not assess the immediate physiological impact of the bleeding, such as **anaemia**.*Thyroid function tests*- **Hypothyroidism** can be a cause of HMB, but routine testing is not recommended unless other clinical signs of **thyroid dysfunction** are present.- This patient's examination is **unremarkable**, making thyroid pathology a less likely primary concern than the immediate risk of anaemia.*Coagulation screen*- Testing for **coagulation disorders** (like von Willebrand disease) is indicated if a woman has had HMB since **menarche** or a personal/family history of bleeding.- Since this patient has already had two children without reported complications, a primary **clotting disorder** is less likely to be the initial diagnostic priority.*Serum ferritin*- While **ferritin** assesses **iron stores**, the **FBC** is the more critical first step as it determines the actual **haemoglobin concentration** and presence of anaemia.- Ferritin is often tested concurrently, but it does not replace the necessity of checking for a **low haematocrit** or **thrombocytopenia** on FBC.

Question 160: According to current UK guidelines, what is the discriminatory beta-hCG level above which a transvaginal ultrasound scan should reliably identify an intrauterine gestational sac in a viable intrauterine pregnancy?

A. 500 IU/L
B. 1,500 IU/L (Correct Answer)
C. 1,000 IU/L
D. 2,500 IU/L
E. 3,000 IU/L

Explanation: ***1,500 IU/L*** - In UK practice, **1,500 IU/L** is the established **discriminatory level** where a gestational sac should be visible via **transvaginal ultrasound (TVUS)** in a viable pregnancy. - If levels exceed this threshold without a visible intrauterine sac, the risk of an **ectopic pregnancy** or **pregnancy of unknown location (PUL)** is significantly increased. *500 IU/L* - This level is too low to reliably expect visualization of a **gestational sac** even with high-resolution **transvaginal imaging**. - Clinical management at this level usually involves serial **beta-hCG monitoring** to assess the trend before definitive imaging diagnoses can be made. *1,000 IU/L* - While some older literature or specific institutions may use **1,000 IU/L**, it is not the standard threshold cited by current **UK guidelines** (such as NICE). - Using a lower threshold increases the risk of **false-positive** diagnoses of ectopic pregnancy in early, viable **intrauterine pregnancies**. *2,500 IU/L* - A level of **2,500 IU/L** is much higher than the standard discriminatory zone and would clearly necessitate a visible sac on **ultrasound**. - This threshold is sometimes used for **transabdominal scans**, which are less sensitive than the **transvaginal** approach used in early pregnancy assessment. *3,000 IU/L* - At **3,000 IU/L**, a viable pregnancy would almost certainly be visible; however, this value is unnecessary as a **diagnostic threshold** for TVUS. - Waiting for the hCG to reach this level before investigating for **ectopic pregnancy** would cause dangerous delays in clinical management.

Question 161: A 42-year-old woman presents with a 4-month history of heavy, prolonged menstrual periods occurring every 18-35 days. She also reports hot flushes and night sweats. Blood tests show: FSH 58 IU/L, LH 42 IU/L, oestradiol 45 pmol/L, haemoglobin 102 g/L. Transvaginal ultrasound shows endometrial thickness of 6mm and normal ovaries. What is the underlying cause of her abnormal bleeding?

A. Anovulatory cycles secondary to premature ovarian insufficiency (Correct Answer)
B. Endometrial hyperplasia
C. Polycystic ovary syndrome
D. Hypothyroidism
E. Adenomyosis

Explanation: ***Anovulatory cycles secondary to premature ovarian insufficiency***- The patient's significantly **elevated FSH (58 IU/L)** and **LH (42 IU/L)**, coupled with **low oestradiol (45 pmol/L)** at age 42, are classic indicators of **premature ovarian insufficiency (POI)**.- These hormonal changes result in **anovulation**, leading to unstable endometrial lining and subsequently **heavy, prolonged, and irregular menstrual bleeding**, along with **vasomotor symptoms** like hot flushes and night sweats due to hypoestrogenism.*Endometrial hyperplasia*- This condition typically arises from **unopposed oestrogen stimulation**, leading to a thickened endometrium, usually much greater than the **6mm** measured in this case.- The patient's **low oestradiol** level contradicts the hormonal environment required for endometrial hyperplasia to develop.*Polycystic ovary syndrome*- While PCOS can cause anovulatory cycles and irregular bleeding, it typically features **normal or low FSH** levels and often an **elevated LH:FSH ratio**, which is opposite to the high FSH and LH observed here.- PCOS diagnosis also requires evidence of **hyperandrogenism** (clinical or biochemical) or polycystic ovarian morphology, neither of which is presented in this case.*Hypothyroidism*- Hypothyroidism can cause menstrual irregularities such as **menorrhagia**, but it does not account for the **markedly elevated FSH and LH** or the low oestradiol levels seen in this patient.- The patient's prominent **vasomotor symptoms** (hot flushes, night sweats) are more characteristic of hypoestrogenism rather than hypothyroidism.*Adenomyosis*- Adenomyosis is a structural uterine disorder characterized by **heavy menstrual bleeding (menorrhagia)** and often painful periods (dysmenorrhea), typically presenting with a **globally enlarged uterus**.- It is a uterine pathology and does not cause the **hypergonadotropic hypogonadism** (high FSH/LH, low oestrogen) and **vasomotor symptoms** that are central to this patient's presentation.

Question 162: A 26-year-old woman who is 6 weeks pregnant following IVF treatment presents with right iliac fossa pain and spotting. Transvaginal ultrasound shows an intrauterine gestational sac with a yolk sac and fetal pole with visible cardiac activity (crown-rump length 5mm). Additionally, a 30mm right adnexal mass with a hyperechoic ring is identified. Serum beta-hCG is 15,000 IU/L. She is haemodynamically stable. What is the most appropriate management?

A. Expectant management with close monitoring
B. Methotrexate therapy
C. Laparoscopic salpingectomy (Correct Answer)
D. Potassium chloride injection into ectopic pregnancy
E. Bilateral salpingectomy

Explanation: ***Laparoscopic salpingectomy*** - This patient presents with a **heterotopic pregnancy**, a simultaneous intrauterine and ectopic pregnancy, a known increased risk following **IVF** treatment. - **Laparoscopic salpingectomy** is the definitive treatment for the ectopic component, removing the 30mm tubal mass and alleviating symptoms while preserving the viable **intrauterine gestation**. *Expectant management with close monitoring* - The 30mm adnexal mass and symptoms of pain and spotting indicate a high risk of **tubal rupture**, making expectant management unsafe and inappropriate. - **Expectant management** is usually reserved for very small, asymptomatic ectopics with falling beta-hCG, which is not the case with a viable intrauterine pregnancy and symptoms. *Methotrexate therapy* - **Methotrexate** is strictly **contraindicated** in this scenario as it is a folate antagonist and would harm or terminate the viable **intrauterine pregnancy**. - Its use is limited to isolated ectopic pregnancies without a concomitant viable intrauterine gestation. *Potassium chloride injection into ectopic pregnancy* - While used for selective reduction, **KCl injection** is less definitive for a tubal ectopic compared to surgical removal and carries risks of incomplete resolution. - It is typically considered for specific types of ectopic pregnancies (e.g., interstitial, cervical) where surgical access might be more challenging. *Bilateral salpingectomy* - There is no medical indication to remove the healthy contralateral fallopian tube, as the problem is a **unilateral ectopic pregnancy**. - **Bilateral salpingectomy** would unnecessarily increase surgical morbidity and compromise future fertility without offering additional benefit for the current situation.

Question 163: A 38-year-old woman with known uterine fibroids presents with heavy menstrual bleeding not controlled by medical management. She experiences flooding every 26 days lasting 10 days and has failed treatment with tranexamic acid and the levonorgestrel intrauterine system. Her haemoglobin is 82 g/L. Pelvic MRI shows a 9 cm intramural fibroid and multiple smaller fibroids. She wishes to preserve her uterus. Which treatment option would be most appropriate?

A. Uterine artery embolization (Correct Answer)
B. Total abdominal hysterectomy
C. Myomectomy
D. Endometrial ablation
E. High-intensity focused ultrasound

Explanation: ***Uterine artery embolization***- **Uterine artery embolization (UAE)** is a highly effective, minimally invasive procedure for treating symptomatic **multiple fibroids** while allowing for **uterine preservation**.- It is particularly suitable for this patient who has failed medical management and has **symptomatic bulk** (9 cm fibroid) that needs reduction without major surgery.*Total abdominal hysterectomy*- This procedure involves the **permanent removal** of the uterus, which directly contradicts the patient's explicit wish to **preserve her uterus**.- While it provides a definitive cure for **heavy menstrual bleeding**, it carries the highest surgical morbidity and longest recovery time among the options.*Myomectomy*- Although it preserves the uterus, the presence of **multiple fibroids** and a large **9 cm intramural fibroid** makes this surgically complex and increases the risk of significant intraoperative **haemorrhage**.- There is a high risk of **fibroid recurrence** from the smaller existing fibroids, potentially necessitating further interventions in the future.*Endometrial ablation*- This procedure is typically **contraindicated** when the uterine cavity is significantly distorted by large **intramural or submucosal fibroids** greater than 3 cm.- It only treats the **endometrial lining** and would not address the symptoms caused by the large **fibroid bulk** or the 9 cm intramural mass.*High-intensity focused ultrasound*- **HIFU** is a newer, less invasive option, but it has **limited availability** and a smaller evidence base compared to established treatments like UAE.- It may be less effective for treating **multiple large fibroids** simultaneously compared to the global effect achieved by embolizing the uterine arteries.

Question 164: A 19-year-old woman presents to the emergency department with sudden onset right-sided abdominal pain and minimal vaginal bleeding. She had a positive pregnancy test at home 3 days ago. Her last menstrual period was 5 weeks ago. Observations: BP 115/75 mmHg, pulse 88 bpm, temperature 36.8°C. Transvaginal ultrasound shows an empty uterus and no adnexal masses. Free fluid is noted in the pouch of Douglas. Serum beta-hCG is 1,200 IU/L. What is the most appropriate initial management?

A. Repeat serum beta-hCG in 48 hours (Correct Answer)
B. Immediate laparoscopy
C. Single dose methotrexate
D. Expectant management with weekly beta-hCG
E. Uterine curettage

Explanation: ***Repeat serum beta-hCG in 48 hours*** - This patient presents with a **pregnancy of unknown location (PUL)**, as her serum beta-hCG (1,200 IU/L) is below the **discriminatory zone** (typically 1,500–2,000 IU/L) where an intrauterine pregnancy should be visible on transvaginal ultrasound. - In a **haemodynamically stable** patient, serial beta-hCG measurements every 48 hours are crucial to establish the trend (rising appropriately, rising suboptimally, or falling) to differentiate between a viable **intrauterine pregnancy**, an **ectopic pregnancy**, or a **miscarriage**. *Immediate laparoscopy* - Surgical intervention is indicated for patients who are **haemodynamically unstable** or have definitive ultrasound evidence of a **ruptured ectopic pregnancy** (e.g., large amount of free fluid, definite adnexal mass with features of rupture). - This patient is clinically stable, and the ultrasound shows an empty uterus with no adnexal masses, making immediate surgery premature and potentially unnecessary. *Single dose methotrexate* - Methotrexate is a medical management option for a **confirmed ectopic pregnancy** that meets specific criteria (e.g., hCG <5,000 IU/L, no fetal cardiac activity, patient stability). - Administering it before further characterization of the PUL carries the risk of inadvertently terminating a potentially viable **early intrauterine pregnancy** if the beta-hCG were to rise normally. *Expectant management with weekly beta-hCG* - Expectant management with weekly monitoring is generally reserved for patients with very low or already **falling beta-hCG levels**, often suggesting a resolving pregnancy of unknown location or a complete miscarriage. - At this initial stage of PUL with an hCG of 1,200 IU/L, a **48-hour interval** is required to establish the biochemical trend swiftly and guide further management, rather than waiting a full week. *Uterine curettage* - Uterine curettage is typically performed to obtain **chorionic villi** for histological confirmation, primarily to distinguish between a non-viable intrauterine pregnancy and an ectopic pregnancy if serial hCG levels are not conclusive or are persistently high without an identifiable IUP. - It is an invasive procedure and not an initial management step for a stable patient with PUL, especially when an early viable IUP cannot be ruled out.

Question 165: A 52-year-old perimenopausal woman presents with intermenstrual bleeding and post-coital bleeding over the past 3 months. She had normal cervical screening 18 months ago. On speculum examination, the cervix appears normal. Transvaginal ultrasound shows endometrial thickness of 18 mm with heterogeneous appearance. What is the most appropriate next investigation?

A. Repeat transvaginal ultrasound in 3 months
B. Hysteroscopy with endometrial biopsy (Correct Answer)
C. Saline infusion sonography
D. Serum CA-125 measurement
E. MRI pelvis

Explanation: ***Hysteroscopy with endometrial biopsy*** - In a 52-year-old perimenopausal woman with **intermenstrual bleeding** and **post-coital bleeding**, combined with an **18 mm heterogeneous endometrial thickness** on ultrasound, there is a high suspicion for **endometrial hyperplasia** or **malignancy**. - **Hysteroscopy** allows for direct visualization of the endometrial cavity and targeted **endometrial biopsy**, which is the gold standard for obtaining a **histological diagnosis**. *Repeat transvaginal ultrasound in 3 months* - This option is inappropriate as it would cause a significant and potentially dangerous delay in diagnosing a possible **endometrial cancer** or **pre-malignant condition**. - Given the patient's age, symptoms, and the highly abnormal **endometrial thickness**, immediate **histological evaluation** is required. *Saline infusion sonography* - While **saline infusion sonography (SIS)** can help delineate intrauterine lesions like **polyps** or **submucosal fibroids**, it is an imaging technique and does not provide a **tissue diagnosis**. - It cannot replace the need for an **endometrial biopsy** in a patient with a thickened, heterogeneous endometrium and abnormal bleeding, where malignancy is a concern. *Serum CA-125 measurement* - **CA-125** is primarily a tumor marker for **ovarian cancer** and is not routinely used as an initial diagnostic test for **abnormal uterine bleeding** or **endometrial pathology**. - A normal **CA-125** level would not rule out **endometrial cancer** and would not negate the need for **endometrial sampling**. *MRI pelvis* - **MRI pelvis** is typically reserved for **staging confirmed gynecological cancers** or for evaluating complex pelvic masses, not as an initial diagnostic investigation for abnormal uterine bleeding with a thickened endometrium. - It is more expensive and, critically, does not provide the **histological diagnosis** necessary to differentiate between benign and malignant endometrial conditions.

Question 166: A 32-year-old nulliparous woman presents with 6 weeks amenorrhoea and mild lower abdominal pain. Transvaginal ultrasound shows an empty uterus with 15 mm endometrial thickness and a 25 mm adnexal mass with a hyperechoic ring. Serum beta-hCG is 2,100 IU/L. She is haemodynamically stable and wishes to preserve her fertility. A repeat beta-hCG 48 hours later is 3,800 IU/L. What is the most appropriate management?

A. Expectant management with serial beta-hCG monitoring
B. Methotrexate therapy (Correct Answer)
C. Laparoscopic salpingectomy
D. Laparoscopic salpingotomy
E. Uterine curettage

Explanation: ***Methotrexate therapy***- The patient has an **unruptured ectopic pregnancy** and is **hemodynamically stable**, making her a candidate for medical management to preserve fertility.- With a **serum beta-hCG <5,000 IU/L** (specifically 3,800 IU/L) and an adnexal mass **<35 mm** without a fetal heartbeat, **Methotrexate** is the preferred pharmacological intervention.*Expectant management with serial beta-hCG monitoring*- This approach is generally reserved for patients with very low and **decreasing beta-hCG levels** (typically <1,500 IU/L).- In this case, the **rising beta-hCG** (from 2,100 to 3,800 IU/L) indicates a proliferating pregnancy that requires active treatment.*Laparoscopic salpingectomy*- This involves the **surgical removal of the fallopian tube**, which is typically indicated for patients with a ruptured ectopic or significant pain.- While effective, it is less desirable for a stable patient specifically wishing to **preserve her fertility** and tubal integrity.*Laparoscopic salpingotomy*- This surgical procedure involves opening the tube to remove the pregnancy; however, it carries a risk of **persistent trophoblastic tissue**.- It is usually reserved for patients with a **contralateral tubal abnormality** when medical management is contraindicated or unsuccessful.*Uterine curettage*- This procedure is used to rule out an **incomplete miscarriage** but has no role in the management of a confirmed extrauterine adnexal mass.- Performing a curettage in this clinical scenario would be inappropriate as the **ultrasound and rising hCG** confirm an ectopic pregnancy rather than a failed intrauterine one.

Question 167: A 45-year-old woman attends the gynaecology clinic with a 6-month history of increasingly heavy menstrual bleeding. Her periods occur regularly every 28 days but last 9 days with flooding and clots. She has completed her family. Blood tests show haemoglobin 95 g/L, MCV 72 fL. Transvaginal ultrasound reveals a normal-sized uterus with 12 mm endometrial thickness and no structural abnormalities. What is the most appropriate first-line pharmacological treatment?

A. Combined oral contraceptive pill
B. Tranexamic acid
C. Levonorgestrel intrauterine system (Correct Answer)
D. Gonadotrophin-releasing hormone analogues
E. Norethisterone

Explanation: ***Levonorgestrel intrauterine system*** - The **LNG-IUS (Mirena/Levosert)** is recommended by **NICE guidelines** as the first-line pharmacological treatment for **heavy menstrual bleeding (HMB)** in women with no structural/histological abnormalities. - It provides highly effective **long-term contraception** and significantly reduces blood loss by causing **endometrial atrophy**, making it suitable for this patient who has completed her family. *Combined oral contraceptive pill* - While it can regulate periods and reduce flow, it is considered a **second-line** option compared to the LNG-IUS for HMB. - The risks associated with the **combined oral contraceptive pill**, such as VTE, may be higher in women over 35, requiring careful assessment of **UKMEC criteria**. *Tranexamic acid* - This is an **antifibrinolytic** taken only during the period; it is a first-line alternative for women who do not want or cannot use **hormonal treatments**. - Although effective at reducing blood loss, it does not provide **contraception** or the superior long-term flow reduction seen with the LNG-IUS. *Gonadotrophin-releasing hormone analogues* - These agents induce a **hypoestrogenic state** and are typically reserved for **pre-operative** shrinking of fibroids or as a second-line specialist treatment. - Their use is limited to **short-term** (usually <6 months) due to the risk of **osteoporosis** and menopausal symptoms. *Norethisterone* - Cyclic oral **progestogens** like Norethisterone are less effective than other treatments for HMB and are no longer recommended as a primary first-line choice. - It is generally used for **short-term control** of acute bleeding rather than the long-term management of chronic HMB.

Question 168: A 28-year-old woman presents to the emergency department with sudden onset severe left iliac fossa pain and vaginal bleeding. Her last menstrual period was 7 weeks ago. She has a history of pelvic inflammatory disease. On examination, she is pale, blood pressure 95/60 mmHg, pulse 110 bpm. Abdominal examination reveals tenderness and guarding in the left iliac fossa. A urine pregnancy test is positive. What is the most appropriate immediate management?

A. Arrange urgent transvaginal ultrasound scan
B. Administer intramuscular methotrexate
C. Initiate resuscitation and arrange emergency laparotomy (Correct Answer)
D. Measure serum beta-hCG levels
E. Perform diagnostic laparoscopy

Explanation: ***Initiate resuscitation and arrange emergency laparotomy*** - The patient exhibits features of a **ruptured ectopic pregnancy** with **hemodynamic instability** (hypotension, tachycardia, and pallor), necessitating immediate life-saving intervention. - **Resuscitation** with intravenous fluids and blood products alongside an **emergency laparotomy** is mandatory to control hemorrhage when a patient is in **hypovolemic shock**. *Arrange urgent transvaginal ultrasound scan* - While ultrasound is useful for diagnosing stable ectopic pregnancies, it should not delay treatment in an **unstable patient** with clinical evidence of rupture. - Clinical diagnosis of a **surgical emergency** takes precedence over imaging in the presence of **peritonitis** and shock. *Administer intramuscular methotrexate* - **Methotrexate** is a medical management option reserved exclusively for **stable, unruptured** ectopic pregnancies with low beta-hCG levels. - It is strictly contraindicated in cases of **hemodynamic instability** or suspected rupture due to the high risk of fatal hemorrhage. *Measure serum beta-hCG levels* - **Serum beta-hCG** is used to monitor pregnancy viability or location in stable patients but adds no value in an acute **rupture** scenario. - Waiting for laboratory results would cause a dangerous delay in the **surgical management** required to save the patient's life. *Perform diagnostic laparoscopy* - **Laparoscopy** is the gold standard for stable patients; however, in a state of **hypovolemic shock**, the increased intra-abdominal pressure from insufflation can worsen hemodynamic collapse. - **Laparotomy** is generally preferred in the unstable patient to allow for faster access and better control of **massive hemoperitoneum**.

Practice by Chapter

Abnormal uterine bleeding

Practice Questions

Ectopic pregnancy

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Gynaecology — MCQs

Gynaecology — MCQs

On this page